EU Risk Management Plan (Version 0.4) 
Page 1 of 100 
The information contained in this document is the property of 
Eli Lilly and Company or its subsidiaries. 
EU Risk Management Plan (Version 0.4) 
Global Patient Safety 
Signatory information is available on request. 
Document ID: VV-PVG-106256 
LY3074828 
Approved on 28 Mar 2023 GMT
EU Risk Management Plan for Mirikizumab (INN or common name) 
RMP version to be assessed as part of the application: 0.4 
Data lock point for this RMP: 06 December 2021 
Date of final sign off: See Cover Page 
Rationale for submitting an updated RMP: In response to the CHMP request dated 
23 March 2023, an update to Table Part V.1 is provided along with additional information in 
SVII.3 to match revisions in the SmPC.  Any company confidential information and privacy data 
have been eliminated. 
Summary of significant changes in this RMP: 
 Details in SVII.3 related to evaluation for TB infection and monitoring of patients during
and after treatment is provided to match requested revisions in the SmPC.
 At the request of CHMP, an update to Table Part V.1 is provided to match the revisions
in the SmPC.
Other RMP versions under evaluation 
RMP version number: None  
Submitted on: Not applicable 
Procedure number: Not applicable 
Details of the currently approved RMP 
Version number: Not applicable 
Approved with procedure: Not applicable 
Date of approval (opinion date): Not applicable 
QPPV oversight declaration: The content of this RMP has been reviewed and approved by the 
marketing authorisation holder’s Qualified Person for Pharmacovigilance (QPPV). The 
electronic signature is available on file. 
Approved on 28 Mar 2023 GMT
Table of content 
Table of content ..............................................................................................................................3
List of Abbreviations .....................................................................................................................6
Part I: Product(s) Overview ..........................................................................................................8
Part II: Safety Specification ........................................................................................................10
Module SI - Epidemiology of the Indication(s) and Target Population(s) ..................................10
SI.1 Ulcerative Colitis ..............................................................................................................10
Module SII – Non-clinical Part of the Safety Specification ........................................................19
SII.1 Toxicity ...........................................................................................................................19
SII.2 Safety Pharmacology ......................................................................................................20
SII.3 Other Toxicity-Related Information or Data ..................................................................20
Module SIII - Clinical Trial Exposure .........................................................................................21
Module SIV - Populations Not Studied in Clinical Trials ...........................................................25
SIV.1 Exclusion Criteria in Pivotal Clinical Studies within the Development 
Programme ...............................................................................................................25
SIV.2 Limitations to Detect Adverse Reactions in Clinical Trial Development 
Programmes .............................................................................................................26
SIV.3 Limitations in Respect to Populations Typically Under-represented in 
Clinical Trial Development Programmes ................................................................27
Module SV - Post-Authorisation Experience ..............................................................................29
SV.1 Post-Authorisation Exposure ..........................................................................................29
Module SVI - Additional EU Requirements for the Safety Specification ..................................30
SVI.1 - Potential for Misuse for Illegal Purposes ....................................................................30
Module SVII - Identified and Potential Risks .............................................................................31
SVII.1 Identification of Safety Concerns in the Initial RMP Submission ...............................31
SVII.2 New Safety Concerns and Reclassification with a Submission of an 
Updated RMP ...........................................................................................................35
SVII.3 Details of Important Identified Risks, Important Potential Risks, and 
Missing Information .................................................................................................36
Module SVIII - Summary of the Safety Concerns ......................................................................48
Part III: Pharmacovigilance Plan (including post-authorisation safety 
studies) ..................................................................................................................................49
III.1 Routine Pharmacovigilance Activities .............................................................................49
III.2 Additional Pharmacovigilance Activities ........................................................................49
III.3 Summary Table of Additional Pharmacovigilance Activities .........................................52
Part IV: Plans for Post-Authorisation Efficacy Studies ...........................................................54
Part V: Risk Minimisation Measures (including evaluation of the 
effectiveness of risk minimisation activities) .....................................................................55
Approved on 28 Mar 2023 GMT
EU Risk Management Plan (Version 0.4) 
Page 4 of 100 
V.1 Routine Risk Minimisation Measures ...............................................................................55
V.2 Additional Risk Minimisation Measures ..........................................................................58
V.3 Summary of Risk Minimisation Measures........................................................................59
Part VI: Summary of the Risk Management Plan ....................................................................63
I - The Medicine and What It is Used for ....................................................................................63
II - Risks Associated with the Medicine and Activities to Minimise or Further 
Characterise the Risks .......................................................................................................63
II.A List of Important Risks and Missing Information ............................................................63
II.B Summary of Important Risks ............................................................................................64
II.C Post-Authorisation Development Plan .............................................................................68
Part VII: Annexes ........................................................................................................................70
Annex 4 - Specific Adverse Drug Reaction Follow-up Forms ................................................71
Annex 6 - Details of Proposed Additional Risk Minimisation Activities (if 
applicable) ..............................................................................................................100
LY3074828 
Approved on 28 Mar 2023 GMT
Table of Contents 
Table 
Page 
Table Part I.1. 
Product Overview ............................................................................................8 
Table SIII.1. 
Duration of Exposure .....................................................................................21 
Table SIII.2. 
Age Group and Gender ..................................................................................22 
Table SIII.3. 
Dose ...............................................................................................................23 
Table SIII.4. 
Ethnic Origin .................................................................................................24 
Table SIV.1. 
Exposure of Special Populations Included or Not in Clinical 
Trial Development Programmes ............................................................................................27 
Table SVIII.1. 
Summary of Safety Concerns ........................................................................48 
Table Part III.1.  Ongoing and Planned Additional Pharmacovigilance 
Activities 
 .......................................................................................................................52 
Table Part V.1. 
Description of Routine Risk Minimisation Measures by 
Safety Concern .......................................................................................................................55 
Table Part V.3. 
Summary Table of Pharmacovigilance Activities and Risk 
Minimisation Activities by Safety Concern ...........................................................................59 
Approved on 28 Mar 2023 GMT
 
List of Abbreviations  
Term 
AE 
ADR 
AIH 
ALP 
ALT 
ASA 
AST 
CCV 
CD 
CHD 
CI 
Definition 
adverse event 
adverse drug reaction 
autoimmune hepatitis 
alkaline phosphatase 
alanine aminotransferase 
amino salicylic acid 
aspartate aminotransferase 
cerebrocardiovascular 
Crohn’s disease 
coronary heart disease 
confidence interval 
COVID-19 
coronavirus disease 2019 
CRC 
DILI 
DVT 
EAIR 
EIMs 
ePPND 
GGT 
HBV 
HCV 
HR 
ICH 
IBD 
IgG 
IL 
IR 
IRR 
IV 
MACE 
MI 
Miri 
NAFLD 
NMSC 
NOAEL 
OR 
colorectal cancer 
drug-induced liver injury 
deep venous thrombosis 
exposure-adjusted incidence rate 
extraintestinal manifestations 
enhanced pre- and post-natal development 
gamma-glutamyl transpeptidase 
hepatitis B virus 
hepatitis C virus 
hazard ratio 
International Council for Harmonisation 
inflammatory bowel disease 
immunoglobulin 
interleukin 
incidence rate 
incidence rate ratio 
intravenous 
major adverse cardiac event 
myocardial infarction 
mirikizumab 
non-alcoholic fatty liver disease 
non-melanoma skin cancer 
no-observed-adverse-effect level 
odds ratio 
Approved on 28 Mar 2023 GMT
 
 
Term 
PE 
Ps 
PSC 
PY 
PYE 
Q8W 
RMP 
RR 
SAE 
SC 
SmPC 
SIR 
SMR 
TEAE 
TB 
TNF 
UC 
ULN 
VTE 
Definition 
pulmonary embolism 
psoriasis 
primary sclerosing cholangitis 
person years 
patient years of exposure 
every 8 weeks 
risk management plan 
relative risk 
serious adverse event 
subcutaneous 
summary of product characteristics 
standardized incidence ratio 
standardized mortality ratio 
treatment-emergent adverse event 
tuberculosis 
tumour necrosis factor 
ulcerative colitis 
upper limit of normal 
venous thromboembolism 
Approved on 28 Mar 2023 GMT
 
Part I: Product(s) Overview  
Table Part I.1. 
Product Overview  
Active substance(s)  
(INN or common name) 
Pharmacotherapeutic group(s) 
(ATC Code) 
Marketing authorisation 
holder  
Medicinal products to which this 
RMP refers 
Invented name(s) in the EEA 
Marketing authorisation 
procedure  
Brief description of the product 
Hyperlink to the Product 
Information 
Indication(s) in the EEA 
Mirikizumab (LY3074828) 
Not available 
Eli Lilly and Company 
1 
Omvoh 
Centralised 
Chemical class: Humanised IgG4 variant monoclonal antibody 
Summary of mode of action: Mirikizumab is a humanised IgG4–variant 
monoclonal antibody that binds to the p19 subunit of IL-23 
Important information about its composition: Mirikizumab is a gene 
recombinant product, and the cell line used to produce mirikizumab was 
derived from host cell line CHO, which was derived from an adult CHO. 
The IV infusion and the SC injection are composed of mirikizumab and the 
inactive ingredients sodium citrate dihydrate, citric acid anhydrous, sodium 
chloride, polysorbate 80, and water for injection. 
The current PI is included in eCTD sequence 1.3.1 
Current: Not applicable  
Proposed: UC 
Dosage in the EEA 
Current: Not applicable 
Proposed: 
The recommended mirikizumab dose regimen has 2 parts: 
 
Induction dosing of 300 mg mirikizumab infused intravenously for at 
least 30 minutes at Weeks 0, 4, and 8. 
  Maintenance dosing of 200 mg mirikizumab injected subcutaneously 
every 4 weeks, starting at Week 12. A full maintenance dose is two 
100 mg pre-filled syringes or two 100 mg pre-filled pens. 
Pharmaceutical form(s) and 
strengths 
Current: Not applicable 
Proposed: The medicinal drug product mirikizumab for IV infusion is 
supplied as a concentrate for solution for infusion in a glass vial and is 
composed of mirikizumab and the inactive ingredients sodium citrate 
dihydrate, citric acid anhydrous, sodium chloride, polysorbate 80, and water 
for injection. Pharmaceutical strength is 300 mg/15 mL (20 mg/mL). 
Approved on 28 Mar 2023 GMT
 
 
 
 
The medicinal drug product mirikizumab for SC injection is supplied as 
100 mg/mL solution in a 1-mL pre-filled syringe and a 1 mL pre-filled pen 
and is composed of mirikizumab and the inactive ingredients sodium citrate 
dihydrate, citric acid anhydrous, sodium chloride, polysorbate 80, and water 
for injection. Pharmaceutical strength is 100 mg/mL. 
Yes 
Is/will the product be subject to 
additional monitoring in the 
EU? 
Abbreviations: ATC = anatomical therapeutic chemical; CHO = Chinese hamster ovary; eCTD = electronic common 
technical document; EEA = European Economic Area; IgG = immunoglobulin G; IL = interleukin; 
INN = International Non-Proprietary Name; IV = intravenous; PI = package insert; RMP = risk management 
plan; SC = subcutaneous; UC = ulcerative colitis. 
Approved on 28 Mar 2023 GMT
Part II: Safety Specification  
Module SI - Epidemiology of the Indication(s) and Target Population(s)  
SI.1 Ulcerative Colitis  
SI.1.1 Incidence  
The incidence of UC worldwide varies by country and/or geographical location and has been 
increasing over time (Benchimol et al. 2011; Benchimol et al. 2014; Ungaro et al. 2017). 
Geographically, the highest IRs of UC have been found in northern Europe while the lowest IRs 
have been reported in Asia and the South America (Ng et al. 2017).  
In the US, from 2000 through 2010, the adjusted annual IR of UC was 12.2 per 100 000 PY and 
it was higher among males (14 cases per 100 000 PY) compared to females (10.7 per 
100 000 PY) (Shivashankar et al. 2017).  
Incidence rates of UC in Europe vary by country. In the UK, reported IRs of UC range from 
14.3 to 23.2 per 100 000 PY (Hamilton et al. 2020; King et al. 2020; Pasvol et al. 2020) and the 
incidence of UC in the UK was found to be higher among males (24.2 per 100 000 PY) 
compared to females (22.1 per 100 000 PY). The incidence of UC was found to be 18.6 per 
100 000 PY in 2013 in Denmark (Lophaven et al. 2017), 20.6 per 100 000 PY in 2017 in Norway 
(Lirhus et al. 2021), and 8.1 per 100 000 PY in 2017 in Spain (Chaparro et al. 2021). 
In Asia and the Middle East, the reported annual IRs of UC range from 0.1 to 6.3 per 
100 000 PY (Ng et al. 2014; Ananthakrishnan et al. 2015; Ungaro et al. 2017).  
SI.1.2 Prevalence  
Similar to the incidence, the prevalence of UC varies by country and or geographical location 
(Molodecky et al. 2012; Ananthakrishnan et al. 2015). Geographically, the highest prevalence of 
UC has been reported in Europe while the lowest has been reported in Asian regions 
(Ng et al. 2017). 
In the US, the point prevalence of UC in 2011 was 286.3 cases per 100 000 persons 
(Shivashankar et al. 2017); it was highest in Whites (89 per 100 000 persons), lowest in Blacks 
(25 per 100 000 persons), 35 per 100 000 persons among Hispanics, and 40 per 100 000 persons 
among Asian Americans (Wang et al. 2013). In Europe, the prevalence of UC varies by country. 
The prevalence of UC was 412/100 000 in an insurance-based cohort study in Germany 
(Hein et al. 2014), 570/100 000 population in 2017 in the UK (King et al. 2020) and 
88.7/100 000 in Spain (Marín-Jiménez et al. 2018). 
Although the lowest prevalence of UC has been found in Asian regions, multiple studies have 
reported increasing prevalence of UC in Asian countries over time. In Hong Kong, the 
prevalence of UC increased from 2.3 to 6.99 per 100 000 over a 9-year period (Lok et al. 2008). 
In Japan the prevalence of UC increased from 7.85 to 63.6 per 100 000 persons between 1984 
and 2005 (Higashi et al. 1988; Asakura et al. 2009), whereas in South Korea, the prevalence of 
Approved on 28 Mar 2023 GMT
UC increased from 0.34 to 76.66 per 100 000 between 1986 and 2015 (Yang et al. 2008; 
Park et al. 2019). 
SI.1.3 Demographics of the Population in the [authorised] 
[proposed] Indication – [age, gender, racial, and/or ethnic origin] 
and Risk Factors for the Disease  
Age 
Generally, the incidence of UC increases gradually from childhood through young adulthood 
with mean age onset between 20 and 40 years (Lophaven et al. 2017; Shivashankar et al. 2017). 
Although some studies have found that the incidence (Keyashian et al. 2019) and prevalence 
(Kappelman et al. 2013) of UC increases with advancing age, most studies have found that the 
association between UC and age shows a bimodal pattern with peaks in both young adults and 
elderly age groups (Shapiro et al. 2016; Lophaven et al. 2017; King et al. 2020). 
Gender 
Associations between gender and the risk for UC vary by country and or study. In the US and 
UK some studies have found females to have a significantly lower risk for UC compared to 
males (Shivashankar et al. 2017; King et al. 2020). However, a population-based retrospective 
cohort study in a western Canadian province found no significant difference in the risk for UC 
between males and females (Osei et al. 2020). In a nationwide population-based cohort study in 
Denmark, the incidence of UC was higher among females compared to males (Lophaven et al. 
2017), whereas in a nationally representative annual survey of the civilian non-institutionalized 
population in the US, the risk of UC was significantly higher among females compared to males 
(OR = 1.81, 95% CI = 1.20-2.72) (Wang et al. 2013). 
Race/ethnicity 
In terms of race, in a nationally representative annual survey of the non-institutionalized civilian 
population in the US conducted between 1996 and 2007, the majority (77%) of adult UC patients 
were found to be White and the prevalence of UC was found to be significantly less among 
Blacks compared to Whites (OR = 0.27; 95% CI = 0.10-0.74) (Wang et al. 2013). Similarly, in 
an electronic health record-based cohort study in the US, both Black adults (OR = 0.41; 95% 
CI = 0.40-0.43) and Hispanic (OR = 0.45; 95% CI = 0.44-0.46) patients were found to be 
significantly less likely to be diagnosed with UC than White adults (Barnes et al. 2021).  
Risk factors  
Although the causes of IBD including UC are poorly understood, family history is one of the 
strongest established risk factors. Moreover, 8% to 14% of patients with UC have a family 
history of IBD with first-degree relatives having 4 times the risk of developing UC (Ungaro et al. 
2017). Genetic risk factors have also been identified in over 200 genetic loci via genome-wide 
association studies (Ungaro et al. 2017). The rising incidence of UC is suggestive of 
environmental risk factors with former smoking established as a major risk factor associated with 
UC (OR = 1.79; 95% CI = 1.37-2.34) (Ungaro et al. 2017). 
Approved on 28 Mar 2023 GMT
SI.1.4 Main Existing Treatment Options  
Commonly used medications for induction of remission of UC include 5-ASA, corticosteroids, 
biologic therapies such as adalimumab, infliximab, golimumab, and vedolizumab, and small 
molecule Janus kinase inhibitors including tofacitinib. Once remission is induced, the same 
medications except corticosteroids can be used to maintain remission, often at a lower dose. An 
administrative claims study of 516 UC patients in Taiwan demonstrated the following 
medication use in the 90 days preceding first UC diagnosis: 5-ASA (25.19%), azathioprine 
(0.19%), and steroids (16.67%) (Keller et al. 2014). In Denmark, a national, clinically based 
cohort of 267 previously naive TNF-inhibitor-treated UC patients reported the following 
medication use: 5-ASA (38.20%), glucocorticoids (49.10%), azathioprine (19.48%), and 
methotrexate (0.75%) (Bank et al. 2015). In the US, biologic use rates increased significantly 
from 2007 to 2016, from 131 per 1000 PY in 2007 (95% CI = 121-140) to 589 per 1000 PY in 
2016 (95% CI = 575-604; p<.001) (Barnes et al. 2020). 
SI.1.5 Natural History of the Indicated Condition in the Population, 
Including Mortality and Morbidity  
Ulcerative colitis is a chronic relapsing and remitting disease characterised by inflammation, 
ulceration, and bleeding in the colon (Sifuentes-Dominguez et al. 2016). Up to 15% of patients 
may present with severe disease (Ungaro et al. 2017). Symptoms at presentation may include 
urgency to defecate, faecal incontinence, fatigue, increased frequency of bowel movements, 
mucus discharge, nocturnal defecations, and abdominal discomfort. The clinical presentation 
varies based on the extent of colonic involvement. Patients with proctitis may present 
predominantly with urgency and tenesmus, whereas in pancolitis, bloody diarrhoea and 
abdominal pain may be more frequent (Ungaro et al. 2017). 
Although the pathogenesis of UC shows similarities in patients affected in childhood and 
adulthood, paediatric patients with UC have demonstrated more extensive disease and more 
severe disease course compared with adult patients with UC (Jakobsen et al. 2011). Clinical 
presentation depends on the site and extent of mucosal inflammation, with the most common 
symptoms in paediatric patients with UC being weight loss, rectal bleeding, diarrhoea, urgency 
to defecate, and abdominal pain (Diefenbach et al. 2006). 
Overall risk of EIMs ranges from 7% to 17% (Fumery et al. 2018), although one-third of UC 
patients may experience EIMs (Ungaro et al. 2017). Articular manifestations are the most 
frequently observed EIMs and include peripheral arthritis (5.5%) and ankylosing spondylitis 
(1%). Specific to spondyloarthropathy, the cumulative incidences over 10, 20, and 30 years after 
UC diagnoses were 5%, 14%, and 22%, respectively. Cutaneous EIMs (1.3%), PSC (0.6%) and 
ocular manifestations (0.6%) have also been observed in UC patients (Fumery et al. 2018). 
Anaemia is a frequent complication among UC patients, with approximately 20% to 24% of UC 
patients anaemic at diagnosis, including 8% with severe anaemia (<10 g/dL). The frequency of 
anaemia appears to decrease over time, however, with only 7% of UC patients experiencing 
anaemia after 10 years of follow-up (Fumery et al. 2018). 
Approved on 28 Mar 2023 GMT
Mortality 
There is no clear association between UC and the overall mortality risk. Studies in certain 
countries have found UC to be associated with increased all-cause mortality risk. In Canada, the 
risk of mortality from all causes was significantly higher among UC patients compared to the 
general population (SMR = 1.21, 95%CI = 1.12-1.32) (Bitton et al. 2016). Additionally, in a 
meta-analysis of studies from various countries on IBD and the risk for mortality, the SMRs for 
all-cause mortality in patients with UC ranged from 0.44 to 7.14 and the all-cause mortality 
summary SMR for UC was found to be significantly higher than the control population 
(SMR = 1.16, 95% CI = 1.04-1.29); however, there was significant heterogeneity among the 
studies (Bewtra et al. 2013).  
Several studies in other countries have found no significant association between UC and the risk 
of mortality from all causes when compared to either non-IBD controls or general population. 
There was no significant difference in the risk for all-cause mortality among UC patients in 
Norway (HR = 1.14, 95% CI = 0.93-1.40) (Hovde et al. 2016), Finland (SMR = 0.90, 95% 
CI = 0.77-1.06) (Manninen et al. 2012) and Australia (SMR = 0.82, 95% CI = 0.68–0.986) 
(Selinger et al. 2013). 
Ulcerative colitis has also been associated with various cause specific mortality risks including 
significantly increased SMRs for gastrointestinal causes (2.81, 2.32-3.34), pulmonary diseases 
(1.24, 1.02-1.46), cardiovascular diseases (1.14, 1.06-1.22), and cancers of the colon (1.90, 1.38-
2.55), rectum (1.79, 1.14-2.69) and biliary tract (5.65, 3.54-8.54) (Jussila et al. 2014). 
SI.1.6 Important Comorbidities  
Psychiatric disorders 
Ulcerative colitis has been associated with various psychiatric disorders including depression, 
anxiety, and suicidality or suicidal ideation.  
Depression 
The prevalence of depression among patients with UC ranges from 11.7% (Ramos-Rodriquez et 
al. 2018) to 32% of patients (Kochar et al. 2018) with an estimated pooled prevalence of 24.0%; 
however, there was significant heterogeneity among the studies (I² = 97.0%) (Barberio et al. 
2021). Studies also show a bidirectional association between UC and depression. Depression has 
been found to be associated with a significantly increased risk of developing UC after controlling 
for demographic and clinical covariates (adjusted HR = 2.23, 95% CI = 1.92-2.60) (Frolkis et al. 
2019). Conversely, several studies have found UC to be associated with a significantly increased 
risk for depression (Bernstein et al. 2019; Choi et al. 2019a; Irving et al. 2021; Tarar et al. 2022). 
One study (Bernstein et al. 2019) found that patients with UC had a significantly higher 
incidence of depression (IRR = 1.43; 95% CI = 1.24-1.64). 
Approved on 28 Mar 2023 GMT
Anxiety 
In a meta-analysis involving 22 studies, the pooled prevalence of anxiety symptoms among 
patients with UC was 34·2% but with significant heterogeneity among the studies (I² = 95·6%) 
(Barberio et al. 2021). UC has also been found to be associated with a significantly increased risk 
for anxiety disorder (IRR = 1.27, 95% CI = 1.11-1.44) (Bernstein et al. 2019). Similarly, another 
study (Choi et al. 2019a) found patients with UC had a significantly increased risk for anxiety 
(HR = 2.06, 95%CI = 1.74-2.44).  
Bipolar disorder 
Ulcerative colitis has been associated with an increased risk for bipolar disorder. In population-
based studies using administrative health data in Canada and Sweden, patients with UC had an 
increased risk for bipolar disorder (IRR = 1.82; 95% CI, 1.33-2.50 and HR = 1.2, 95% 
CI = 1.1-1.4, respectively) (Bernstein et al. 2019; Ludvigsson et al. 2021). 
Suicidality 
Results from 2 large population-based studies (Gradus et al. 2010) and (Jess et al. 2013) from 
Denmark found patients with UC to have a significantly increased risk of completed suicide 
compared to a general population (OR = 1.9, 95% CI = 1.4-2.4, and HR = 1.26, 95% 
CI = 1.08-1.49, respectively). However, a large cohort study in Canada did not report an 
increased risk of completed suicide for patients with UC compared to a general population 
(HR = 0.94, 95% CI 0.42-2.12) (Bernstein et al. 2015).  
Cardiovascular disorders 
Cerebrocardiovascular events 
The IRs for various cerebrovascular events among patients with UC range from 1.98 to 4.56 per 
1000 PY (Huang et al. 2014; Kristensen et al. 2014; Choi et al. 2019b). Specifically, the IRs for 
stroke among UC patients range from 2.23 to 4.45 per 1000 PY (Huang et al. 2014; Kristensen et 
al. 2014; Choi et al. 2019b). Several studies have found UC to be associated with an increased 
risk of stroke (Keller et al. 2014; Xiao et al. 2015; Yuan et al. 2016; Chen et al. 2021). One study 
using health insurance data from Taiwan found UC to be associated with a significantly 
increased risk for stroke (HR = 2.045, 95% CI = 1.374-3.043) compared to control subjects 
(Keller et al. 2014). Similarly, in a nationwide Swedish register-based study, UC was found to be 
associated with a significantly increased risk for both haemorrhagic and ischaemic stroke 
(SIR = 1.37, 95% CI = 1.13-1.66 and SIR = 1.21, 95% CI = 1.21-1.31, respectively) (Zöller et al. 
2012). However, other studies found no significant association between UC and the risk for 
stroke (Dregan et al. 2014; Kristensen et al. 2014; Choi et al. 2019b). For example, there was no 
statistically significant association between UC and the risk for stroke among patients in Korea 
(HR = 1.05; 95% CI, 0.95-1.16) (Choi et al. 2019b) as well as in Denmark (IRR = 1.10, 95% 
CI = 0.99-1.22) (Kristensen et al. 2014). 
Approved on 28 Mar 2023 GMT
Coronary heart disease 
The incidence of CHD was found to be higher among patients with UC (25.3/10 000 PY) 
compared to matched general population controls (17.8/10 000 PY) and patients with UC were 
found to have a significantly increased risk for CHD when compared to the general population 
(IRR = 1.26, 95%CI = 1.05-1.51) (Bernstein et al. 2008). Similarly, another study found patients 
with UC to have a higher risk for CHD compared to individuals without IBD (IRR = 1.22, 95% 
CI = 1.13-1.32) (Rungoe et al. 2013). However, one study found no significant association 
between UC and the risk for CHD (HR = 1.13, 95%CI = 0.95-1.35) (Dregan et al. 2014). 
The IR for MI was found to be higher among patients with UC (3.42/1000 PY) compared to 
matched general population controls in Denmark (1.95/1000 PY) and patients with UC were 
found to have a significantly higher risk for MI compared to the general population (RR = 1.17, 
95% CI = 1.03-1.33) (Kristensen et al. 2013). However, no significant association between UC 
and the risk for MI among patients in Korea (HR = 1.11, 95%CI = 0.99-1.24) (Choi et al. 
2019b). 
Venous thromboembolism 
The incidence of VTE, which includes DVT and PE, among patients with UC ranges from 
11/10 000 PY to 24/10 000 PY (Kappelman et al. 2011; Isene et al. 2014; Vegh et al. 2015) and 
the incidence of VTE among patients with UC (24/10 000 PY) was found to be higher than the 
rate in controls without UC (13/10 000 PY) (Kappelman et al. 2011). In addition, several studies 
have found UC to be associated with a significantly higher risk for VTE after adjustment for 
potential confounders. In one study, UC was found to be associated with a significantly higher 
risk of any VTE (HR = 1.9; 95%CI = 1.8-2.0) as well as unprovoked VTE or VTE occurring in 
the absence of malignancy or recent surgery, fracture or pregnancy (HR = 1.5; 95%CI = 1.4-1.7) 
when compared to controls (Kappelman et al. 2011). Similarly, one study found UC to be 
associated with a significantly higher risk for VTE when compared to controls without UC or 
CD (RR = 1.64, 95%CI = 1.62-1.66) (Saleh et al. 2011) while another found an HR of 1.27 
(95%CI = 1.10-1.45) (Galloway et al. 2020). A metanalysis of these studies indicated a 
significant pooled association between UC and risk for VTE (RR = 2.57; 95%CI = 2.02-3.28). 
However, there was significant heterogeneity between the studies (I2 = 94.6%) (Yuhara et al. 
2013). 
Deep venous thrombosis 
Reported IRs of DVT among patients with UC range from 14/10 000 PY to 30/10 000 PY 
(Bernstein et al. 2001a; Kappelman et al. 2011; Liu et al. 2021) and the incidence of DVT was 
found to be higher among UC patients (14.3/10 000 PY) when compared to controls without UC 
(8.2/10 000 PY) (Kappelman et al. 2011). Several studies have also reported a significant 
association between UC and the risk for any DVT (HR = 1.8; 95% CI = 1.6-2.0 [Kappelman et 
al. 2011], IRR = 2.77; 95% CI = 2.07-3.69 [Bernstein et al. 2001a], and RR = 1.77; 95% 
CI = 1.74-1.80 [Saleh et al. 2011]). In addition, UC has also been associated with an increased 
risk for unprovoked DVT or DVT occurring in the absence of malignancy or recent surgery, 
fracture or pregnancy, HR = 1.5 (95% CI = 1.3-1.7) (Kappelman et al. 2011).  
Approved on 28 Mar 2023 GMT
Pulmonary embolism 
The incidence of PE among patients with UC has been estimated at 5 to 10/10 000 PY 
(Kappelman et al. 2011; Liu et al. 2021) and it was found to be higher among patients with UC 
(10/10 000 PY) compared to non-IBD controls (5/10 000 PY) (Kappelman et al. 2011). 
Ulcerative colitis has also been associated with a significantly higher risk for PE. One study in 
Danish children and adults (Kappelman et al. 2011) found UC to be associated with a 
significantly higher risk for both any PE (HR = 2.0, 95% CI = 1.8-2.2) and unprovoked PE or PE 
occurring in the absence of malignancy or recent surgery, fracture, or pregnancy (HR = 1.6, 
95% CI = 1.4-1.9). Another study (Saleh et al. 2011) also reported a significantly higher risk of 
PE among UC patients (RR = 1.40, 95% CI = 1.37-1.44). 
Malignancy 
Studies examining the association between UC and the overall risk of malignancies have 
produced mixed results. Although some studies have found UC to be associated with a 
significantly increased risk of malignancies overall (Jussila et al. 2013; Burisch et al. 2022), 
other studies found no significant increase (Van den Heuvel et al. 2016; Taborelli et al. 2020). 
Reported IRs of CRC among patients with UC range from 66.4 per 100 000 PY in a population-
based prospective cohort from North Jutland County, Denmark (Jess et al. 2013) to 250 per 
100 000 PY in a prospective French Population-based registry study of patients above 60 years 
of age (Cheddani et al. 2016). Studies examining the association between UC and the risk for 
CRC based on estimates of the SIR have produced mixed results with some reporting an 
increased SIR for CRC (Jussila et al. 2013; Manninen et al. 2013; Hovde et al. 2017) while 
others found no significantly increased SIR (Jess et al 2013; So et al. 2017; Taborelli et al. 2020). 
However, the incidence of CRC was found to be consistently significantly higher among UC 
patients when compared to non-IBD controls (Herrinton et al. 2012; King et al. 2020; Olén et al. 
2020). The incidence of CRC among UC patients (135.3/100 000 PY) in the UK was found to be 
significantly higher compared to the rate (94.9/100 000 PY) in non-IBD controls (HR = 1.40, 
95% CI = 1.23-1.59). Similar findings were reported in the US (IRR = 1.6, 95% CI = 1.3-2.0) 
(Herrinton et al. 2012), Denmark (HR = 1.30, 95% CI = 1.17-1.45) (Olén et al. 2020), Sweden 
(HR = 1.87, 95% CI = 1.75-2.00), and both Sweden and Denmark combined (HR = 1.66, 95% 
CI = 1.57-1.76). A meta-analysis of 116 studies estimated the overall prevalence of CRC in any 
patient with UC was 3.7% (95% CI = 3.2-4.2%) (Eaden et al. 2001). Risk factors for CRC 
among patients with UC include younger age of UC onset, increasing age, disease severity and 
duration, pan sclerosing cholangitis and genetics or family history of CRC (Lakatos et al. 2006; 
Olén et al. 2020).  
Patients with UC have also been found to have increased risk for various extra intestinal 
malignancies including non-melanoma skin cancer (Burisch et al. 2022), melanoma (Hovde et al. 
2017; Burisch et al. 2022), pancreatic cancer (Burisch et al. 2022), thyroid cancer (Hovde et al. 
2017; Burisch et al. 2022), and lymphoma. The risk of lymphoma among UC patients has been 
found to be particularly higher during thiopurine therapy (Long et al. 2012; Khan et al. 2013; 
Singh et al. 2014b; Hagen et al. 2018). A 4-fold increased risk of lymphoma was found among 
Approved on 28 Mar 2023 GMT
UC patients during treatment with thiopurines when compared to patients not treated with 
thiopurines (HR = 4.2, 95% CI = 2.5-6.8) but the risk was no longer increased after patients 
discontinued thiopurine therapy (HR = 0.5, 95% CI = 0.2-1.3) (Khan et al. 2013). 
Hepatobiliary disorders 
Ulcerative colitis has been associated with various hepatobiliary disorders including transient 
elevations of liver enzymes with no known cause and persistent elevations most commonly due 
to PSC, AIH, cholelithiasis, and NAFLD (Gizard et al. 2014).  
Elevated liver enzymes 
In a retrospective case series analysis of 141 patients with UC, an increase in serum 
aminotransferases (ALT, AST, ALP, GGT, or total bilirubin) was detected in 19.9% of the 
patients with UC (Cappello et al. 2014). In a case control study that included 317 patients with 
UC, the estimated prevalence of elevated ALT, GGT, and ALP ≥2xULN were 5.7%, 5.7%, and 
3.8%, respectively (Riegler et al. 1998), whereas in a case series study of 534 patients with UC, 
the prevalence rates of elevated ALP and ALT levels >2xULN based on the highest recorded 
value during follow-up were 6% and 10%, respectively (Aitola et al. 1994). In a population-
based cohort study that used UK biobank data, patients with UC were found to have a 
significantly higher risk for elevated ALT ≥2xULN (OR = 1.86, 95% CI = 1.21-2.87), GGT 
≥2xULN (OR = 1.47, 95% CI = 1.30-1.66), GGT ≥5xULN (OR = 1.89, 95% CI = 1.21-2.94), 
and ALP ≥2xULN (OR = 4.22, 95% CI = 2.81-6.36) compared to controls (Voss et al. 2021). 
Primary sclerosing cholangitis 
The incidence of PSC among patients with UC was estimated at 8.4 per 10 000 PY and it was 
found to be higher than the rate (1.2 per 10 000 PY) in controls (Burisch et al. 2019). The 
estimated prevalence of PSC among patients with UC ranges from 0.76% to 5.4% (Gizard et al. 
2014) and approximately 70% of patients with PSC have associated IBD, predominantly (>75%) 
UC (De Vries et al. 2015). In addition, UC has been associated with a significantly increased risk 
for PSC overall (IRR = 6.85, 95% CI = 4.27-10.97) (Burisch et al 2019) and in both men 
(OR = 30.3, 95% CI = 11.0-83.0) and women (OR = 9.5, 95% CI = 2.7-32) separately, when 
compared to the general population (Bernstein et al. 2001b). 
Autoimmune hepatitis 
In a cross-sectional study of 31 066 patients with UC matched to 60 951 controls in the Danish 
National Patient Registries, the prevalence of AIH was higher among patients with UC (0.31%) 
compared to the controls (0.04%) and UC was found to be associated with a significantly 
increased risk for AIH (OR = 8.6, 95% CI = 5.4-13.6) (Halling et al. 2017). Similarly, in a 
retrospective analysis of a large population-based, commercial electronic health record database 
in the US, the risk for AIH was found to be significantly higher among patients with UC 
compared to controls (OR = 10.50, 95% CI = 9.55-11.55) (Tunio et al. 2021). 
Approved on 28 Mar 2023 GMT
Cholelithiasis 
The incidence of cholelithiasis has been found to be higher among patients with UC (0.75/100 
PY) compared to matched controls (0.61/100 PY) (Parente et al. 2007). Estimates of the 
prevalence of cholelithiasis among patients with UC range from 4.6% to 36.4% (Gizard et al. 
2014) and in a population-based cohort study that used the UK biobank data, the prevalence of 
cholelithiasis among patients with UC (5.9%) was significantly higher than the prevalence in the 
controls (3.9%) (p<.001). Ulcerative colitis has also been associated with a significantly 
increased risk for cholelithiasis after adjustment for potential confounders (OR = 1.57, 
95% CI = 1.37-1.81) (Voss et al. 2021). 
Non-alcoholic fatty liver disease 
The prevalence of NAFLD among patients with UC ranges from 1.5% to 55% with an estimated 
mean prevalence of 23% (Gizard et al. 2014). In addition, UC was found to be associated with 
more than a 4-fold increased risk for mild steatosis (OR = 4.80, 95% CI = 1.64-14.04) and 7-fold 
increased risk for moderate to severe steatosis (OR = 7.49, 95% CI = 2.36-23.76), and this 
association was independent from other risk factors such as glucose and body mass index 
(Mancina et al. 2020). 
Other autoimmune diseases 
In addition to PSC and AIH, there is a recognized increased incidence of other autoimmune 
conditions in patients with UC. In particular, patients with UC had approximately a 2- to 2.5-fold 
increased risk of systemic rheumatoid connective tissue disorders such as rheumatoid arthritis, 
fibromyalgia, ankylosing spondylitis, systemic lupus erythematosus; endocrine disorders such as 
diabetes type I, Addison disease, Graves’ disease, Hashimoto thyroiditis, and other digestive 
conditions including celiac disease and pernicious anaemia compared to controls (Wilson et al. 
2016). Women are particularly at increased risk of developing additional autoimmune diseases. 
The prevalence of comorbid autoimmune conditions among UC patients varies across studies. A 
review of IBD patients from a clinic in Switzerland identified the prevalence of following 
various autoimmune conditions among UC patients: arthritis (21%), ankylosing spondylitis (2%), 
pyoderma gangrenosum (2%), erythema nodosum (3%), and Ps (1%) (Vavricka et al. 2011). 
Another study of IBD patients in Greece identified the prevalence of following various 
autoimmune conditions among patients with UC: arthritis (14.7%), ankylosing spondylitis 
(0.6%), erythema nodosum (2.8%), pyoderma gangrenosum (0.9%), and Ps (2.1%) (Karmiris et 
al. 2016). 
Approved on 28 Mar 2023 GMT
 
 
Module SII – Non-clinical Part of the Safety Specification  
SII.1 Toxicity  
Key Issues Identified from Repeat-Dose Toxicity Studies 
To assess the toxicity of mirikizumab and establish a margin of safety for clinical trials, a 4-week 
toxicity study and two 6-month toxicity studies in normal cynomolgus monkeys were conducted. 
The second 6-month study was conducted at higher doses compared to the prior studies, to 
achieve higher systemic exposures. Safety pharmacology was evaluated as part of the 4-week 
study, and fertility was evaluated as part of the first 6-month study. The potential for effects on 
fertility was evaluated in sexually mature monkeys in the first 6-month study. The potential for 
effects on the developing foetus and on post-natal development was assessed in an ePPND study. 
The monkey is a pharmacologically relevant species for assessing non-clinical toxicity because 
mirikizumab binds with similar affinity to human and cynomolgus monkey IL-23 (21 pM and 
55 pM, respectively). 
The administration of mirikizumab to cynomolgus monkeys resulted in no adverse 
mirikizumab-related findings at weekly doses of 1 and 30 mg/kg SC, or 100 mg/kg IV for 4 
weeks (with an 8-week recovery period), or at weekly doses of 10 and 100 mg/kg SC for 6 
months. Therefore, the NOAEL was 100 mg/kg per week IV for the 4-week study and 100 
mg/kg per week SC for the first 6-month study. 
In the second, high-dose 6-month monkey study, the administration of mirikizumab twice 
weekly at doses of 100 mg/kg IV or 300 mg/kg IV (i.e., 200 or 600 mg/kg per week) resulted in 
no adverse findings considered related to neutralization of IL-23. However, at the end of the 6-
month dosing period, 1 monkey in the 600 mg/kg per week dose group had clinical laboratory 
and anatomic pathology findings without clinical signs that were indicative of an off-target 
idiosyncratic (i.e., low-incidence, non-dose responsive) immune-mediated haemolytic effect of 
mirikizumab administration. Therefore, in the second 6-month study, the NOAEL was 
200 mg/kg per week IV. Off-target, immune-mediated safety findings in monkeys are generally 
not considered predictive of similar events in humans. 
Reproductive Toxicity 
The mirikizumab fertility assessment was conducted in the first 6-month repeat-dose toxicity 
study through the evaluation of reproductive organ weight and histopathology in sexually mature 
monkeys. No drug-related effects were observed in reproductive organ weights or in the 
histopathology of reproductive tissues from male or female monkeys after the 6-month treatment 
period. 
The impact of mirikizumab on embryo-foetal development, pregnancy outcome, and peri- and 
post-natal development, was assessed in an ePPND study in monkeys. Pregnant monkeys were 
administered mirikizumab at 300 mg/kg per dose twice weekly (i.e., 600 mg/kg per week) from 
gestation day 21 ± 1 until parturition. The infants were evaluated for up to 6 months following 
birth. There were no mirikizumab-related adverse effects (maternal, foetal, or infant).  
Approved on 28 Mar 2023 GMT
SII.2 Safety Pharmacology  
A safety pharmacology assessment performed during the 4-week monkey study included 
evaluation of cardiovascular safety, neurological safety, and specific vital signs. No drug-related 
changes occurred in any of these parameters.  
SII.3 Other Toxicity-Related Information or Data  
Local tolerance 
No adverse drug-related effects at IV or SC injection sites were observed in cynomolgus 
monkeys receiving mirikizumab. 
Tissue cross-reactivity 
No specific staining was observed in a full panel of tissues from normal human or monkey 
donors. 
Carcinogenicity 
Animal studies to assess the carcinogenic potential of mirikizumab have not been conducted. In 
accordance with ICH S1A and S6(R1) guidance (ICH 1995, 2011), Lilly has concluded that 
mirikizumab presents a low cancer risk to human patients based on: 
  an assessment of published literature, which supports that neutralisation of IL-23 would 
not be expected to increase cancer risk, 
  high selectivity against IL-23, with no off-target toxicity observed in toxicology studies, 
  no evidence of increased cellular proliferation (hyperplasia or pre-neoplastic lesions) in 
toxicology studies, and 
  no evidence of effects on cells or organ systems responsible for facets of tumour 
immunosurveillance (circulating lymphocytes, natural killer cell function, primary 
immune response, and lymphoid organ histopathology) in toxicology studies. 
Conclusion 
Based on the lack of toxicity at exposures exceeding the highest anticipated clinical exposures 
and lack of tissue cross-reactivity, the non-clinical safety profile of mirikizumab supports 
registration and continued clinical investigation. Mirikizumab resulted in no AEs in monkeys 
when administered once weekly (IV) for 4 weeks, once weekly (SC) for 6 months, or twice 
weekly (IV) for 6 months at doses of up to 100 mg/kg. Exposures associated with these dose 
levels provide margins of safety of up to 30-fold based on the induction dose of 300 mg IV and 
up to 100-fold at the maintenance dose of 200 mg SC for the UC indication. 
Approved on 28 Mar 2023 GMT
 
 
 
 
Module SIII - Clinical Trial Exposure  
Table SIII.1. 
Duration of Exposure  
In this RMP, the safety of mirikizumab is evaluated in 2 integrated datasets: 
  All Mirikizumab Exposures Integrated Analysis Set, comprised of all clinical trial data in 
patients with UC, CD, and Ps treated with mirikizumab in completed and ongoing 
unblinded Phase 2 and 3 studies, and 
  UC Mirikizumab Exposures Integrated Analysis Set, comprised of all clinical trial data in 
patients with UC treated with mirikizumab in completed and ongoing unblinded studies. 
Duration of exposure 
All Mirikizumab Exposures Integrated Analysis Set 
>0 week to < 4weeks  
≥4 weeks to <8 weeks 
≥8 weeks to <12 weeks 
≥12 weeks to <16 weeks 
≥16 weeks to <24 weeks 
≥24 weeks to <32 weeks 
≥32 weeks to <52 weeks 
≥52 weeks to <104 weeks 
≥104 weeks 
Total patient year 
UC Mirikizumab Exposures Integrated Analysis Set 
Duration of exposure 
>0 week to < 4weeks 
≥4 weeks to <8 weeks 
≥8 weeks to <12 weeks 
≥12 weeks to <16 weeks 
≥16 weeks to <24 weeks 
≥24 weeks to <32 weeks 
≥32 weeks to <52 weeks 
≥52 weeks to <104 weeks 
≥104 weeks  
Total patient year for UC 
Patients 
35 
35 
55 
131 
111 
233 
173 
964 
2061 
7801.3 
Patients 
10 
22 
34 
118 
50 
186 
96 
476 
450 
2250.9 
Abbreviations: miri = mirikizumab; UC = ulcerative colitis. 
Source: /lillyce/prd/ly3074828/regulatory/subm_uc/output/shared/tfl/t_ex_expo_amiri_allm.rtf 
Approved on 28 Mar 2023 GMT
 
 
 
Table SIII.2. 
Age Group and Gender  
All Mirikizumab Exposures Integrated Analysis Set 
Age group 
Patients 
Adults (<65 years) 
Elderly people 
65-74 years 
75-84 years 
≥85 years 
Total 
UC Mirikizumab Exposures Integrated Analysis Set  
Age group 
Adults (<65 years) 
Elderly people 
65-74 years 
75-84 years 
≥85 years 
Total 
M 
2272 
210 
191 
19 
0 
2482 
812 
60 
55 
5 
0 
872 
F 
1199 
117 
98 
19 
0 
1316 
Patient year 
F 
M 
2364.7 
4793.4 
234.9 
408.4 
197.5 
380.1 
37.4 
28.2 
0 
0 
2599.6 
5201.7 
Patients 
Patient year 
523 
47 
41 
6 
0 
570 
1272.6 
77.6 
73.2 
4.4 
0 
1350.2 
829.2 
71.5 
63.3 
8.2 
0 
900.7 
Abbreviations: miri = mirikizumab; UC = ulcerative colitis. 
Source: /lillyce/prd/ly3074828/regulatory/subm_uc/output/shared/tfl/ad_t_ex_expo_byagesex_amiri_allm.rtf 
Approved on 28 Mar 2023 GMT
 
 
 
Table SIII.3. 
Dose  
Dose of exposure 
All Mirikizumab Exposures Integrated Analysis Set 
30 miri PRN SC 
30 miri Q8W SC 
50 miri Q4W IV 
100 miri PRN SC 
100 miri Q8W SC 
125 miri Q8W SC 
200 miri Q12W SC 
200 miri Q4W IV 
200 miri Q4W SC 
250 miri Q8W SC 
250 miri Q4W SC 
300 miri PRN SC 
300 miri Q8W SC 
300 miri Q4W IV 
300 miri Q4W SC 
600 miri Q4W IV 
1000 miri Q4W IV 
Total 
UC Mirikizumab Exposures Integrated Analysis Set 
Dose of exposure 
50 miri Q4W IV 
200 miri Q12W SC 
200 miri Q4W IV 
200 miri Q4W SC 
300 miri Q4W IV 
600 miri Q4W IV 
1000 miri Q4W IV 
Total 
Patients 
Patient year 
15 
51 
63 
30 
51 
559 
46 
93 
1061 
1736 
1572 
34 
165 
1135 
141 
118 
237 
3798 
Patients 
63 
46 
62 
1061 
1135 
86 
96 
1442 
21 
15.4 
15.0 
40.9 
15.7 
1111.7 
65.8 
28.2 
1734.7 
3130.3 
507.0 
52.0 
213.2 
377.3 
325.1 
35.2 
112.8 
7801.3 
Patient year 
15.0 
65.8 
14.8 
1734.7 
377.3 
21.7 
21.6 
2250.9 
Abbreviations: IV = intravenous; miri = mirikizumab; PRN = as needed; Q4W = every 4 weeks; Q8W = every 8 
weeks; SC = subcutaneous; UC = ulcerative colitis. 
Source: /lillyce/prd/ly3074828/regulatory/subm_uc/output/shared/tfl/ad_t_ex_expo_bytrtdos_amiri_allm.rtf. 
Approved on 28 Mar 2023 GMT
 
 
Table SIII.4. 
Ethnic Origin  
Ethnic origin 
All Mirikizumab Exposures Integrated Analysis Set 
American Indian or Alaska Native 
Asian 
Black or African American 
Native Hawaiian or other Pacific Islander 
White 
Multiple 
Missing 
Total 
Ethnic origin 
UC Mirikizumab Exposures Integrated Analysis Set 
American Indian or Alaska Native 
Asian 
Black or African American 
Native Hawaiian or other Pacific Islander 
White 
Multiple 
Missing 
Total 
Patients 
Patient year 
78 
757 
69 
5 
2868 
10 
11 
3798 
11 
304 
19 
1 
1094 
3 
10 
1442 
171.6 
1471.1 
155.5 
9.3 
5965.0 
19.6 
9.2 
7801.3 
10.1 
418.0 
36.4 
2.3 
1773.8 
2.1 
8.2 
2250.9 
Abbreviations: miri = Mirikizumab; UC = ulcerative colitis. 
Source: /lillyce/prd/ly3074828/regulatory/subm_uc/output/shared/tfl/ad_t_ex_expo_byrace_amiri_allm.rtf 
Approved on 28 Mar 2023 GMT
 
 
 
 
Module SIV - Populations Not Studied in Clinical Trials  
SIV.1 Exclusion Criteria in Pivotal Clinical Studies within the Development 
Programme  
Criteria: Patients below 18 years of age 
Reason for exclusion: The safety and efficacy for patients below 18 years of age have not been 
established. To establish the efficacy and safety of this molecule, Phase 3 clinical trials were 
conducted first in adults. Phase 2 trials in patients 2 to below 18 years of age are currently 
ongoing and Phase 3 studies in this paediatric age group are planned. 
Is it considered to be included as missing information?: No 
Rationale: Section 8.4 of the prescribing information will clearly state that the safety and 
efficacy of mirikizumab in children and adolescents of 2 to below 18 years of age have not yet 
been established. Additionally, approved, alternative therapeutic options are available for the 
treatment of UC in paediatric patients. It was agreed with Regulatory Agencies (US and EU) to 
start paediatric development once a positive risk-benefit in adults has been established. Phase 2 
trials in this population are currently ongoing. 
Criteria: Women who are pregnant or lactating 
Reason for exclusion: This is a standard exclusion criterion in clinical development. Although 
there were no adverse effects on the embryos, foetuses, and offspring demonstrated in 
non-clinical studies using pregnant monkeys, insufficient information on the effects of 
mirikizumab on maternal health or the foetus prohibited the inclusion of pregnant women in the 
development programme. Women of childbearing potential are expected to comprise a 
significant proportion of the target UC population. There were 28 pregnancies from maternal 
exposure and 41 pregnancies from paternal exposure reported during the clinical development 
programme. 
Is it considered to be included as missing information? Yes 
Rationale: Not applicable 
Criteria: Serious infection, herpes zoster infection (current or past), TB, positive test for 
HBV or HCV 
Reason for exclusion: These criteria excluded individuals with previous or concomitant serious 
infections that may have increased the risk for safety observations if allowed participation in the 
study based on theoretical concerns and to minimise confounding factors in data interpretation. 
Is it considered to be included as missing information? No 
Approved on 28 Mar 2023 GMT
 
 
Rationale: While there are insufficient data on the safety of mirikizumab in the above-
mentioned subpopulations, per international guidelines on good clinical practices, these patients 
should not initiate treatment with immunosuppressive/immunomodulatory agents. The 
prevalence of these conditions in the target population is anticipated to be low. However, in line 
with the SmPC special warnings and precautions for use, treatment with mirikizumab should not 
be initiated in patients with any clinically important active infection until the infection resolves 
or is adequately treated. A contraindication in Section 4.3 instructs that patients with clinically 
important active infections (active TB) should not take mirikizumab. The risks and benefits of 
treatment prior to initiating the use of mirikizumab in patients with a chronic infection or a 
history of recurrent infection should be considered. Patients should be instructed to seek medical 
advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious 
infection develops, discontinuation of mirikizumab should be considered until the infection 
resolves.  
Patients with current or recent serious infection, current herpes zoster or history, positive HBV or 
HCV, and active TB were excluded from the studies. However, infectious events occurred during 
the clinical programme, and clinical data are now available to provide the basis of label 
recommendations as described in the SmPC and local labels. 
Criteria: Exposure to or receipt of a live vaccine  
Reason for exclusion: While there are insufficient data on the safety of mirikizumab in patients 
receiving live vaccines, per international guidelines on good clinical practices, those patients 
should not initiate treatment with immunosuppressive/immunomodulatory agents due to the 
potential impact those agents may have on the development of protective antibody responses to 
the vaccine, increasing the risk for infective complications. In line with the SmPC special 
warnings and precautions for use, the use of live vaccines in patients treated with mirikizumab 
should be avoided. No data are available on the response to live or non-live vaccines.  
Is it considered to be included as missing information? No 
Rationale: Live vaccines were not studied in patients receiving mirikizumab, and concomitant 
administration is not recommended. In line with the SmPC, local labelling will advise that live 
vaccines should not be administered concurrent with receiving mirikizumab. 
SIV.2 Limitations to Detect Adverse Reactions in Clinical Trial Development 
Programmes  
The clinical development programme is unlikely to detect certain types of adverse reactions, 
such as rare adverse reactions or adverse reactions with a long latency.  
Approved on 28 Mar 2023 GMT
SIV.3 Limitations in Respect to Populations Typically Under-represented in 
Clinical Trial Development Programmes  
Table SIV.1. 
Exposure of Special Populations Included or Not in Clinical Trial 
Development Programmes  
Type of special population  
Exposure 
Pregnant women 
Breastfeeding women 
Patients with relevant comorbidities:  
Patients with hepatic impairment 
Patients with renal impairment 
Patients with cardiovascular impairment  
Immunocompromised patients  
Patients with a disease severity different from 
inclusion criteria in clinical trials 
Population with relevant different ethnic and racial 
origin 
Subpopulations carrying relevant genetic 
polymorphisms 
Pregnancy was an exclusion criterion in the clinical 
development programme  
Not included in the clinical development programme 
Mirikizumab has not been specifically studied in 
patients with renal, hepatic or cardiovascular 
impairment. 
Immunocompromised patients were excluded from 
mirikizumab clinical trials 
The clinical development programme included patients 
with moderately to severely active UC. Patients with 
mild disease were not specifically studied.  
Mirikizumab Phase 3 clinical trials enrolled patients 
globally. Patients of non-White origin were included in 
the clinical trials.  
Of the treated population, 18.4% were Hispanic or 
Latino, 80.9% were non-Hispanic/non-Latino, and 
ethnicity data were missing for 0.7%; 75.5% were white 
or Caucasian, 19.9% were Asian, 2.1% were American 
Indian or Alaskan natives, 1.8% were Black or African  
American, 0.3% reported multiple races, and 0.1% were 
native Hawaiians or Pacific Islanders. Race data were 
missing for 0.3%.  
Although there were few Black or African American 
participants in the mirikizumab studies, the distribution 
of patients of different racial origins is generally 
reflective of the anticipated target population. There 
have been no significant differences in tolerability, 
safety, and efficacy profiles with regard to racial and/or 
ethnic origin observed with mirikizumab treatment in 
clinical studies. 
Not applicable. Patient-level genetic polymorphisms 
were not specifically studied in the clinical development 
programme. 
Approved on 28 Mar 2023 GMT
 
 
 
 
 
 
 
Type of special population  
Exposure 
Elderly  
Other 
Mirikizumab clinical trials enrolled patients 85 years 
and younger in age, including 7.6% were 65 to 74 years, 
and 1.0% were 75 to 84 years. Patients older than 85 
years of age were not included in mirikizumab clinical 
trials.  
The available data do not suggest meaningful difference 
in safety between age categories to warrant 
considerations based on age. 
Not applicable 
Approved on 28 Mar 2023 GMT
 
 
 
 
 
Module SV - Post-Authorisation Experience  
SV.1 Post-Authorisation Exposure  
Mirikizumab has not yet obtained marketing authorisation. Therefore, no post-authorisation 
exposure data are available yet.  
SV.1.1 Method Used to Calculate Exposure  
Not applicable. 
SV.1.2 Exposure  
Not applicable. 
Approved on 28 Mar 2023 GMT
 
 
Module SVI - Additional EU Requirements for the Safety Specification  
SVI.1 - Potential for Misuse for Illegal Purposes  
The potential for misuse for illegal purposes is not anticipated based on the mechanism of action, 
lack of adverse reactions associated with mood or mind alterations, and no findings that 
mirikizumab causes physical or mental dependency. Furthermore, mirikizumab induction 
therapy as IV infusion is administered in the health care setting and, therefore, a potential for 
misuse for illegal purposes is not anticipated. Based on pack sizes, which vary by geography, the 
potential for misuse for illegal purpose is additionally minimised. 
Approved on 28 Mar 2023 GMT
 
 
Module SVII - Identified and Potential Risks  
SVII.1 Identification of Safety Concerns in the Initial RMP Submission  
SVII.1.1 Risks Not Considered Important for Inclusion in the List of 
Safety Concerns in the RMP  
Risks with minimal clinical impact on patients (in relation to the severity of the indication 
treated): None. 
Adverse reactions with clinical consequences, even serious, but occurring with a low frequency 
and considered to be acceptable in relation to the severity of the indication treated: None. 
Known risks that require no further characterisation and are followed up via routine 
pharmacovigilance, namely through signal detection and adverse reaction reporting, and for 
which the risk minimisation messages in the product information are adhered by prescribers: 
  Upper respiratory tract infections: Upper respiratory tract infections have been reported 
commonly and require no further characterisation beyond routine pharmacovigilance 
activities and product labelling. 
Injection site reactions: Injection site reactions have been reported commonly and require 
no further characterisation beyond routine pharmacovigilance activities and product 
labelling. 
 
  Rash: Rash has been reported commonly and require no further characterisation beyond 
routine pharmacovigilance activities and product labelling. 
  Headache: Headache has been reported commonly and requires no further 
characterisation beyond routine pharmacovigilance activities and product labelling. 
  Arthralgia: Arthralgia has been reported commonly and requires no further 
 
characterisation beyond routine pharmacovigilance activities and product labelling. 
  Herpes zoster: Herpes zoster has been reported uncommonly and requires no further 
characterisation beyond routine pharmacovigilance activities and product labelling. 
Infusion-related hypersensitivity reaction: Infusion-related reactions have been reported 
uncommonly and require no further characterisation beyond routine pharmacovigilance 
activities and product labelling. 
Infusion site reaction: Infusion site reaction has been reported uncommonly and requires 
no further characterisation beyond routine pharmacovigilance activities and product 
labelling. 
 
Known risks that do not impact the risk-benefit profile: None. 
Other reasons for considering the risks not important: None. 
Approved on 28 Mar 2023 GMT
SVII.1.2 Risks Considered Important for Inclusion in the List of 
Safety Concerns in the RMP  
Important Identified Risks: None 
Important Potential Risk 1: Serious Infections 
Risk-benefit impact: 
Although there was no imbalance for infections in patients treated with mirikizumab compared 
to placebo across the datasets, exposure is limited to the clinical trial population. Patients with 
active, chronic, recurring, and/or opportunistic infections were excluded from the mirikizumab 
clinical trials, and the potential for the development of serious recurrent or reactivated infections 
in a larger population or with longer exposures to mirikizumab is unknown at this time.  
In patients with UC in the Phase 2 and Phase 3 studies, serious infections were reported 
commonly during treatment with mirikizumab. Of the 33 serious infections, the most frequently 
reported were pneumonia (15.2%) and appendicitis (12.1%), and none was a reactivated 
infection.  When including time off mirikizumab and the post-treatment follow-up time, serious 
infections were also reported commonly. Although the majority of patients recovered, serious 
infections due to COVID-19/coronavirus infection or sequelae of COVID-19 infection resulted 
in the deaths of 1 patient while receiving mirikizumab and 2 patients while off mirikizumab. One 
patient with UC discontinued mirikizumab due to a serious infection of pneumonia and 
recovered without an adverse clinical outcome.  
Across all mirikizumab exposures in Phase 2 and Phase 3 clinical trials for UC, CD, and Ps, 
serious infections were reported commonly during treatment with mirikizumab. When including 
time off mirikizumab and the post-treatment follow-up time, serious infections were also 
reported commonly. Although the majority of patients recovered, serious infections due to 
COVID-19/coronavirus infection or sequelae of COVID-19 infection resulted in the deaths of 7 
patients, 5 while receiving mirikizumab (1 patient with UC as described above and 4 patients 
with Ps) and 2 while off mirikizumab (both patients with UC, as described above). Ten patients 
in this dataset discontinued mirikizumab due to their serious infection, including the 5 patients 
who died as previously described and 5 who recovered or were recovering without adverse 
clinical outcomes.  
Important Potential Risk 2: Severe Liver Injury 
Risk-benefit impact: 
In patients with UC in the Phase 2 and Phase 3 studies, severe hepatic AEs were reported 
uncommonly (n = 3, 0.2%), none of which were reported as an SAE. One patient with UC met 
Hy’s law criteria with a maximum ALT ≥3xULN and maximum total bilirubin ≥2xULN and no 
Approved on 28 Mar 2023 GMT
 
 
 
alternative aetiology for the elevations based on the reported information. Taking into 
consideration the available information, this case was assessed as a probable DILI. Three 
patients with UC discontinued mirikizumab due to a hepatic TEAE, AIH (n = 1, 0.1%) and 
hepatic enzyme increased (n = 2, 0.1%), which resolved or were resolving without adverse 
clinical outcomes. 
Across all mirikizumab exposures in Phase 2 and Phase 3 clinical trials for UC, CD, and Ps, 
severe hepatic AEs were reported uncommonly (n = 18, 0.5%), 2 of which were also reported as 
SAEs. Fourteen patients across the clinical development programme discontinued mirikizumab 
due to a treatment-emergent hepatic event. Of these, 13 discontinued due to increased or 
abnormal liver function tests/enzymes (n = 12) and increased ALP (n = 1), which resolved 
without adverse clinical outcomes. Confounding factors for the patients who discontinued 
mirikizumab due to a treatment emergent hepatic event include concomitant medications with 
known adverse effects on the liver, past and current alcohol use, and medical conditions, 
including sclerosing cholangitis, alcoholic liver disease, hepatitis A, hepatitis D, hepatitis E, 
hyperbilirubinemia, NAFLD, latent TB, increased AST, TB, and unspecific abnormal hepatic 
function and liver disorder.  
Hepatic enzyme elevations, specifically ALT and AST, are uncommon ADRs for mirikizumab 
based on numeric differences in patients with elevated ALT ≥5xULN treated with mirikizumab 
compared to placebo (0.8% and 0%, respectively, in Study AMBG) and AST ≥5xULN treated 
with mirikizumab compared to placebo (0.2% and 0%, respectively, in Study AMAN and 0.8% 
and 0%, respectively, in Study AMBG). 
Important Potential Risk 3: Malignancies 
Risk-benefit impact: 
Some studies have found that UC is associated with an increased risk of cancer relative to the 
general population (Karlén et al. 1999; Jussila et al. 2013; Jung et al. 2017; Burisch et al. 2022). 
As such, the observed rate of malignancies seen in the mirikizumab-treated population in the 
clinical development program is considered to reflect the presence of this co-morbidity in the 
target population rather than a potential effect of the drug. In the UC clinical development 
programme, the IRs for malignancies overall and specifically for cancer of the rectum, colon 
cancer, prostate cancer, and NMSC were consistent with the reported background IRs in the UC 
population. 
Current clinical and non-clinical data do not suggest a causal association between mirikizumab 
and malignant tumours. Malignancy events are events of long latency and thus, the potential for 
development with longer exposures to mirikizumab is unknow at this time with limited duration 
of exposure. However, the benefits of mirikizumab to patients with moderately to severely active 
UC are believed to outweigh any potential risk of malignancy. 
Approved on 28 Mar 2023 GMT
 
 
 
Important Potential Risk 4: MACE 
Risk-benefit impact:  
Cardiovascular disorders are known, important co-morbidities in the UC population. Based on 
cumulative data across the mirikizumab clinical development program, the IR of MACE 
(IR=0.2) is below the range of the background IR in the UC population (1.1 IR), and moderate-
to-severe Ps population (0.4 to 1.5 IR) and within rates for other IL-23p19 inhibitors (IR=0.2 to 
0.6) approved for the treatment of Ps. Current clinical and non-clinical data do not suggest a 
causal association between mirikizumab and MACE. MACE are rare events. Thus, the potential 
for development with larger and longer exposures to mirikizumab is unknown at this time with 
limited duration of exposure. However, the benefits of mirikizumab to patients with moderately 
to severely active UC are believed to outweigh the potential risk of MACE. 
Missing information 1: Safety of mirikizumab in pregnant women and lactating women. 
Risk-benefit impact: 
The current data are too limited to draw conclusions about the effect of mirikizumab exposure 
during pregnancy in humans, and no data are available to assess the safety of mirikizumab in 
lactating women. 
No adverse effects were noted on reproductive organs or tissues in young adult or sexually 
mature male or female monkeys at any dose tested in all studies. In ePPND study in monkeys, 
there were no mirikizumab-related adverse effects (maternal, foetal, or infant) at the dose level 
tested. 
Pregnant women were excluded from entering mirikizumab clinical studies. Women of 
childbearing potential agreed to comply with protocol-specified contraceptive requirements, and 
male participants were not required to use contraception. Pregnancy occurring in female clinical 
trial participants was a criterion for permanent discontinuation of mirikizumab in all studies, and 
pregnant participants and partner pregnancies who consented are followed to pregnancy 
completion. 
Approved on 28 Mar 2023 GMT
 
Across all indications, there are limited safety data on the use of mirikizumab in pregnant women 
treated with mirikizumab. To date, of the 1316 females exposed to mirikizumab, 28 have become 
pregnant, and the outcomes of these pregnancies are provided below: 
Outcome 
Normal outcome 
Elective abortiona 
Spontaneous abortion 
Unknown as lost to follow-upb 
Still in utero at data cutoff 
Premature birth 
No. of Events 
(n) 
7 
6 
3 
4 
7 
1 
Percent (%) of Total Female Exposure  
(n/28) 
25% 
21% 
11% 
14% 
25% 
4% 
Abbreviation: n = number of participants within each specific category 
a  One case of elective abortion was reported in a healthy volunteer from Study AMBD. 
b  One case of pregnancy with an unknown outcome was reported in a healthy volunteer from Study AMBW. 
Developmental toxicity studies in pregnant monkeys revealed no evidence of harm to the foetus 
or infant. Labels will reflect that there are insufficient human data to establish the safety of 
mirikizumab during pregnancy. As a precautionary measure, it is preferable to avoid the use of 
mirikizumab during pregnancy. Women of childbearing potential should use an effective method 
of contraception during treatment and for at least 10 weeks after treatment. 
It is not known whether mirikizumab is excreted in human milk or absorbed systemically after 
ingestion. Administer mirikizumab to nursing women only if the potential benefit to the mother 
justifies the potential risk to the infant. 
Although the risk of mirikizumab to pregnant women with UC is not expected to be different, 
mirikizumab use during pregnancy is considered missing information. Therefore, an 
observational database study in a larger population than in clinical development will be 
conducted because of the limited data on pregnancy outcomes. Should emerging experience of 
use in pregnancy reveal clinically relevant adverse outcomes to the mother, foetus, and/ or baby, 
this could have an impact on the benefit-risk of mirikizumab use in female patients with UC. 
SVII.2 New Safety Concerns and Reclassification with a Submission of an 
Updated RMP  
Not applicable. 
Approved on 28 Mar 2023 GMT
 
 
 
 
SVII.3 Details of Important Identified Risks, Important Potential Risks, 
and Missing Information  
SVII.3.1 Presentation of Important Identified Risks and Important 
Potential Risks  
Important Identified Risks: None 
Important Potential Risk 1: Serious Infections 
Potential mechanisms:  
Mirikizumab is an immunomodulatory drug and, as such, may increase the risk of developing an 
infection or exacerbate an existing infection.  
Evidence source(s) and strength of evidence: 
In patients with UC across the Phase 2 and Phase 3 studies, serious infections (n = 33, 2.3%) 
were reported commonly during treatment with mirikizumab. When including time off 
mirikizumab and the post-treatment follow-up period, serious infections (n = 39, 2.7%) were also 
reported commonly. Although the majority of patients recovered, serious infections due to 
coronavirus or COVID-19 infections resulted in the deaths of 3 patients with UC, 1 while 
receiving mirikizumab and 2 while off mirikizumab. 
Across all mirikizumab exposures in Phase 2 and Phase 3 clinical trials for UC, CD, and Ps, 
serious infections (n = 99, 2.6%) have been reported commonly during treatment with 
mirikizumab. When including time-off mirikizumab and the post-treatment follow-up time, 
serious infections (n = 108, 2.8%) were also reported commonly. Although the majority of 
patients recovered, serious infections due to COVID-19 or coronavirus infections or sequelae of 
COVID-19 infection resulted in the deaths of 7 patients, 5 patients while receiving mirikizumab 
and 2 patients while off mirikizumab. 
All deaths due to coronavirus or COVID-19 infection or sequelae of COVID-19 infection in the 
mirikizumab programme occurred early in the COVID-19 pandemic, prior to the availability of 
effective treatments and vaccinations. Furthermore, these patients with fatal COVID-19 
infections were at increased risk for hospitalisation, severe disease, and/or death due to 
COVID-19 based on one or more of the following criteria: age of 65 years or older, body mass 
index ≥25 kg/m2, diabetes mellitus, cardiovascular disease, and/or arterial hypertension. None of 
these deaths from severe COVID-19/coronavirus infection or sequelae of COVID-19 infection 
were determined by the investigator or sponsor to be related to mirikizumab. 
Characterisation of the risk: 
Serious infections were those that met the criteria of an SAE.  
Placebo-Controlled Ulcerative colitis Exposures: 
Approved on 28 Mar 2023 GMT
 
 
 
In the UC population in the placebo-controlled induction Study AMAN, the frequency of serious 
infections was similar for patients who received mirikizumab (0.7%) compared to patients who 
received placebo (0.6%). 
In the UC Maintenance Mirikizumab Responders analysis set in the maintenance Study AMBG, 
serious infections were reported more frequently in patients who received placebo (1.6%) 
compared with patients who received mirikizumab (0.8%). 
All UC Exposures: 
In the UC population exposed to mirikizumab in the Phase 2 and Phase 3 clinical trials, 
(N = 1442), serious infections were reported commonly (n = 33, 2.3%, IR 1.5 per 100 PY) in 
patients during treatment with mirikizumab and also commonly (n = 39, 2.7%) if including time 
off mirikizumab. The EAIR of serious infections in this analysis set was 1.5 per 100 PY (95% 
CI = 1.0 - 2.1). The most frequently reported serious infections during treatment with 
mirikizumab were pneumonia (n = 5, 0.3%), appendicitis (n = 4, 0.3%), and gastroenteritis 
(n = 3, 0.2%). All other serious infections were reported at a frequency of 0.1% or less. When 
including the time off mirikizumab, the most frequently reported serious infections were 
pneumonia (n = 6, 0.4%), appendicitis (n = 4, 0.3%), gastroenteritis (n = 3, 0.2%), and sepsis 
(n = 3, 0.2%). All other serious infections were reported at a frequency of 0.1% or less. 
Three patients with UC died from coronavirus or COVID-19 infections: 
  One patient died from COVID-19 while receiving mirikizumab on the long-term 
extension Study I6T-MC-AMAP 
  Two patients died from coronavirus/COVID-19 infection while off mirikizumab: 
o  1 patient with UC who received mirikizumab on the induction Study I6T-MC-
AMAN and was receiving placebo on the maintenance Study I6T-MC-AMBG. 
This death occurred 171 days after the last dose of mirikizumab. 
o  1 patient with UC who received mirikizumab on the induction Study I6T-MC-
AMAN and maintenance Study I6T-MC-AMBG, discontinued from Study 
AMBG due to a malignancy, and withdrew consent after completing the early 
termination visit.  The death due to coronavirus infection was reported in the 
follow-up information for the malignancy SAE and was reported to have occurred 
89 days after the last dose of mirikizumab in the context of a coronavirus 
infection. 
All Mirikizumab Exposures: 
In all mirikizumab exposures in Phase 2 and Phase 3 clinical trials for UC, CD, and Ps 
(N = 3798), serious infections were reported commonly (n = 99, 2.6%, IR 1.3 per 100 PY) in 
patients during treatment with mirikizumab. The EAIR of serious infections in this analysis set 
was 1.3 per 100 PY (95% CI = 1.0 - 1.6). The most frequently reported serious infections during 
treatment with mirikizumab were COVID-19 pneumonia (n = 18, 0.5%), pneumonia (n = 13, 
0.3%), and appendicitis (n = 9, 0.2%). All other serious infections were reported at a frequency 
of 0.1% or less. When including time off mirikizumab, serious infections were reported 
commonly (n = 108, 2.8%), and the most frequently reported serious infections were COVID-19 
Approved on 28 Mar 2023 GMT
pneumonia (n = 18, 0.5%), pneumonia (n = 14, 0.4%), appendicitis (n = 9, 0.2%), and COVID-
19 (n = 7, 0.2%). All other serious infections were reported at a frequency of 0.1% or less. In 
addition to the deaths of patients with UC described above, 4 patients with Ps died from COVID-
19 infection or sequelae of this infection while receiving mirikizumab in the long-term extension 
Study I6T-MC-AMAH. 
Blinded Phase 3 CD Study:  
One death due to a serious infection with sepsis was reported in a patient with CD who received 
blinded study drug on the ongoing Study I6T-MC-AMAM and died during the post-treatment 
follow-up period, 144 days after the last dose of blinded study drug. 
Risk factors and risk groups: 
Risk groups or specific risk factors for serious infections have not been identified from the 
clinical development programme. Due to the immunomodulatory effect of medicines in the anti-
IL23 class, patients with evidence of untreated latent TB or other active, chronic, or recurrent 
infections or a history thereof may be at greater risk of reactivation or exacerbation of their 
underlying infection, even though this has not been reported in the mirikizumab clinical 
development programme. 
Preventability: 
Careful monitoring of patients for early detection of signs of infection and application of 
appropriate intervention may help to prevent infections from becoming serious. The monitoring 
of patients in this clinical development programme may have helped with the early detection of 
infections and may have contributed to recovery from their serious infections for the majority of 
patients. Label language on infections will raise awareness regarding this risk, aimed for similar 
outcomes in the post-marketing phase. With the availability of COVID-19 vaccinations and 
medications, it is expected that the frequency of severe COVID-19 infections and/ or sequalae 
may decrease and/or outcomes may improve. 
The label will include a contraindication for patients with active TB and will state that anti-TB 
therapy should be considered prior to initiating treatment in patients with a past history of latent 
or active TB in whom an adequate course of treatment cannot be confirmed. It will also state that 
patients receiving mirikizumab should be monitored for signs and symptoms of active TB during 
and after treatment. Additionally, the label will warn that mirikizumab should not be initiated in 
patients with any clinically important active infection until the infection resolves or is adequately 
treated. The risks and benefits of treatment should be considered prior to initiating use of 
mirikizumab in patients with a chronic infection or a history of recurrent infection.  
Impact on the risk-benefit balance of the product: 
The current impact of serious infections on the risk-benefit balance of mirikizumab is considered 
to be low. This assessment is based on the cumulative exposures across the Ps, UC, and CD 
treatment groups, including 3798 patients (7801.3 PYE) in UC 1442 patients (2250.9 PYE), and 
the EAIR of serious infections in mirikizumab-treated patients of 1.3 per 100 PYE (1.5 per 100 
PY in UC). Serious infections were reported commonly in both datasets, and the majority 
Approved on 28 Mar 2023 GMT
 
recovered without sequalae or adverse clinical outcomes. The most frequently reported serious 
infections in mirikizumab-treated patients across all indications were COVID-19 pneumonia, 
pneumonia, and appendicitis, and in UC patients specifically, pneumonia, appendicitis, and 
gastroenteritis. Across the treatment groups, 10 patients discontinued mirikizumab due to their 
serious infection, including the 5 patients who died as previously described and 5 who recovered 
or were recovering without adverse clinical outcomes. 
Patients with UC are at risk for systemic rheumatoid disease and may, therefore, be at an 
increased risk of infection due to the underlying disease and/or prevalent use of concomitant 
immunosuppressive therapy. Given that an association between immunomodulatory therapy and 
infection is known to treating physicians, it is expected that infections are readily diagnosed and 
managed in clinical care. Therefore, the impact of serious infections on the risk-benefit balance 
is considered low, and labelling is expected to mitigate the potential risk of serious infections. 
Public health impact: 
Mirikizumab will be indicated for a defined subset of the population with moderately to severely 
active UC. In UC patients in the Phase 2 and Phase 3 clinical trials, the frequency of serious 
infections during treatment with mirikizumab was low, and the majority of patients recovered 
with no sequalae. The impact of serious infections on public health is considered to be low. 
Important Potential Risk 2: Severe Liver Injury  
Potential mechanisms:   
No biological mechanism to explain the observed increases in ALT and AST levels has been 
identified in the context of mirikizumab treatment. Furthermore, no adverse hepatic effects were 
observed in the non-clinical studies. 
Evidence source(s) and strength of evidence: 
For the UC population exposed to mirikizumab in the Phase 2 and Phase 3 clinical trials, 
elevated ALT 5xULN and 10xULN were reported by 0.4 % and 0.1% of patients in the 
mirikizumab treatment group respectively. Elevated AST 5xULN and 10xULN were reported 
by 0.7% and 0.1% of patients in the mirikizumab treatment group, respectively. 
For all mirikizumab exposures in Phase 2 and Phase 3 clinical trials for UC, CD, and Ps, elevated 
ALT and AST 10xULN was reported for each analyte in 0.1% of mirikizumab-treated patients. 
Most of these liver enzyme elevations/increases were considered mild to moderate in severity 
and 3 patients with Ps had AST and or ALT elevations that were reported as serious. None were 
associated with an adverse clinical outcome. Overall, 0.32% of patients discontinued due to a 
TEAE of liver enzyme elevation. Most recovered from the liver enzyme elevations while 
continuing on mirikizumab treatment and with no further adverse effects. 
One patient with UC met Hy’s law criteria with a maximum ALT of 17.9xULN, maximum AST 
of 9.9xULN, and maximum bilirubin of 2.4xULN. This TEAE of “hepatic enzyme increased” 
was reported as moderate severity and as non-serious. As no alternative aetiology for liver 
function tests LFT elevation could be determined, an association with mirikizumab treatment 
could not be excluded. Therefore, based on the potential of significantly elevated 
Approved on 28 Mar 2023 GMT
aminotransferases being indicative of possible severe liver injury, it is considered an important 
potential risk. 
Characterisation of the risk: 
Placebo-Controlled Ulcerative colitis Exposures: 
In the placebo-controlled periods of Studies AMAN and AMBG, transaminase elevations were 
reported in a small number of patients (≤1%), although there were more patients with 
treatment-emergent maximum elevations in ALT or AST ≥3xULN and ≥5xULN in the UC 
Maintenance Mirikizumab Responder analysis set. 
All Ulcerative colitis Exposures: 
For the UC population exposed to mirikizumab in the Phase 2 and Phase 3 clinical trials, 65 
patients (4.5%, IR 3.0 per 100 PY) reported at least 1 narrow scope hepatic TEAE, of which 21 
were ALT increased and 19 were AST increased. For 1 patient, the hepatic AE of cholecystitis 
acute was reported as serious. Three patients discontinued mirikizumab due to a hepatic AE, 
including 2 patients for hepatic enzyme increased and 1 patient for autoimmune hepatitis. 
For the UC population, elevations in transaminases were observed in both mirikizumab-treated 
patients and those who received placebo. The IRs for ALT elevations were lower for 
mirikizumab-treated patients compared to placebo except for the elevations of ALT ≥10xULN, 
which occurred only in patients who received mirikizumab. The IRs for AST elevations were 
higher in the mirikizumab-treated patients than placebo.  
Table SVII.1. 
Patients Meeting Elevated Hepatic Criteria Maximum Post-Baseline 
Values (ALT and AST)  
Maximum Post-baseline 
Category, n (%) [IR] 
ALT 3xULN 
ALT 5xULN 
ALT 10xULN 
AST 3xULN 
AST 5xULN 
AST 10xULN 
UC Placebo 
N = 384 
Nx = 377 
PYE = 197.2 
4 (1.1) 
[2.0] 
2 (0.5) 
[1.0] 
0 
2 (0.5) 
[1.0] 
0 
0 
All UC Miri 
N = 1442 
Nx = 1427 
PYE = 2250.9 
28 (2.0) 
[1.2] 
10 (0.7) 
[0.4] 
3 (0.2) 
[0.1] 
30 (2.1) 
[1.3] 
15 (1.1)  
[0.7] 
2 (0.1) 
[0.1] 
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; IR = incidence rate; 
miri = mirikizumab; N = number of participants in the safety analysis set; n = number of participants in specified 
category; Nx = number of participants in the baseline category and that have at least 1 postbaseline measurement; 
PYE = patient years of exposure; UC= ulcerative colitis; ULN = upper limit of normal. 
Approved on 28 Mar 2023 GMT
 
All Mirikizumab Exposures: 
For all mirikizumab exposures in Phase 2 and Phase 3 clinical trials for UC, CD, and Ps, 256 
patients (6.7%, IR 3.4 per 100 PY) reported at least 1 narrow scope treatment emergent hepatic 
AE, and 8 patients reported a serious hepatic AE, including 7 patients with Ps and 1 patient with 
UC (referenced above). Fourteen patients discontinued mirikizumab due to a hepatic AE. 
For all mirikizumab exposures in Phase 2 and Phase 3 clinical trials for UC, CD, and Ps, 
elevations in transaminases were observed in both mirikizumab-treated patients and those who 
received placebo. The IRs for ALT elevations were lower for mirikizumab-treated patients 
compared to placebo except for the ≥10xULN elevations, which occurred only in patients who 
received mirikizumab. The IRs for AST elevations were similar for mirikizumab-treated patients 
and placebo except for the ≥10xULN elevations, which occurred only in patients who received 
mirikizumab.  
Table SVII.2 
Patients Meeting Elevated Hepatic Criteria Maximum Post-Baseline 
Values (ALT and AST)  
Maximum Post-baseline 
Category, n (%) [IR] 
ALT 3xULN 
ALT 5xULN 
ALT 10xULN 
AST 3xULN 
AST 5xULN 
AST 10xULN 
All Placebo 
N = 719 
Nx = 711 
PYE = 289.6 
9 (1.3) 
[3.0] 
5 (0.7) 
[1.7] 
0 
4 (0.6) 
[1.3] 
1 (0.1) 
[0.3] 
0 
All Miri 
N = 3798 
Nx = 3773 
PYE = 7801.3 
115 (3.0) 
[1.5] 
24 (0.6) 
[0.3] 
8 (0.2) 
[0.1] 
104 (2.8) 
[1.3] 
42 (1.1) 
[0.5] 
9 (0.2) 
[0.1] 
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; IR =incidence rate; 
miri = mirikizumab; N = number of participants in the safety analysis set; n = number of participants in specified 
category; Nx = number of participants in the baseline category and that have at least 1 postbaseline measurement; 
PYE = patient years of exposure; ULN = upper limit of normal. 
Risk factors and risk groups:   
In the UC, CD, and Ps programmes, no specific risk groups or specific risk factors have been 
identified, although concurrent use of alcohol and/or medications with a known risk of liver 
enzyme elevation or DILI may result in a higher frequency of liver enzyme elevations and 
possible liver injury. Additionally, clinical observations of transient elevations of liver enzymes 
with no known cause and persistent elevations most commonly due to PSC, AIH, cholelithiasis, 
and NAFLD, and some herbal, dietary, and traditional healing and supplemental products may 
Approved on 28 Mar 2023 GMT
 
also contribute to a higher frequency of liver enzyme elevations and possible liver injury. In the 
UC programme, no specific risk factors have been identified. 
Preventability:   
As no risk groups or risk factors have been identified, elevations in liver enzymes are unlikely to 
be preventable. Early detection of liver enzyme elevations and application of an appropriate 
intervention may help to prevent outcomes from becoming serious, therefore, the proposed 
monitoring will allow early detection of changes that may later increase and/or require 
intervention.   
ALT increased and AST increased are ADRs for mirikizumab, and the warning and precaution 
language will advise that if increases in ALT or AST are observed and drug-associated liver 
injury is suspected, mirikizumab should be discontinued until this diagnosis is excluded. 
Impact on the risk-benefit balance of the product: 
A majority of hepatic AEs reported in all mirikizumab exposures in Phase 2 and Phase 3 clinical 
trials for UC, along with the data from all mirikizumab exposures including patients with CD and 
Ps, were mild to moderate in severity and did not result in discontinuation of mirikizumab. No 
AEs of treatment-emergent DILI related to mirikizumab were reported and the one case meeting 
Hy’s law criteria had rapid resolution of liver enzymes upon discontinuation of mirikizumab. 
Across the mirikizumab programme, a total of 14 patients discontinued mirikizumab due to a 
hepatic AE. Other than 1 patient with UC who discontinued due to AIH and 1 patient with Ps 
who discontinued due to Hepatitis B DNA positive assay, all other discontinuations were due to 
increased hepatic enzyme/liver function tests (n = 12). Based on the available clinical data, the 
current impact on the risk-benefit balance of mirikizumab is considered low. Labelling is 
expected to inform prescribers of the potential risk of severe liver injury. 
Public health impact: 
Mirikizumab will be indicated for a clearly defined subset of the population with moderately to 
severely active UC, and the impact of severe liver injury on public health is considered to be 
low. 
Important Potential Risk 3: Malignancies 
Potential mechanisms: 
IL-23 expression or overexpression is observed in several human tumour types and is, in many 
cases, associated with a poorer prognosis. The pro-tumour effects of IL-23 are attributable to 
mechanisms including stimulation of inflammatory cell-derived cytokines, chemokines, and 
growth factors, evasion of immune surveillance, the promotion of angiogenesis, and increased 
invasive activity. Experiments demonstrating that the ablation of IL-23 function through either 
genetic manipulation (for example, knockout mice) or pharmacology (for example, anti-IL-23 
antibodies) leads to decreased tumour incidence or delayed progression, support the equivalent, 
inverse hypothesis that decreased IL-23 activity may protect from tumour development. The 
Approved on 28 Mar 2023 GMT
 
 
 
current clinical and non-clinical data do not suggest that mirikizumab causes malignant tumours 
or promotes tumour growth. 
Evidence source(s) and strength of evidence: 
Some studies have found UC to be associated with an increased risk of malignancy (Jussila et al. 
2013; Manninen et al. 2013; Hovde et al. 2017), which may be confounded by behavioral risk 
factors and current use of certain therapies to treat the disease (for example, thiopurine use). 
In participants with UC who received mirikizumab, the frequency of malignancies and NMSC 
was low, and the data suggest there was no increase in the frequency of malignancy events with 
increasing duration of mirikizumab treatment. The IR of malignancies in this population (0.8 per 
100 PYs) was consistent with the IRs reported in the general population of patients with UC in 
observational studies (Biancone et al. 2016, Taborelli et al. 2020) and did not suggest an 
increased risk associated with mirikizumab use. 
Characterisation of the risk: 
Frequency 
Among participants with UC in the clinical development programme (N=1442; total 
PYE=2250.9), 19 participants reported ≥ 1 TE malignancy (0.8 per 100 PYE), which included 14 
participants with malignancies excluding NMSC and 5 participants with NMSC. 
Across the entire mirikizumab clinical development program, including participants with Ps, UC, 
and CD (N=3798; total PYE=7801.3), 58 participants reported ≥ 1 TE malignancy (0.7 per 100 
PYE), which included 41 participants with malignancies excluding NMSC and 18 participants 
with NMSC. 
Risk factors and risk groups: None identified. 
Preventability: 
Early detection based on enhanced routine monitoring, which is common medical practice in a 
population at risk, has a significant impact on the progression of malignant disease, treatment 
success, or even prevention if pre-cancerous lesions are identified and addressed appropriately. 
Impact on the risk-benefit balance of the product: 
Based on the cumulative data, there is insufficient scientific evidence to suggest an association 
between mirikizumab and malignancy at this time. Patients with UC are at a known increased 
risk for malignancy, which may be additionally confounded by individual behavioral risk factors 
and concurrent use of certain therapies to treat the disease. 
This assessment is based on the clinical profile from the UC clinical trial database, with exposure 
from 1442 patients (2250.9 PYE). In the UC clinical development programme, malignancy has 
been reported in 19 participants, with an IR of 0.8 per 100 PYE.  The IRs for malignancies 
Approved on 28 Mar 2023 GMT
 
 
 
 
 
overall and specifically for cancer of the rectum, colon cancer, prostate cancer, and NMSC were 
consistent with the reported background IRs in the UC population. 
UC is associated with an increased risk of cancer relative to the general population (Karlén et al. 
1999; Jussila et al. 2013; Jung et al. 2017; Burisch et al. 2022).  As such, the observed rate of 
malignancies seen in the mirikizumab-treated population in the clinical development program is 
considered to reflect the presence of this co-morbidity in the target population rather than a 
potential effect of the drug. 
Lilly will monitor reported events of malignancy in the context of mirikizumab exposure through 
routine pharmacovigilance activities and based on the proposed additional pharmacovigilance 
activity on long-term safety entitled “Observational Secondary Database Study to Assess the 
Long-Term Safety of Mirikizumab,” of which malignancy is an objective. 
Public health impact:  
Given the low incidence of malignancy events in the range of disease-related background rates 
and that a potential risk of malignancy will only affect a small fraction of the adult population, 
the potential public health impact is considered negligible at this time. 
Important Potential Risk 4:  MACE  
Potential mechanisms: 
Autoimmune diseases are known to be associated with increased cardiovascular morbidity and 
mortality (Pujades-Rodriguez et al. 2016). Chronic and systemic inflammation, largely attributed 
to the presence of pro-inflammatory cytokines and auto-antibodies, is thought to underlie these 
observed associations. The role of IL-23 as a pro-inflammatory cytokine in vascular 
inflammation and atherosclerosis is not known. 
Furthermore, there is no conclusive mechanism regarding CCV disease with IL-23p19 inhibition. 
Some authors have suggested that a risk may exist due to a therapeutically induced acute change 
in the immunologic environment, specifically inhibition of helper T cell sub-type 17, which may 
disrupt homeostasis between pro-atherogenic and protective effects. Because IL-23 plays a key 
role in maintaining homeostasis within the CCV system, it has been hypothesised that inhibition 
of IL-23 may result in pathogenic shifts which destabilise atherosclerotic plaques; however, 
clinical relevance of these hypotheses is uncertain. 
Evidence source(s) and strength of evidence: 
In the UC treatment population, there was no observed association between mirikizumab 
treatment and MACE. No cases of MACE were observed in the UC placebo-controlled 
population. There was a small imbalance of MACE between treatment groups in the placebo-
Approved on 28 Mar 2023 GMT
 
 
 
 
controlled Ps study population, with the randomisation ratio of mirikizumab to placebo of 6:1 
being a contributing factor.  
IRs for MACE observed in the All UC Mirikizumab Integrated Analysis Set. (IR=0.2) and the 
All Mirikizumab Exposures Integrated Analysis Set (IR=0.3) are lower than background rates 
observed in the UC (IR=1.1) and Ps (IR=0.4 to 1.5) populations. 
Characterisation of the risk: 
In participants with UC, adjudicated and confirmed MACE were reported in 5 
participants (0.4%, IR=0.2, 95% CI 0.1, 0.5) in the All UC Mirikizumab Exposures 
Integrated Analysis Set. The IR for adjudicated and confirmed MACE is below published 
rates for the background population with UC (IR=1.1). 
In participants with psoriasis, adjudicated and confirmed MACE were reported in 
  5 participants (0.4%, IR=1.2, CI 0.4, 2.9) in the Ps Induction Placebo-Controlled 
Integrated Analysis Set. The IR of MACE in this population is within the range of the 
background IR for patients with moderate-to-severe Ps (IR=0.4 to 1.5). 
In all participants treated with mirikizumab, adjudicated and confirmed MACE were reported for 
  26 participants (0.7%, IR=0.3, CI 0.2, 0.5) in the All Mirikizumab Exposures Integrated 
Analysis Set. This IR of adjudicated and confirmed MACE is below the range of the 
background IR in the UC population (1.1 IR) and moderate-to-severe Ps population (0.4 
to 1.5 IR) and within rates for other IL-23p19 inhibitors (IR=0.2 to 0.6) approved for the 
treatment of Ps. 
Risk factors and risk groups: 
None identified 
Preventability:  
Cardiovascular disorders, including CCV events, CHD, VTE, DVT, and PE, are known, 
important co-morbidities of the UC population and may increase the risk of MACE. 
Furthermore, chronic inflammation increases the risk for MACE (Hansson 2005).  Controlling 
inflammation through the use of mirikizumab could decrease the risk of MACE. 
Impact on the risk-benefit balance of the product: 
Based on the cumulative data, there is insufficient scientific evidence to suggest an association 
between mirikizumab and MACE. Patients with UC are at a known increased risk for 
cardiovascular disorders. This assessment is based on the clinical profile from the UC clinical 
trial database, with exposure from 1442 patients (2250.9 PYE).  In the UC clinical development 
programme, 5 participants were confirmed after independent adjudication to have experienced a 
MACE, with an IR of 0.2 per 100 PYE. The totality of the data, in which few TE MACE were 
Approved on 28 Mar 2023 GMT
 
 
 
reported from all participants with UC and Ps and the lack of a conclusive biological mechanism 
for MACE with IL-23p19 inhibition, do not represent sufficient scientific evidence of a 
relationship with mirikizumab treatment. 
Lilly will monitor reported events of MACE in the context of exposure to mirikizumab through 
routine pharmacovigilance activities and based on the proposed additional pharmacovigilance 
activity on long-term safety entitled “Observational Secondary Database Study to Assess the 
Long-Term Safety of Mirikizumab,” of which MACE is an objective. 
Public health impact:  
Given the low incidence of MACE in the range of disease-related background rates and that a 
potential risk of MACE will only affect a small fraction of the adult population, the potential 
public health impact is considered negligible at this time. 
Approved on 28 Mar 2023 GMT
 
 
 
 
SVII.3.2 Presentation of the Missing Information  
Missing Information: Safety of mirikizumab in pregnant women and lactating women. 
Evidence source: 
Based on the mechanism of action, non-clinical data, and limited to no clinical trial data, the 
safety profile of mirikizumab is not expected to be different in pregnant women and lactating 
women. 
Population in need of further characterisation: 
Pregnant women and lactating women with moderately to severely active UC. 
Approved on 28 Mar 2023 GMT
 
 
Module SVIII - Summary of the Safety Concerns  
Table SVIII.1. 
Summary of Safety Concerns  
Summary of safety concerns 
Important identified risks 
Important potential risks 
Missing information 
None  
  Serious infections 
  Severe liver injury 
  Malignancies  
  MACE  
  Safety of mirikizumab in pregnant women and lactating women 
Abbreviation: MACE = major adverse cardiac event. 
Approved on 28 Mar 2023 GMT
Part III: Pharmacovigilance Plan (including post-
authorisation safety studies)  
III.1 Routine Pharmacovigilance Activities  
Routine pharmacovigilance activities beyond adverse reactions reporting and signal 
detection: 
Routine follow-up will be conducted on events of special interest. 
Specific adverse reaction follow-up questionnaires for safety concerns: 
 
 
 
 
 
 
 
 
 
 
 
 
Spontaneous Follow-up Form – Infection 
Spontaneous Follow-up Form – Extrapulmonary Tuberculosis 
Spontaneous Follow-up Form – Pulmonary Tuberculosis 
Spontaneous Follow-up Form – Pregnancy Data Collection – Maternal 
Spontaneous Follow-up Form – Pregnancy Data Collection – Paternal 
Spontaneous Follow-up Form – Pregnancy Outcome – Maternal 
Spontaneous Follow-up Form – Pregnancy Outcome – Paternal 
Spontaneous Follow-up Form – Breast feeding 
Spontaneous Follow-up Form – Hepatic Disorders 
Spontaneous Follow-up Form – Cancer 
Spontaneous Follow-up Form – Cardiac Disorders 
Spontaneous Follow-up Form – Cerebrovascular Accident 
Other forms of routine pharmacovigilance activities for safety concerns: 
Routine review of EudraVigilance data will be performed in conjunction with Lilly’s routine 
signal evaluation processes. 
III.2 Additional Pharmacovigilance Activities  
Study Short Name and Title:  
Observational Secondary Database Cohort Study on Mirikizumab Exposure and Pregnancy. 
Rationale and Study Objectives: 
Pregnant women were not included in the mirikizumab clinical development programme. 
However, the indicated population for mirikizumab of patients with UC includes women of 
childbearing age. Therefore, exposure to mirikizumab during pregnancy may occur during 
post-marketing. Although there were no mirikizumab-related adverse effects on embryo-foetal 
development, pregnancy outcome, and peri- and post-natal development in pregnant monkeys 
administered mirikizumab, effects pregnancy, and foetal or infant outcomes in humans have not 
been fully determined. Therefore, the purpose of this study is to determine the pregnancy, and 
foetal or infant outcomes among pregnant women with a diagnosis of UC who are exposed to 
mirikizumab.  
Approved on 28 Mar 2023 GMT
The pregnancy, maternal and foetal or infant outcomes of interest include: 
  Pregnancy outcomes: recognised spontaneous abortions, stillbirths, elective terminations, 
and preterm delivery  
  Foetal or infant outcomes: small for gestational age, and major and minor congenital 
malformations. 
Study objectives 
1.  To monitor the use of mirikizumab among women of childbearing age. 
2.  To determine the incidence of pregnancy and foetal or infant outcomes among the limited 
number of pregnant women with a diagnosis of UC who are exposed to mirikizumab 
during pregnancy. 
3.  If sufficient sample size of women exposed to mirikizumab during pregnancy and infants 
linked to the exposed pregnancies are identified, to compare the incidence of pregnancy 
and foetal or infant outcomes of pregnant women with a diagnosis of UC who are 
exposed to mirikizumab during pregnancy to pregnant women with a diagnosis of UC 
who are not exposed to mirikizumab and/or who are exposed to other medications 
indicated for the treatment of UC. 
Study Design: 
Observational cohort study using secondary data from administrative claims databases in the US. 
Study Population: 
Pregnant women with a diagnosis of with UC. 
Milestones: 
The proposed milestones are as follows: 
Milestones 
Start of data collection 
Study progress report 
Interim report 
Final study report 
Anticipated due date* 
Within 2 years of first regulatory approval 
To be provided with the PSUR† 
Approximately 4 years after the start of data collection  
31 Dec 2031 
Abbreviation: PSUR = periodic safety update report. 
*Dates are estimated and will be finalised once appropriate data source and vendor are identified. 
†After the start of data collection. 
Study Short Name and Title 
Observational Secondary Database Study to Assess the Long-Term Safety of Mirikizumab 
Rationale and Study Objectives: 
Data from clinical trials demonstrate that mirikizumab is effective in the treatment of patients 
with moderate to severe UC. However, the long-term safety of mirikizumab exposure in terms of 
events with a low frequency and/or long latency among patients with UC in routine clinical 
practice has not been fully characterised.  
Approved on 28 Mar 2023 GMT
Study Objectives 
The objective of this study is to examine the incidence of severe liver injury, serious infections, 
including opportunistic infections, malignancies excluding  non-melanoma skin cancer (NMSC) 
and MACE among patients with a diagnosis of UC who are exposed to mirikizumab compared to 
patients with a diagnosis of UC who are not exposed to mirikizumab and/or who are exposed to 
other medications indicated for the treatment of UC in real world clinical practice in the US. The 
incidence of the study outcomes will also be examined among subgroups of interest including 
elderly patients 65 years of age and older. 
Study Design: 
Observational cohort study using secondary data from administrative claims databases in the US. 
Study Population: 
Adult patients 18 years of age or older with a diagnosis of UC 
Milestones: 
The proposed milestones are as follows: 
Milestones 
Start of data collection 
Study progress report 
Interim report 
Final study report 
Anticipated due date* 
Within 2 years of first regulatory approval 
To be provided with the PSUR† 
Approximately 7 years after the start of data collection 
31 Dec 2037 
Abbreviation: PSUR = periodic safety update report. 
*Dates are estimated and will be finalised once appropriate data source and vendor are identified. 
†After the start of data collection. 
Approved on 28 Mar 2023 GMT
III.3 Summary Table of Additional Pharmacovigilance Activities  
Table Part III.1. 
Ongoing and Planned Additional Pharmacovigilance Activities  
Study (study 
short name, and 
title) 
Status 
(planned/ongoing) 
Category 1 - Imposed mandatory additional pharmacovigilance activities that are conditions of the marketing 
authorisation  
Safety 
concerns 
addressed 
(list) 
Due dates 
(in 
DD/Mon/YYYY 
format)* 
Milestones  
(required by 
regulators) 
Summary of objectives 
None 
Category 2 – Imposed mandatory additional pharmacovigilance activities that are specific obligations in the 
context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances 
None 
Category 3 - Required additional pharmacovigilance activities  
Missing 
Observational 
information: 
Secondary 
Use in 
Database Cohort 
pregnancy. 
Study on 
Mirikizumab 
Exposure and 
Pregnancy 
mirikizumab among 
women of childbearing 
age.  
Study progress 
report 
Start of data 
collection 
  To monitor the use of 
Interim report 
Within 2 years of 
first regulatory 
approval 
Planned 
To be submitted 
with the PSUR 
(after the start of 
data collection) 
Approximately 4 
years after start 
of data collection 
31 Dec 2031 
Final report 
  To determine the 
incidence of 
pregnancy- and 
foetal/infant outcomes 
among pregnant 
women with ulcerative 
colitis who are 
exposed to 
mirikizumab during 
pregnancy. 
 
If sufficient sample 
size allows, to 
compare the incidence 
of pregnancy and 
foetal/infant outcomes 
of women with 
ulcerative colitis who 
are exposed to 
mirikizumab during 
pregnancy to women 
with ulcerative colitis 
who are not exposed to 
mirikizumab and/or 
who are exposed to 
other medications 
indicated for the 
Approved on 28 Mar 2023 GMT
 
 
 
 
 
 
 
 
Safety 
concerns 
addressed 
(list) 
Milestones  
(required by 
regulators) 
Due dates 
(in 
DD/Mon/YYYY 
format)* 
Important 
potential risks: 
Severe liver 
injury, serious 
infections, 
malignancy, 
and MACE.  
Start of data 
collection 
Within 2 years of 
first regulatory 
approval 
Study progress 
report 
Interim report 
Final report 
To be submitted 
with the PSUR 
(after the start of 
data collection) 
Approximately 7 
years after the 
start of data 
collection 
31 Dec 2037 
Study (study 
short name, and 
title) 
Status 
(planned/ongoing) 
Observational 
Secondary 
Database Study to 
Assess the Long-
Term Safety of 
Mirikizumab 
Planned 
Summary of objectives 
treatment of ulcerative 
colitis during 
pregnancy. 
  To examine the 
incidence of severe 
liver injury, serious 
infections including 
opportunistic 
infections, 
malignancies 
excluding non-
melanoma skin cancer 
and MACE among 
patients with 
ulcerative colitis who 
are exposed to 
mirikizumab 
compared to patients 
with ulcerative colitis 
who are not exposed to 
mirikizumab and/or 
who are exposed to 
other medications 
indicated for the 
treatment of ulcerative 
colitis, in real world 
clinical practice in the 
US. 
Abbreviations: MACE = major adverse cardiovascular event; PSUR = periodic safety update report. 
*Dates are estimated and will be finalised once appropriate data source and vendor are identified. 
Approved on 28 Mar 2023 GMT
 
 
 
 
 
 
 
 
 
Part IV: Plans for Post-Authorisation Efficacy Studies  
Not applicable. 
Approved on 28 Mar 2023 GMT
 
Part V: Risk Minimisation Measures (including evaluation of 
the effectiveness of risk minimisation activities)  
V.1 Routine Risk Minimisation Measures  
Table Part V.1. 
Description of Routine Risk Minimisation Measures by Safety 
Concern   
Safety concern 
Serious infections  
Routine risk minimisation activities  
Routine risk communication: 
  SmPC Section 4.3 
  SmPC Section 4.4 
  PL Section 2 
Routine risk minimisation activities recommending specific clinical measures to 
address the risk: 
SmPC Section 4.3 contains a contraindication for the use of mirikizumab in patients 
with: 
  clinically important active infections (active TB). 
SmPC Section 4.4 advises:  
  Mirikizumab may increase the risk of severe infection (see Section 4.8). 
Treatment with mirikizumab should not be initiated in patients with a 
clinically important active infection until the infection resolves or is 
adequately treated. The risks and benefits of treatment should be considered 
prior to initiating use of mirikizumab in patients with a chronic infection or a 
history of recurrent infection. Patients should be instructed to seek medical 
advice if signs or symptoms of clinically important acute or chronic infection 
occur. If a serious infection develops, discontinuation of mirikizumab should 
be considered until the infection resolves. 
Pre-treatment evaluation for tuberculosis 
  Prior to initiating treatment, patients should be evaluated for TB infection. 
Patients receiving mirikizumab should be monitored for signs and symptoms 
of active TB during and after treatment. Anti-TB therapy should be 
considered prior to initiating treatment in patients with a past history of latent 
or active TB in whom an adequate course of treatment cannot be confirmed. 
PL Section 2 advises: 
Do not use mirikizumab if you have important active infections (active TB). 
Approved on 28 Mar 2023 GMT
 
 
Safety concern 
Routine risk minimisation activities  
  Mirikizumab can potentially cause serious infections. You must look out for 
signs of these conditions while you are using mirikizumab. 
  Treatment with mirikizumab should not be started if you have an active 
infection until the infection is gone. 
  After starting the treatment, tell your doctor right away if you have any 
symptoms of an infection such as 
fever 
chills 
o 
o 
o  muscle aches 
o 
o 
o 
o 
o  pain during urination 
cough 
shortness of breath 
runny nose 
sore throat 
  Also tell your doctor if you have recently been near anyone who might have 
TB. 
  Your doctor will examine you and may do a test for TB, before you have 
 
mirikizumab. 
If your doctor thinks you are at risk of an active TB, you may be given 
medicines to treat it. 
Pack size: Not applicable 
Legal status: Not applicable 
Severe Liver Injury 
Routine risk communication: 
  SmPC Sections 4.4 and 4.8 
  PL Section 2 
Routine risk minimisation activities recommending specific clinical measures to 
address the risk: 
SmPC Section 4.4 advises: 
  Cases of drug-induced liver injury (including one case meeting Hy’s Law criteria) 
occurred in patients receiving mirikizumab in clinical trials. 
  Liver enzymes and bilirubin should be evaluated at baseline and monthly during 
induction (including extended induction period, if applicable). Thereafter, liver 
enzymes and bilirubin should be monitored (every 1-4 months) according to 
standard practice for patient management and as clinically indicated. If increases 
in ALT or AST are observed and drug-induced liver injury is suspected, 
mirikizumab must be discontinued until this diagnosis is excluded. 
SmPC Section 4.8 indicates: 
  Overall mirikizumab treatment periods in the ulcerative colitis clinical 
development programme (including the placebo-controlled and open-label 
induction and maintenance periods), there have been elevations of ALT to 3x 
upper limit of normal (ULN) (2.0%), 5xULN (0.7%) and 10xULN (0.2%) and 
AST to 3xULN (2.1%), 5xULN (1.1%), and 10xULN (0.1%) in patients 
receiving mirikizumab (see Section 4.4). These elevations have been noted with 
and without concomitant elevations in total bilirubin. 
PL Section 2 advises 
Approved on 28 Mar 2023 GMT
 
Safety concern 
Routine risk minimisation activities  
  Your doctor will conduct blood tests before starting and during treatment with 
mirikizumab to check if your liver is functioning normally. If blood tests are 
abnormal, your doctor might interrupt therapy with mirikizumab and do 
additional tests on your liver to determine the cause. 
Malignancies 
Pack size: Not applicable 
Legal status: Not applicable 
Routine risk communication: None 
MACE 
Routine risk communication: None 
Safety of mirikizumab 
in pregnant women and 
lactating women 
Routine risk communication: 
  SmPC Section 4.6 
  PL Section 2 
Routine risk minimisation activities recommending specific clinical measures to 
address the risk: 
SmPC Section 4.6 provides guidance:  
  Women of childbearing potential should use an effective method of contraception 
during treatment and for at least 10 weeks after treatment. 
  There is a limited amount of data from the use of mirikizumab in pregnant 
 
women. Animal studies do not indicate direct or indirect harmful effects with 
respect to reproductive toxicity (see Section 5.3). As a precautionary measure, it is 
preferable to avoid the use of mirikizumab during pregnancy.  
It is unknown whether mirikizumab is excreted in human milk. Human IgGs are 
known to be excreted in breast milk during the first few days after birth, which is 
decreasing to low concentrations soon afterwards; consequently, a risk to the 
breast-fed infant cannot be excluded during this short period. A decision must be 
made whether to discontinue breast-feeding or to discontinue/abstain from Omvoh 
therapy taking into account the benefit of breast feeding for the child and the 
benefit of therapy for the woman. 
PL Section 2 advises:  
 
If you are pregnant, think you may be pregnant, or are planning to have a baby, 
ask your doctor for advice before using this medicine. It is preferable to avoid 
the use of mirikizumab in pregnancy. The effects of mirikizumab in pregnant 
women are not known. If you are a woman of childbearing potential, you are advised 
to avoid becoming pregnant and should use adequate contraception while using 
mirikizumab and for at least 10 weeks after the last mirikizumab dose.  
If you are breast feeding or are planning to breast-feed, talk to your doctor before 
using this medicine. 
 
Pack size: Not applicable. 
Legal status: Not applicable. 
Approved on 28 Mar 2023 GMT
 
 
 
Abbreviation: ALT = alanine aminotransferase; AST = aspartate aminotransferase; MACE = major adverse cardiac 
event; PL = package leaflet; SmPC = summary of product characteristics; TB = tuberculosis; ULN = upper limit 
of normal. 
V.2 Additional Risk Minimisation Measures  
Routine risk minimisation activities as described in Part V.1 are sufficient to manage the safety 
concerns of the medicinal product. 
Approved on 28 Mar 2023 GMT
 
 
V.3 Summary of Risk Minimisation Measures  
Table Part V.3. 
Summary Table of Pharmacovigilance Activities and Risk 
Minimisation Activities by Safety Concern  
Safety Concern 
Serious infections 
Risk Minimisation Measures  
Routine risk minimisation measures: 
  SmPC Section 4.3 
Contraindications 
  SmPC Section 4.4 Special 
Warnings and Precautions for 
Use 
  PL Section 2 
Additional risk minimisation measures: 
None proposed 
Pharmacovigilance Activities 
Routine pharmacovigilance activities beyond 
adverse reactions reporting and signal 
detection include the following: 
  Spontaneous Follow-up Form - Infection 
  Spontaneous Follow-up Form - 
Extrapulmonary Tuberculosis 
  Spontaneous Follow-up Form - 
Pulmonary Tuberculosis 
Additional pharmacovigilance activities: An 
Observational Secondary Database Study to 
Assess the Long-term Safety of 
Mirikizumab. 
  To examine the incidence of severe 
liver injury, serious infections 
including opportunistic infections, 
malignancies excluding non-
melanoma skin cancer (NMSC), and 
MACE among patients with a 
diagnosis of UC who are exposed to 
mirikizumab compared to patients 
with a diagnosis of UC who are not 
exposed to mirikizumab and/or who 
are exposed to other medications 
indicated for the treatment of UC, in 
real world clinical practice in the 
US. 
Severe liver injury 
Routine risk minimisation measures: 
  SmPC Section 4.4 Special Warnings 
and Precautions for Use 
  SmPC Section 4.8 Undesirable 
Routine pharmacovigilance activities beyond 
adverse reactions reporting and signal 
detection include the following: Spontaneous 
Follow-up Form - Hepatic Disorders 
Effects 
  PL Section 2 
Additional risk minimisation measures: 
None proposed 
Additional pharmacovigilance activities: An 
Observational Secondary Database Study to 
Assess the Long-term Safety of 
Mirikizumab.  
  To examine the incidence of severe 
liver injury, serious infections 
including opportunistic infections, 
malignancies excluding non-
Approved on 28 Mar 2023 GMT
 
 
 
 
Safety Concern 
Risk Minimisation Measures  
Pharmacovigilance Activities 
Malignancies 
Routine risk minimisation measures: 
None 
Additional risk minimisation measures: 
None proposed 
MACE 
Routine risk minimisation measures: 
None 
Additional risk minimisation measures: 
None proposed 
melanoma skin cancer (NMSC), and 
MACE among patients with a 
diagnosis of UC who are exposed to 
mirikizumab compared to patients 
with a diagnosis of UC who are not 
exposed to mirikizumab and/or who 
are exposed to other medications 
indicated for the treatment of UC, in 
real world clinical practice in the 
US. 
Routine pharmacovigilance activities beyond 
adverse reactions reporting and signal 
detection include the following: 
  Spontaneous Follow-up Form - Cancer 
Additional pharmacovigilance activities: An 
observational secondary database study to 
assess the long-term safety of mirikizumab. 
  To examine the incidence of severe 
liver injury, serious infections 
including opportunistic infections, 
malignancies excluding non-
melanoma skin cancer (NMSC), 
and MACE among patients with a 
diagnosis of UC who are exposed to 
mirikizumab compared to patients 
with a diagnosis of UC who are not 
exposed to mirikizumab and/or who 
are exposed to other medications 
indicated for the treatment of UC, in 
real world clinical practice in the 
US. 
Routine pharmacovigilance activities beyond 
adverse reactions reporting and signal 
detection include the following: 
  Spontaneous Follow-up Form – Cardiac 
Disorders 
  Spontaneous Follow-up Form -
Cerebrovascular Accident 
Additional pharmacovigilance activities: An 
observational secondary database study to 
assess the long-term safety of mirikizumab.  
Approved on 28 Mar 2023 GMT
 
 
 
 
 
 
 
Safety Concern 
Risk Minimisation Measures  
Pharmacovigilance Activities 
Safety of 
mirikizumab in 
pregnant women and 
lactating women 
Routine risk minimisation measures: 
  SmPC Section 4.6 Fertility, 
Pregnancy, and Lactation 
  PL Section 2 
Additional risk minimisation measures: 
None proposed 
  To examine the incidence of, severe 
liver injury, serious infections 
including opportunistic infections, 
malignancies excluding non-
melanoma skin cancer (NMSC), and 
MACE among patients with a 
diagnosis of UC who are exposed to 
mirikizumab compared to patients 
with a diagnosis of UC who are not 
exposed to mirikizumab and/or who 
are exposed to other medications 
indicated for the treatment of UC, in 
real world clinical practice in the 
US. 
Routine pharmacovigilance activities beyond 
adverse reactions reporting and signal 
detection include the following: 
  Spontaneous Follow-up Form – 
Pregnancy Data Collection – Maternal 
  Spontaneous Follow-Up Form – 
Pregnancy Data Collection – Paternal 
  Spontaneous Follow-Up Form – 
Pregnancy Outcome – Maternal 
  Spontaneous Follow-Up Form – 
Pregnancy Outcome – Paternal 
  Spontaneous Follow-Up Form – Breast 
Feeding 
Additional pharmacovigilance activities: An 
Observational Secondary Database Cohort 
Study on Mirikizumab Exposure and 
Pregnancy: 
Approved on 28 Mar 2023 GMT
 
Safety Concern 
Risk Minimisation Measures  
Pharmacovigilance Activities 
  To monitor the use of mirikizumab 
among women of childbearing age. 
 
  To determine the incidence of 
pregnancy and foetal or infant 
outcomes among pregnant women 
with ulcerative colitis who are 
exposed to mirikizumab during 
pregnancy. 
If sufficient sample sizes allow to 
compare the incidence of pregnancy 
and foetal/infant outcomes of 
pregnant women with ulcerative 
colitis who are exposed to 
mirikizumab during pregnancy to 
women with ulcerative colitis who 
are not exposed to mirikizumab 
and/or who are exposed to other 
medications indicated for the 
treatment of ulcerative colitis. 
Abbreviations: MACE = major adverse cardiac event; NMSC = non-melanoma skin cancer; PL = package leaflet; 
SmPC = summary of product characteristics; UC = ulcerative colitis. 
*Dates are estimated and will be finalised once appropriate data source and vendor are identified. 
Approved on 28 Mar 2023 GMT
 
 
Part VI: Summary of the Risk Management Plan  
Summary of Risk Management Plan for Mirikizumab (LY3074828)  
This is a summary of the RMP for mirikizumab. The RMP details important risks of 
mirikizumab, how these risks can be minimised, and how more information will be obtained 
about mirikizumab’s risks and uncertainties (missing information). 
Mirikizumab’s SmPC and its package leaflet give essential information to health care 
professionals and patients on how mirikizumab should be used.  
This summary of the RMP for mirikizumab should be read in the context of all this information 
including the assessment report of the evaluation and its plain-language summary, all of which is 
part of the European Public Assessment Report].  
Important new concerns or changes to the current ones will be included in updates of 
mirikizumab’s RMP. 
I - The Medicine and What It is Used for  
Mirikizumab is indicated for UC (see SmPC for the full indication). Mirikizumab is the active 
substance, and it is given by IV infusion (after dilution) and by subcutaneous injection. 
Further information about the evaluation of mirikizumab’s benefits can be found in 
mirikizumab’s European Public Assessment Report, including in it’s plain-language summary, 
available on the European Medicines Agency website, under the medicine’s webpage. 
II - Risks Associated with the Medicine and Activities to Minimise or 
Further Characterise the Risks  
Important risks of mirikizumab, together with measures to minimise such risks and the proposed 
studies for learning more about mirikizumab’s risks, are outlined below. 
Measure to minimise the risks identified for medicinal products can be specific information, such 
as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to 
patients and health care professionals. 
This constitutes routine risk minimisation measure. 
In addition to this measure, information about adverse reactions is collected continuously and 
regularly analysed, including Periodic Safety Update Report assessment so that immediate action 
can be taken as necessary. This measure constitutes routine pharmacovigilance activities. 
II.A List of Important Risks and Missing Information  
Important risks of mirikizumab are risks that need special risk management activities to further 
investigate or minimise the risk, so that the medicinal product can be safely administered. 
Important risks can be regarded as identified or potential. Identified risks are concerns for which 
there is sufficient proof of a link with the use of mirikizumab. Potential risks are concerns for 
which an association with the use of this medicine is possible based on available data, but this 
Approved on 28 Mar 2023 GMT
association has not been established yet and needs further evaluation. Missing information refers 
to information on the safety of the medicinal product that is currently missing and needs to be 
collected (e.g., on the long-term use of the medicine). 
List of important risks and missing information  
Important identified risks 
Important potential risks 
None 
  Serious infections 
  Severe liver injury 
  Malignancies  
  MACE 
  Safety of mirikizumab in pregnant women and lactating women 
Missing information 
Abbreviation: MACE = major adverse cardiac event. 
II.B Summary of Important Risks  
Important potential risk: Serious infections 
Evidence for linking the risk to the 
medicine 
Risk factors and risk groups 
In patients with UC across the Phase 2 and Phase 3 studies, serious 
infections (n = 33, 2.3%) were reported commonly during treatment with 
mirikizumab. When including time-off mirikizumab and the 
post-treatment follow-up period, serious infections (n = 39, 2.7%) were 
also reported commonly. Although the majority of patients recovered, 
serious infections due to coronavirus or COVID-19 infections resulted in 
the deaths of 3 patients with UC, 1 while receiving mirikizumab and 2 
while off mirikizumab. 
Across all mirikizumab exposures in Phase 2 and Phase 3 clinical trials for 
UC, CD, and Ps, serious infections (n = 99, 2.6%) have been reported 
commonly during treatment with mirikizumab. When including time-off 
mirikizumab and the post-treatment follow-up time, serious infections 
(n = 108, 2.8%) were also reported commonly. Although the majority of 
patients recovered, serious infections due to COVID-19 or coronavirus 
infections or sequelae of COVID-19 infection resulted in the deaths of 7 
patients, 5 patients while receiving mirikizumab and 2 patients while off 
mirikizumab.  
All deaths due to coronavirus or COVID-19 infection or sequelae of 
COVID-19 infection in the mirikizumab programme occurred early in the 
COVID-19 pandemic, prior to the availability of effective treatments and 
vaccinations. Furthermore, these patients with fatal COVID-19 infections 
were at increased risk for hospitalization, severe disease, and/or death due 
to COVID-19 based on one or more of the following criteria: age 65 
years, BMI 25 kg/m2, diabetes mellitus, cardiovascular disease, and/or 
arterial hypertension. None of these deaths from severe COVID-
19/coronavirus infection or sequelae of COVID-19 infection were 
determined by the investigator or sponsor to be related to mirikizumab. 
Risk groups or specific risk factors for serious infections have not been 
identified from the clinical development programme. Due to the 
immunomodulatory effect of medicines in the anti-IL23 class, patients 
with evidence of untreated latent TB or other active, chronic, or recurrent 
infections or a history thereof may be at greater risk of reactivation or 
exacerbation of their underlying infection, even though this has not been 
reported in the mirikizumab clinical development programme. 
Approved on 28 Mar 2023 GMT
 
 
Risk minimisation measures 
Routine risk minimisation measures: 
  SmPC Section 4.3, Contraindications  
  SmPC Section 4.4, Special Warnings and Precautions for Use 
  PL Section 2 
Additional pharmacovigilance 
activities 
Additional risk minimisation measures: None proposed 
Additional pharmacovigilance activities: Observational Secondary 
Database Study to Assess the Long-Term Safety of Mirikizumab. 
See Section II.C of this summary for an overview of the post-authorisation 
development plan. 
Important potential risk: Severe Liver Injury 
Evidence for linking the risk to the 
medicine 
Risk factors and risk groups 
Risk minimisation measures 
For the UC population exposed to mirikizumab in the Phase 2 and Phase 3 
clinical trials, elevated ALT ≥5xULN and ≥10xULN were reported by 
0.4 % and 0.1% of patients in the mirikizumab treatment group 
respectively.  Elevated AST ≥5xULN and ≥10xULN were reported by 
0.7% and 0.1% of patients in the mirikizumab treatment group 
respectively. 
For all mirikizumab exposures in Phase 2 and Phase 3 clinical trials for 
UC, CD, and Ps, elevated ALT and AST ≥10xULN was reported for each 
analyte in 0.1% of mirikizumab-treated patients. 
Most of these liver enzyme elevations/increases were considered mild to 
moderate in severity and 3 patients with Ps had AST and or ALT 
elevations that were reported as serious. None were associated with an 
adverse clinical outcome. Overall, 0.34% of patients discontinued due to a 
TEAE of liver enzyme elevation. Most recovered from the liver enzyme 
elevations while continuing on mirikizumab treatment and with no further 
adverse effects. 
One patient with UC met Hy’s law criteria with a maximum ALT of 
17.9xULN, maximum AST of 9.9xULN, and maximum bilirubin of 
2.4xULN. This TEAE of “hepatic enzyme increased” was reported as 
moderate severity and as non-serious. As no alternative aetiology for LFT 
elevation could be determined, an association with mirikizumab treatment 
could not be excluded. Therefore, based on the potential of significantly 
elevated aminotransferases being indicative of possible severe liver injury, 
it is considered an important potential risk. 
In the UC, CD, and Ps programmes, no specific risk groups or specific risk 
factors have been identified, although concurrent use of alcohol and/or 
medications with a known risk of liver enzyme elevation or DILI may 
result in a higher frequency of liver enzyme elevations and possible liver 
injury. Additionally, clinical observations of transient elevations of liver 
enzymes with no known cause and persistent elevations most commonly 
due to PSC, AIH, cholelithiasis, and NAFLD, and some herbal, dietary, 
and traditional healing and supplemental products may also contribute to a 
higher frequency of liver enzyme elevations and possible liver injury. In 
the UC programme, no specific risk factors have been identified 
Routine risk minimisation measures: 
  SmPC Section 4.4, Special Warnings and Precautions for Use 
Approved on 28 Mar 2023 GMT
 
 
  SmPC Section 4.8, Undesirable Effects 
  PL Section 2 
Additional pharmacovigilance 
activities 
Additional risk minimisation measures: None proposed 
Additional pharmacovigilance activities: Observational Secondary 
Database Study to Assess the Long-Term Safety of Mirikizumab. 
See Section II.C of this summary for an overview of the post-authorisation 
development plan. 
Important potential risk: Malignancies  
Evidence for linking the risk to the 
medicine 
There are theoretical considerations which could link the pharmacologic 
mode of action of mirikizumab to the development of tumours; however, 
the current clinical and non-clinical data do not suggest that mirikizumab 
causes malignant tumours or promotes tumour growth. 
Risk factors and risk groups 
No specific risk factors for malignancy in relation to treatment with 
mirikizumab have been identified. 
Risk minimisation measures 
None  
Additional pharmacovigilance 
activities 
Additional pharmacovigilance activities: Observational secondary 
database study to assess the long-term safety of mirikizumab. 
See Section II.C of this summary for an overview of the post-authorisation 
development plan. 
Important potential risk: MACE 
Evidence for linking the risk to the 
medicine 
There is no conclusive mechanism of action for cerebrocardiovascular 
disease with IL-23p19 inhibition. A risk may exist due to a therapeutically 
induced acute change in the immunologic environment, specifically 
inhibition of helper T cell sub-type 17, which may disrupt homeostasis 
between pro-atherogenic and protective effects. Because IL-23 plays a key 
role in maintaining homeostasis within the cerebrocardiovascular (CCV) 
system, it has been hypothesised that inhibition of IL-23 may result in 
pathogenic shifts which destabilise atherosclerotic plaques; however, 
clinical relevance of these hypotheses are uncertain. 
Risk factors and risk groups 
No specific risk factors for MACE in relation to treatment with 
mirikizumab have been identified. 
Risk minimisation measures 
None 
Additional pharmacovigilance 
activities 
Additional pharmacovigilance activities: Observational secondary 
database study to assess the long-term safety of mirikizumab. 
See Section II.C of this summary for an overview of the post-authorisation 
development plan. 
Approved on 28 Mar 2023 GMT
 
 
 
Abbreviation: AIH = autoimmune hepatitis; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
BMI = body mass index; CD = Crohn’s disease; COVID-19 = coronavirus disease 2019; DILI = drug-induced 
liver injury; IL = interleukin; LFT = liver function test; MACE = major adverse cardiovascular event; n = 
number of patients in the specified category; NAFLD = non-alcoholic fatty liver disease; Ps = psoriasis; 
PSC = primary sclerosing cholangitis; SmPC = summary of product characteristics; TB = tuberculosis; 
TEAE = treatment-emergent adverse event; UC = ulcerative colitis; ULN = upper limit of normal. 
Approved on 28 Mar 2023 GMT
 
 
Missing information: Safety of mirikizumab in pregnant women and lactating women 
Risk minimisation measures 
Routine risk minimisation measures 
  SmPC Section 4.6, Fertility, Pregnancy, and Lactation 
  PL Section 2 
Additional pharmacovigilance 
activities 
Additional risk minimisation measures: None proposed 
Additional pharmacovigilance activities: Observational Secondary 
Database Cohort Study on Mirikizumab Exposure and Pregnancy 
See Section II.C of this summary for an overview of the post-authorisation 
development plan. 
Abbreviation: PL = package leaflet; SmPC = summary of product characteristics. 
II.C Post-Authorisation Development Plan  
II.C.1 Studies that are Conditions of the Marketing Authorisation  
There are no studies that are conditions of the marketing authorisation or specific obligation of 
mirikizumab. 
II.C.2 Other Studies in Post-Authorisation Development Plan  
Study short name: Observational Secondary Database Cohort Study on Mirikizumab Exposure 
and Pregnancy. 
Purpose of the study: Pregnant women were not included in the mirikizumab clinical 
development programme. However, the indicated population for mirikizumab of patients with 
UC includes women of childbearing age. Therefore, exposure to mirikizumab during pregnancy 
may occur during post-marketing setting. Although there were no mirikizumab-related adverse 
effects on embryo-foetal development, pregnancy outcome, and peri- and post-natal development 
in pregnant monkeys administered mirikizumab, effects on pregnancy and foetal or infant 
outcomes in humans have not been fully determined. Therefore, the purpose of this study is to 
determine the pregnancy, and foetal or infant outcomes among pregnant women with a diagnosis 
of UC who are exposed to mirikizumab. 
The pregnancy, maternal and foetal or infant outcomes of interest include: 
1.  Pregnancy outcomes: recognized spontaneous abortions, stillbirths, elective terminations, 
and preterm delivery  
2.  Foetal or infant outcomes: small for gestational age, and major and minor congenital 
malformations. 
Study objectives 
1.  To monitor the use of mirikizumab among women of childbearing age. 
2.  To determine the incidence of pregnancy and foetal or infant outcomes among pregnant 
women with a diagnosis of UC who are exposed to mirikizumab during pregnancy. 
3.  If sufficient sample size of women exposed to mirikizumab during pregnancy and infants 
linked to the exposed pregnancies are identified, to compare the incidence of pregnancy 
and foetal or infant outcomes of pregnant women with a diagnosis of UC who are 
exposed to mirikizumab during pregnancy to pregnant women with a diagnosis of UC 
Approved on 28 Mar 2023 GMT
 
 
who are not exposed to mirikizumab and/or who are exposed to other medications 
indicated for the treatment of UC. 
Study short name: Observational Secondary Database Study to Assess the Long-Term Safety of 
Mirikizumab. 
Purpose of the study: Data from clinical trials demonstrate that mirikizumab is effective in the 
treatment of patients with moderate to severe UC. However, the long-term safety of mirikizumab 
exposure in terms of events with a low frequency and/or long latency among patients with 
ulcerative colitis in routine clinical practice has not been fully characterised.  
Study Objectives 
The objective of this study is to examine the incidence of severe liver injury, serious infections, 
including opportunistic infections, malignancies excluding non-melanoma skin cancer (NMSC), 
and MACE among patients with a diagnosis of UC who are exposed to mirikizumab compared to 
patients with UC who are not exposed to mirikizumab and/or who are exposed to other 
medications indicated for the treatment of UC in real world clinical practice in the US. The 
incidence of the study outcomes will also be examined among subgroups of interest including 
elderly patients 65 years of age and older. 
Approved on 28 Mar 2023 GMT
 
 
EU Risk Management Plan (Version 0.4) 
Page 70 of 100 
Part VII: Annexes 
Annex 
Page 
Annex 4 - Specific Adverse Drug Reaction Follow-up Forms ................................................71
Annex 6 - Details of Proposed Additional Risk Minimisation Activities (if 
applicable) ...............................................................................................................100
LY3074828 
Approved on 28 Mar 2023 GMT
Annex 4 - Specific Adverse Drug Reaction Follow-up Forms  
Follow-up forms  
Specific Adverse Event Follow-up Form 
Event(s) Associated with the Form 
Form #1 
Form #2 
Form #3 
Form #4 
Form #5 
Form #6 
Form #7 
Form #8 
Form #9 
Form #10 
Form #11 
Form #12 
Infection 
Extrapulmonary Tuberculosis 
Pulmonary Tuberculosis 
Pregnancy Data Collection - Maternal 
Pregnancy Data Collection - Paternal 
Pregnancy Outcome - Maternal 
Pregnancy Outcome - Paternal 
Breastfeeding 
Hepatic Disorders 
Cancer 
Cardiac Disorders 
Cerebrovascular Accident 
Approved on 28 Mar 2023 GMT
 
 
 
 
 
 
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
,-./01-2(cid:4)34-5167(cid:4)89:;<=>9
?@1-7(cid:4)
I5J/0K@L/5(cid:4)M0/4B2-2(cid:4)ND7
(cid:4)
M@L-51q6(cid:4)r@K-(cid:4)/0(cid:4)I5BL@C67
G
v(cid:4) w(cid:4) x9y9>z9
u-52-07(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:20)(cid:13)(cid:11)(cid:8)(cid:18)(cid:7)(cid:8)(cid:19)(cid:11)(cid:24)(cid:22)(cid:4)*(cid:11)(cid:2)(cid:2)(cid:11)+(cid:14)(cid:24)(cid:13)(cid:4)*(cid:11)(cid:25)(cid:12)
ABCCD(cid:4)E@6-(cid:4)F7
OBP5@1Q0-RI5BL@C67
(cid:4)
G
S@T7
UVWWX(cid:4)YZ[\(cid:4)]W^_‘W(cid:4)a‘bVcdb(cid:4)[‘ecbX(cid:4)f(cid:4)Yghh\(cid:4)hiifjhkl(cid:4)mn(cid:4)iopl
(cid:4)
,@{-7
|}~<}(cid:127)(cid:128)}9
(cid:129)(cid:127)(cid:128)}9
(cid:136)-BPs17
(cid:130)(cid:131)}<y
(cid:132)(cid:133)(cid:134);(cid:135)
M@L-51q6(cid:4)NB01s(cid:4)?@1-(cid:4)/0(cid:4)tP-7
G
(cid:139)-BPs17
(cid:131)(cid:137)
y(cid:138)
H
(cid:128)9
<(cid:140)
89(cid:143)(cid:128)<}=>9(cid:145)
v(cid:135);(cid:158)~;9<(cid:159)(cid:145)
v>(cid:135)(cid:140)~(cid:131)}=>9(cid:145)
(cid:144)>(cid:127);(cid:4)z(cid:134);9(cid:4);(cid:156);9(cid:133)(cid:4)><<~(cid:135);(cid:143)(cid:145)
(cid:141)>~(cid:133);(cid:145)
(cid:144)}(cid:133);(cid:4)(cid:144)(cid:153)|(cid:145)
(cid:144)}(cid:133);(cid:4)(cid:141);(cid:127)(cid:133)}(cid:135)(cid:133);(cid:143)(cid:145)
8:(cid:4)(cid:144)(cid:128)(cid:127)<>9=9~;(cid:143)£(cid:4)(cid:143)(cid:128)(cid:143)(cid:4)(cid:133)(cid:134);(cid:4);(cid:156);9(cid:133)(cid:4)(cid:135);(cid:127)>(cid:131)(cid:156);¡ ¢;(cid:127) (cid:154)>
8:(cid:4)(cid:141);(cid:127)(cid:133)}(cid:135)(cid:133);(cid:143)£(cid:4)(cid:143)(cid:128)(cid:143)(cid:4)(cid:133)(cid:134);(cid:4);(cid:156);9(cid:133)(cid:4)><<~(cid:135)¡ ¢;(cid:127) (cid:154)>
(cid:141);(cid:142)>(cid:135)(cid:133);(cid:143)(cid:4)(cid:144)(cid:135)~(cid:138)(cid:145)(cid:4)
(cid:4)
(cid:4)
(cid:152)>(cid:133)(cid:153)|>9(cid:133)(cid:135)>(cid:131)(cid:4)(cid:154)~(cid:140)(cid:137);(cid:135)(cid:155)(cid:128):(cid:4)}(cid:156)}(cid:128)(cid:131)}(cid:137)(cid:131);(cid:157)(cid:145)
(cid:144)>(cid:127);(cid:145)
(cid:146)V(cid:147)V(cid:148)V(cid:149)(cid:150)(cid:151)‘_
(cid:160)(cid:133)}(cid:135)(cid:133)(cid:4)(cid:144)}(cid:133);(cid:145)
(cid:144)(cid:135)~(cid:138)(cid:4)(cid:144)(cid:153)|¡ (cid:154)> ¢;(cid:127)
(cid:144)(cid:135)~(cid:138)(cid:4)(cid:141);(cid:127)(cid:133)}(cid:135)(cid:133);(cid:143)¡ (cid:154)> ¢;(cid:127)
(cid:4)
u-5-0@C
⁄¥ƒ§¤'“«“¤‹(cid:4)›¥«¤'ﬁ“ﬂ¥
(cid:176)(cid:159)(cid:142);(cid:4)>:(cid:4)89:;<=>9
–(cid:135);(cid:127);9=9(cid:138)(cid:4)(cid:160)(cid:128)(cid:138)9(cid:127)(cid:4)}9(cid:143)(cid:4)(cid:160)(cid:159)(cid:140)(cid:142)(cid:133)>(cid:140)(cid:127)
(cid:141);(cid:131);(cid:156)}9(cid:133)(cid:4)w;(cid:143)(cid:128)<}(cid:131)(cid:4)†(cid:128)(cid:127)(cid:133)>(cid:135)(cid:159)(cid:4)}9(cid:143)(cid:4)(cid:141)(cid:128)(cid:127)y(cid:4):}<(cid:133)>(cid:135)(cid:127)
,-C-4@51(cid:4)2B@P5/6L{(cid:4)61Q2B-67
r/0K@C(cid:4),@5P-
N@6-CB5-(cid:4)(cid:181)@CQ-
t‡5/0K@C(cid:4)(cid:181)@CQ-
IK.0/4-K-51(cid:4)(cid:181)@CQ-
?@1-7
?@1-7
?@1-7
|~(cid:131)(cid:133)~(cid:135);(cid:127)
(cid:129)9=(cid:138);9(cid:4)(cid:144);(cid:133);<=>9
(cid:160);(cid:135)>(cid:131)>(cid:138)(cid:128)<(cid:4)(cid:160)(cid:133)~(cid:143)(cid:128);(cid:127)
8(cid:140)}(cid:138)(cid:128)9(cid:138)(cid:4)(cid:160)(cid:133)~(cid:143)(cid:128);(cid:127)
(cid:176)(cid:128)(cid:127)(cid:127)~;(cid:4)(cid:130)(cid:128)>(cid:142)(cid:127)(cid:159)
A@‡/0@1/0D(cid:4),-6QC167
A@‡/0@1/0D(cid:4)·-61
(cid:154);~(cid:133)(cid:135)>(cid:142)(cid:134)(cid:128)(cid:131)(cid:127)
†};(cid:140)>(cid:138)(cid:131)>(cid:137)(cid:128)9
¶(cid:130)|
–(cid:131)}(cid:133);(cid:131);(cid:133)(cid:127)
(cid:129)(cid:152)(cid:176)
(cid:129)(cid:160)(cid:176)
(cid:129)(cid:131)y}(cid:131)(cid:128)9;
(cid:142)(cid:134)>(cid:127)(cid:142)(cid:134)}(cid:133)}(cid:127);
(cid:130)(cid:128)(cid:131)(cid:128)(cid:135)~(cid:137)(cid:128)9
|(cid:135);}=9(cid:128)9;
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:30)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:31)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4) !(cid:20)"(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4) #$$"(cid:4)$%%(cid:14)(cid:29)$&’(cid:4)((cid:10)(cid:4)%)(cid:30)’
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
(cid:4)
*+,(cid:4)-./,(cid:4)0102-(cid:4)304+-05(cid:4)-6(cid:4)+(cid:4)7/448(cid:4)539:;
(cid:4)
(cid:4)
<=>?@ABC=
J102-(cid:4)69-K6L0
(cid:4)D
(cid:4)E0,(cid:4)(cid:4)(cid:4)(cid:4)(cid:4) (cid:4)F6
(cid:4)G2H26I2
M0K610305
F6-(cid:4)M0K610305
(cid:4)M0K6103/2:
*63,0205
(cid:4)G2H26I2
M0K610305(cid:4)I/-.(cid:4)N0O9044+(cid:4)PQ40+,0(cid:4)R361/50(cid:4)50-+/4,ST
Q40+,0(cid:4)R361/50(cid:4)3+U62+40(cid:4)V63(cid:4)304+-0520,,(cid:4)+,,0,,L02-T
(cid:4)
(cid:4)
(cid:4)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:29)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:30)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:31) (cid:20)!(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4)(cid:31)"##!(cid:4)#$$(cid:14)%#&’(cid:4)((cid:10)(cid:4)$)(cid:29)’
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
,-./01-2(cid:4)34-5167(cid:4)89:;<=>?@AB<;C(cid:4)D>EF;G>?AHIH
(cid:20)(cid:13)(cid:11)(cid:8)(cid:18)(cid:7)(cid:8)(cid:19)(cid:11)(cid:24)(cid:22)(cid:4)*(cid:11)(cid:2)(cid:2)(cid:11)+(cid:14)(cid:24)(cid:13)(cid:4)*(cid:11)(cid:25)(cid:12)
LMNNO(cid:4)PK6-(cid:4)Q7
ZM[5K1\0-]T5MWKN67
(cid:4)
R
^K_7
‘abbc(cid:4)defg(cid:4)hbijkb(cid:4)lkmanom(cid:4)fkpnmc(cid:4)q(cid:4)drssg(cid:4)sttqusvw(cid:4)xy(cid:4)tz{w
(cid:4)
,K(cid:134)-7
(cid:135)<>G<HI<B
(cid:136)HI<B
(cid:140)-M[~17
(cid:137)?<G(cid:132)
(cid:138):(cid:139)F;
XKW-51|6(cid:4)YM01~(cid:4)JK1-(cid:4)/0(cid:4)(cid:127)[-7
R
(cid:142)-M[~17
?E
(cid:132)(cid:141)
S
IB
G@
JK1-7(cid:4)
T5U/0VKW/5(cid:4)X0/4M2-2(cid:4)YO7
(cid:4)
XKW-51|6(cid:4)}KV-(cid:4)/0(cid:4)T5MWKN67
R
(cid:129)(cid:4) (cid:130)(cid:4) (cid:131)B(cid:132)BA(cid:133)B
(cid:128)-52-07(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:143)F=A;:F(cid:144)(cid:4)(cid:145);>(cid:141)(cid:146)(cid:4)
(cid:4)
(cid:4)
(cid:153)A:(cid:154)(cid:135)AB:;A?(cid:4)(cid:155)>@EF;(cid:156)I(cid:157)(cid:4)<(cid:158)<I?<E?F(cid:159)(cid:146)
(cid:145)AHF(cid:146)
(cid:147)a(cid:148)a(cid:149)a(cid:150)(cid:151)(cid:152)kj
£:<;:(cid:4)(cid:145)<:F(cid:146)
(cid:145);>(cid:141)(cid:4)(cid:145)(cid:154)(cid:135)⁄ (cid:155)A ¥FH
(cid:145);>(cid:141)(cid:4)(cid:143)FH:<;:F(cid:144)⁄ (cid:155)A ¥FH
(cid:4)
£I:F(cid:156)H(cid:159)(cid:4)A(cid:157)(cid:4)(cid:160)B(cid:157)FG¡AB(cid:146)
§¤'“«‹›ﬁﬂ(cid:176)–«“†(cid:4)‡›·(cid:181)“¶›ﬁ(cid:176)•‚•
X0-6-5W5[(cid:4)ZOV.1/V6
(cid:135)A>(cid:141)(cid:139)
£=>:>@
»FI(cid:141)(cid:139):(cid:4)?AHH
(cid:129)AG<?(cid:4)BF>;A?A(cid:141)IG<?(cid:4)…B(cid:144)IB(cid:141)H
,-N-4K51(cid:4)XK61(cid:4)(cid:190)-2M(cid:134)KN(cid:4)(cid:142)M61/0O
D>EF;G>?AHIH
‰AHI¡(cid:158)F(cid:4)‰‰(cid:145)
(cid:160)B(cid:144)IG<¡AB(cid:146)
(cid:129);F¢>FBGC(cid:146)
(cid:129)A;@>?<¡AB(cid:146)
(cid:145)AHF(cid:4)(cid:133)(cid:139)FB(cid:4)F(cid:158)FB:(cid:4)AGG>;F(cid:144)(cid:146)
(cid:143)A>:F(cid:146)
(cid:145)<:F(cid:4)(cid:145)(cid:154)(cid:135)(cid:146)
(cid:145)<:F(cid:4)(cid:143)FH:<;:F(cid:144)(cid:146)
(cid:160)(cid:157)(cid:4)(cid:145)IHGAB¡B>F(cid:144)ƒ(cid:4)(cid:144)I(cid:144)(cid:4):(cid:139)F(cid:4)F(cid:158)FB:(cid:4);FHA?(cid:158)F⁄ ¥FH (cid:155)A
(cid:160)(cid:157)(cid:4)(cid:143)FH:<;:F(cid:144)ƒ(cid:4)(cid:144)I(cid:144)(cid:4):(cid:139)F(cid:4)F(cid:158)FB:(cid:4)AGG>;⁄ ¥FH (cid:155)A
(cid:129)F(cid:158)F;
(cid:155)I(cid:141)(cid:139):(cid:4)H(cid:133)F<:H
„<F@A=:CHIH
‰C>;I<
„F<(cid:144)<G(cid:139)F
(cid:135)AB(cid:157)>HIAB
(cid:137)<G(cid:132)(cid:4)=<IB
”AIB:(cid:4)H(cid:133)F??IB(cid:141)
£(cid:132)IB(cid:4)?FHIABH
(cid:153)C@=(cid:139)<(cid:144)FBA=<:(cid:139)C
(cid:155)>G(cid:139)<?(cid:4);I(cid:141)I(cid:144)I:C
(cid:136)B<F@I<
(cid:136)EBA;@<?(cid:4)G(cid:139)FH:(cid:4)9¿;<C
£@A(cid:132)IB(cid:141)
(cid:135)A;¡GAH:F;AI(cid:144)(cid:4)>HF
(cid:145)I<EF:FH(cid:4)@F??I:>H
(cid:129)<@I?C(cid:4)@F@EF;(cid:4)(cid:133)I:(cid:139)(cid:4)D(cid:137)
„F<(cid:158)C(cid:4)<?GA(cid:139)A?(cid:4)>HF
‰AHI¡(cid:158)F(cid:4)(cid:160)(cid:129)(cid:155)¿C(cid:4);F?F<HF(cid:4)<HH<C
(cid:129);A@(cid:4)D(cid:137)(cid:4)FB(cid:144)F@IG(cid:4)<;F<
(cid:137)(cid:135)(cid:192)(cid:4)I@@>BI`<¡AB
D;F<:@FB:(cid:4)(cid:133)I:(cid:139)(cid:4)(cid:160)(cid:155)„
„(cid:160)´(cid:4)IB(cid:157)FG¡AB
(cid:136)>:AI@@>BF(cid:4)(cid:144)IHA;(cid:144)F;
(cid:130)<?I(cid:141)B<BGC
(cid:135)<BGF;(cid:4)G(cid:139)F@A(cid:4);9
(cid:138):(cid:139)F;(cid:4);F?F(cid:158)<B:(cid:4)(cid:139)IH:A;C(cid:146)
P/5(cid:134)/VM1K51(cid:4)(cid:190)-2M(cid:134)KW/56(cid:4)](cid:4)Z\ˆ61K5(cid:134)-6
(cid:135)>;;FB:(cid:4)<?GA(cid:139)A?(cid:4)>HF
(cid:135)>;;FB:(cid:4)H@A(cid:132)IB(cid:141)
(cid:145);>(cid:141)(cid:4)<E>HF
(cid:135)A;¡GAH:F;AI(cid:144)H(cid:156)H=FGI(cid:157)C(cid:159)(cid:146)
(cid:160)@@>BA@A(cid:144)>?<:A;H(cid:156)H=FGI(cid:157)C(cid:159)(cid:146)
(cid:138):(cid:139)F;(cid:4)@F(cid:144)IG<¡ABH(cid:146)
LKˆ/0K1/0O(cid:4)˜-616(cid:4)](cid:4)T54-6W[KW/56
£(cid:132)IB(cid:4):FH:(cid:4)(cid:157)A;(cid:4)D(cid:137)
(cid:160)(cid:129)(cid:155)¿C(cid:4);F?F<HF(cid:4)<HH<C
£=>:>@(cid:4)H@F<;(cid:4)(cid:157)A;(cid:4)D(cid:137)
£=>:>@(cid:4)G>?:>;F(cid:4)(cid:157)A;(cid:4)D(cid:137)
‰AHI¡(cid:158)F
‰AHI¡(cid:158)F
‰AHI¡(cid:158)F
‰AHI¡(cid:158)F
(cid:155)F(cid:141)<¡(cid:158)F
(cid:155)F(cid:141)<¡(cid:158)F
(cid:155)F(cid:141)<¡(cid:158)F
(cid:155)F(cid:141)<¡(cid:158)F
Approved on 28 Mar 2023 GMT
(cid:155)A:(cid:4)(cid:145)ABF
(cid:155)A:(cid:4)(cid:145)ABF
(cid:155)A:(cid:4)(cid:145)ABF
(cid:155)A:(cid:4)(cid:145)ABF
‰FB(cid:144)IB(cid:141)
‰FB(cid:144)IB(cid:141)
‰FB(cid:144)IB(cid:141)
‰FB(cid:144)IB(cid:141)
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:30)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:31)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4) !(cid:20)"(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4) #$$"(cid:4)$%%(cid:14)(cid:29)$&’(cid:4)((cid:10)(cid:4)%)(cid:30)’
*+,(cid:4)-./01023
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
?-@(cid:4)AB1;B/.5
405678.
405678.
9.2:78.
9.2:78.
9.2:78.
9.2:78.
9.2:78.
90;(cid:4)<0=.
90;(cid:4)<0=.
90;(cid:4)<0=.
90;(cid:4)<0=.
90;(cid:4)<0=.
4.=>6=2
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
4.=>6=2
4.=>6=2
4.=>6=2
4.=>6=2
405678.
405678.
405678.
]RS^PZ(cid:4)VP_‘W
aPXWZb_W(cid:4)cPZYW
dQ_RS^PZ(cid:4)cPZYW
e^fSRgW^W_T(cid:4)cPZYW
hPTW[
hPTW[
hPTW[
C/6=.(cid:4)AB1;B/.5
D0=.(cid:4)E://0F(cid:4)AB1;B/.5
G;H./(cid:4)AB1;B/.5I-6;.J
?H.5;(cid:4)K:>602/:LH
?H.5;(cid:4)?M
G;H./(cid:4)5;B>6.5N
OPQRSPTRSU(cid:4)VWXYZTX[
OPQRSPTRSU(cid:4)\WXT
9.B;/0LH615
*:.E0210i6=
jD?
41:;.1.;5
klM
k-M
k1m:16=.(cid:4)LH05LH:;:5.
D616/Bi6=
?/.:7=6=.
?-@(cid:4)?.11(cid:4)?0B=;
?-@(cid:4)n1BA05.
C/6=:13565
G;H./N
(cid:4)
j:5(cid:4);H65(cid:4).8.=;(cid:4)/.1:;.>(cid:4);0(cid:4):(cid:4)l6113(cid:4)>/B2o
(cid:4)
(cid:4)
pqrstuvwxyzts{(cid:4)|v}~s(cid:127)vwy(cid:128)(cid:129)(cid:128)
(cid:132)8.=;(cid:4)0B;A0E.
(cid:4)(cid:130)
(cid:4)(cid:131).5(cid:4)(cid:4)(cid:4)(cid:4)(cid:4) (cid:4)90
(cid:4)C=m=0F=
K.A08./.>
90;(cid:4)K.A08./.>
(cid:4)K.A08./6=2
j0/5.=.>
(cid:4)C=m=0F=
K.A08./.>(cid:4)F6;H(cid:4)-.(cid:133)B.11:(cid:4)I41.:5.(cid:4)L/086>.(cid:4)>.;:615JN
41.:5.(cid:4)L/086>.(cid:4)/:70=:1.(cid:4)(cid:134)0/(cid:4)/.1:;.>=.55(cid:4):55.55E.=;N
(cid:4)
(cid:4)
(cid:4)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:29)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:30)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:31) (cid:20)!(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4)(cid:31)"##!(cid:4)#$$(cid:14)%#&’(cid:4)((cid:10)(cid:4)$)(cid:29)’
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
,-./01-2(cid:4)34-5167(cid:4)89:;<=>?@(cid:4)A9BC?D9:<EFE
(cid:20)(cid:13)(cid:11)(cid:8)(cid:18)(cid:7)(cid:8)(cid:19)(cid:11)(cid:24)(cid:22)(cid:4)*(cid:11)(cid:2)(cid:2)(cid:11)+(cid:14)(cid:24)(cid:13)(cid:4)*(cid:11)(cid:25)(cid:12)
IJKKL(cid:4)MH6-(cid:4)N7
WJX5H1Y0-ZQ5JTHK67
(cid:4)
O
[H\7
]^__‘(cid:4)abcd(cid:4)e_fgh_(cid:4)ihj^klj(cid:4)chmkj‘(cid:4)n(cid:4)aoppd(cid:4)pqqnrpst(cid:4)uv(cid:4)qwxt
(cid:4)
,H(cid:131)-7
(cid:132)>9D>EF>=
(cid:133)EF>=
(cid:138)-JX{17
(cid:134):>D(cid:129)
(cid:135)(cid:136)(cid:137)C?
UHT-51y6(cid:4)VJ01{(cid:4)GH1-(cid:4)/0(cid:4)|X-7
O
(cid:140)-JX{17
:B
(cid:129)(cid:139)
P
F=
D;
GH1-7(cid:4)
Q5R/0SHT/5(cid:4)U0/4J2-2(cid:4)VL7
(cid:4)
UHT-51y6(cid:4)zHS-(cid:4)/0(cid:4)Q5JTHK67
O
~(cid:4) (cid:127)(cid:4) (cid:128)=(cid:129)=<(cid:130)=
}-52-07(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:141)C(cid:142)<?(cid:136)C(cid:143)(cid:4)(cid:144)?9(cid:139)(cid:145)(cid:4)
(cid:4)
(cid:4)
(cid:152)<(cid:136)(cid:153)(cid:132)<=(cid:136)?<:(cid:4)(cid:154)9;BC?(cid:155)F(cid:156)(cid:4)>(cid:157)>F:>B:C(cid:158)(cid:145)
(cid:144)<EC(cid:145)
(cid:146)^(cid:147)^(cid:148)^(cid:149)(cid:150)(cid:151)hg
¢(cid:136)>?(cid:136)(cid:4)(cid:144)>(cid:136)C(cid:145)
(cid:144)?9(cid:139)(cid:4)(cid:144)(cid:153)(cid:132)£ (cid:154)< ⁄CE
(cid:144)?9(cid:139)(cid:4)(cid:141)CE(cid:136)>?(cid:136)C(cid:143)£ (cid:154)< ⁄CE
(cid:4)
U0-6-5T5X(cid:4)WLS.1/S6
ƒ§¤'“«‹›ﬁ(cid:4)ﬂ§(cid:176)–›†§¤“‡·‡
(cid:132)<9(cid:139)(cid:137)
¢(cid:142)9(cid:136)9;
•CF(cid:139)(cid:137)(cid:136)(cid:4):<EE
,-K-4H51(cid:4)UH61(cid:4)‚-2J(cid:131)HK(cid:4)(cid:140)J61/0L
A9BC?D9:<EFE
8<EF(cid:160)(cid:157)C(cid:4)88(cid:144)
(cid:159)=(cid:143)FD>(cid:160)<=(cid:145)
~?C¡9C=D@(cid:145)
~<?;9:>(cid:160)<=(cid:145)
(cid:144)<EC(cid:4)(cid:130)(cid:137)C=(cid:4)C(cid:157)C=(cid:136)(cid:4)<DD9?C(cid:143)(cid:145)
(cid:141)<9(cid:136)C(cid:145)
(cid:144)>(cid:136)C(cid:4)(cid:144)(cid:153)(cid:132)(cid:145)
(cid:144)>(cid:136)C(cid:4)(cid:141)CE(cid:136)>?(cid:136)C(cid:143)(cid:145)
(cid:159)(cid:156)(cid:4)(cid:144)FED<=(cid:160)=9C(cid:143)¥(cid:4)(cid:143)F(cid:143)(cid:4)(cid:136)(cid:137)C(cid:4)C(cid:157)C=(cid:136)(cid:4)?CE<:(cid:157)C£ ⁄CE (cid:154)<
(cid:159)(cid:156)(cid:4)(cid:141)CE(cid:136)>?(cid:136)C(cid:143)¥(cid:4)(cid:143)F(cid:143)(cid:4)(cid:136)(cid:137)C(cid:4)C(cid:157)C=(cid:136)(cid:4)<DD9?£ ⁄CE (cid:154)<
~C(cid:157)C?
(cid:154)F(cid:139)(cid:137)(cid:136)(cid:4)E(cid:130)C>(cid:136)E
(cid:181)>C;<(cid:142)(cid:136)@EFE
(cid:181)C>(cid:143)>D(cid:137)C
(cid:132)<=(cid:156)9EF<=
(cid:134)>D(cid:129)(cid:4)(cid:142)>F=
¶<F=(cid:136)(cid:4)E(cid:130)C::F=(cid:139)
¢(cid:129)F=(cid:4):CEF<=E
(cid:152)@;(cid:142)(cid:137)>(cid:143)C=<(cid:142)>(cid:136)(cid:137)@
(cid:133)B=<?;>:(cid:4)D(cid:137)CE(cid:136)(cid:4)„”?>@
¢;<(cid:129)F=(cid:139)
(cid:132)<?(cid:160)D<E(cid:136)C?<F(cid:143)(cid:4)9EC
(cid:144)F>BC(cid:136)CE(cid:4);C::F(cid:136)9E
~>;F:@(cid:4);C;BC?(cid:4)(cid:130)F(cid:136)(cid:137)(cid:4)A(cid:134)
(cid:181)C>(cid:157)@(cid:4)>:D<(cid:137)<:(cid:4)9EC
8<EF(cid:160)(cid:157)C(cid:4)(cid:159)~(cid:154)”@(cid:4)?C:C>EC(cid:4)>EE>@
~?<;(cid:4)A(cid:134)(cid:4)C=(cid:143)C;FD(cid:4)>?C>
(cid:134)(cid:132)»(cid:4)F;;9=F…>(cid:160)<=
A?C>(cid:136);C=(cid:136)(cid:4)(cid:130)F(cid:136)(cid:137)(cid:4)(cid:159)(cid:154)(cid:181)
(cid:181)(cid:159)‰(cid:4)F=(cid:156)CD(cid:160)<=
(cid:133)9(cid:136)<F;;9=C(cid:4)(cid:143)FE<?(cid:143)C?
(cid:127)>:F(cid:139)=>=D@
(cid:132)>=DC?(cid:4)D(cid:137)C;<(cid:4)?„
(cid:135)(cid:136)(cid:137)C?(cid:4)?C:C(cid:157)>=(cid:136)(cid:4)(cid:137)FE(cid:136)<?@(cid:145)
M/5(cid:131)/SJ1H51(cid:4)‚-2J(cid:131)HT/56(cid:4)Z(cid:4)WY(cid:190)61H5(cid:131)-6
(cid:132)9??C=(cid:136)(cid:4)>:D<(cid:137)<:(cid:4)9EC
(cid:132)9??C=(cid:136)(cid:4)E;<(cid:129)F=(cid:139)
(cid:144)?9(cid:139)(cid:4)>B9EC
(cid:132)<?(cid:160)D<E(cid:136)C?<F(cid:143)E(cid:155)E(cid:142)CDF(cid:156)@(cid:158)(cid:145)
(cid:159);;9=<;<(cid:143)9:>(cid:136)<?E(cid:155)E(cid:142)CDF(cid:156)@(cid:158)(cid:145)
(cid:135)(cid:136)(cid:137)C?(cid:4);C(cid:143)FD>(cid:160)<=E(cid:145)
IH(cid:190)/0H1/0L(cid:4)¿-616(cid:4)Z(cid:4)Q54-6TXHT/56
¢(cid:129)F=(cid:4)(cid:136)CE(cid:136)(cid:4)(cid:156)<?(cid:4)A(cid:134)
(cid:159)~(cid:154)”@(cid:4)?C:C>EC(cid:4)>EE>@
¢(cid:142)9(cid:136)9;(cid:4)E;C>?(cid:4)(cid:156)<?(cid:4)A(cid:134)
¢(cid:142)9(cid:136)9;(cid:4)D9:(cid:136)9?C(cid:4)(cid:156)<?(cid:4)A(cid:134)
(cid:133)=(cid:160)(cid:139)C=(cid:4)(cid:144)C(cid:136)CD(cid:160)<=
(cid:181)(cid:159)‰(cid:4)¢C?<:<(cid:139)@
8<EF(cid:160)(cid:157)C
8<EF(cid:160)(cid:157)C
8<EF(cid:160)(cid:157)C
8<EF(cid:160)(cid:157)C
8<EF(cid:160)(cid:157)C
8<EF(cid:160)(cid:157)C
(cid:154)C(cid:139)>(cid:160)(cid:157)C
(cid:154)C(cid:139)>(cid:160)(cid:157)C
(cid:154)C(cid:139)>(cid:160)(cid:157)C
(cid:154)C(cid:139)>(cid:160)(cid:157)C
(cid:154)C(cid:139)>(cid:160)(cid:157)C
(cid:154)C(cid:139)>(cid:160)(cid:157)C
Approved on 28 Mar 2023 GMT
(cid:154)<(cid:136)(cid:4)(cid:144)<=C
(cid:154)<(cid:136)(cid:4)(cid:144)<=C
(cid:154)<(cid:136)(cid:4)(cid:144)<=C
(cid:154)<(cid:136)(cid:4)(cid:144)<=C
(cid:154)<(cid:136)(cid:4)(cid:144)<=C
(cid:154)<(cid:136)(cid:4)(cid:144)<=C
8C=(cid:143)F=(cid:139)
8C=(cid:143)F=(cid:139)
8C=(cid:143)F=(cid:139)
8C=(cid:143)F=(cid:139)
8C=(cid:143)F=(cid:139)
8C=(cid:143)F=(cid:139)
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:30)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:31)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4) !(cid:20)"(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4) #$$"(cid:4)$%%(cid:14)(cid:29)$&’(cid:4)((cid:10)(cid:4)%)(cid:30)’
*+,-.(cid:4)*/
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
0.+,1(cid:4)-.234,-5
6789:7;9:<(cid:4)=>?@A;?B
6789:7;9:<(cid:4)C>?;
D9:E7A(cid:4)=7FG>
H7?>AIF>(cid:4)J7A@>
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
K8F9:E7A(cid:4)J7A@>
LEM:9N>E>F;(cid:4)J7A@>
O7;>B
O7;>B
O7;>B
P,2.1QR+4S-
TU,VQWSQX4Y
Z[*
\SU.,S,.-
]^/
]_/
]S‘US4Y,(cid:4)R+Q-R+U.U-,
[4S412X4Y
*1,UaY4Y,
0.+,15
(cid:4)
ZU-(cid:4).+4-(cid:4),b,Y.(cid:4)1,SU.,3(cid:4).Q(cid:4)U(cid:4)^4SSc(cid:4)312Wd
(cid:4)
(cid:4)
efghijklm(cid:4)nfoplqfgirsr
xb,Y.(cid:4)Q2.yQV,
(cid:4)t
(cid:4)u,-(cid:4)(cid:4)(cid:4)(cid:4)(cid:4) (cid:4)PQ
(cid:4)vY‘YQwY
z,yQb,1,3
PQ.(cid:4)z,yQb,1,3
(cid:4)z,yQb,14YW
ZQ1-,Y,3
(cid:4)vY‘YQwY
z,yQb,1,3(cid:4)w4.+(cid:4)_,{2,SSU(cid:4)|\S,U-,(cid:4)R1Qb43,(cid:4)3,.U4S-}5
\S,U-,(cid:4)R1Qb43,(cid:4)1UaQYUS,(cid:4)~Q1(cid:4)1,SU.,3Y,--(cid:4)U--,--V,Y.5
(cid:4)
(cid:4)
(cid:4)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:29)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:30)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:31) (cid:20)!(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4)(cid:31)"##!(cid:4)#$$(cid:14)%#&’(cid:4)((cid:10)(cid:4)$)(cid:29)’
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
,-./01-2(cid:4)34-5167(cid:4)89:;<=<>?(cid:4)@=A=(cid:4)BCDD:>EC<F(cid:4)G=A:9<=D
(cid:20)(cid:13)(cid:11)(cid:8)(cid:18)(cid:7)(cid:8)(cid:19)(cid:11)(cid:24)(cid:22)(cid:4)*(cid:11)(cid:2)(cid:2)(cid:11)+(cid:14)(cid:24)(cid:13)(cid:4)*(cid:11)(cid:25)(cid:12)
JKLLM(cid:4)NI6-(cid:4)O7
XKY5I1Z0-[R5KUIL67
(cid:4)
P
\I]7
^_‘‘a(cid:4)bcde(cid:4)f‘ghi‘(cid:4)jik_lmk(cid:4)dinlka(cid:4)o(cid:4)bpqqe(cid:4)qrrosqtu(cid:4)vw(cid:4)rxyu
(cid:4)
,I(cid:132)-7
B=(cid:133)>=(cid:134)(cid:135)=<
(cid:136)(cid:134)(cid:135)=<
(cid:140)-KY|17
(cid:137)D=>(cid:130)
(cid:138)A(cid:139):9
VIU-51z6(cid:4)WK01|(cid:4)HI1-(cid:4)/0(cid:4)}Y-7
P
(cid:142)-KY|17
D(cid:141)
(cid:130);
Q
(cid:135)<
>G
HI1-7(cid:4)
R5S/0TIU/5(cid:4)V0/4K2-2(cid:4)WM7
(cid:4)
VIU-51z6(cid:4){IT-(cid:4)/0(cid:4)R5KUIL67
P
(cid:127)(cid:4) (cid:128)(cid:4) (cid:129)<(cid:130)<C(cid:131)<
~-52-07(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:143):(cid:144)C9A:(cid:145)(cid:4)@9(cid:133);(cid:146)(cid:4)
(cid:4)
(cid:4)
(cid:153)CA(cid:154)BC<A9CD(cid:4)(cid:155)(cid:133)G(cid:141):9(cid:156)(cid:135)(cid:157)(cid:4)=(cid:158)=(cid:135)D=(cid:141)D:(cid:159)(cid:146)
@C(cid:134):(cid:146)
(cid:147)_(cid:148)_(cid:149)_(cid:150)(cid:151)(cid:152)ih
¢A=9A(cid:4)@=A:(cid:146)
@9(cid:133);(cid:4)@(cid:154)B£ (cid:155)C ⁄:(cid:134)
@9(cid:133);(cid:4)(cid:143):(cid:134)A=9A:(cid:145)£ (cid:155)C ⁄:(cid:134)
(cid:160)<(cid:145)(cid:135)>=EC<(cid:146)
(cid:127)9:¡(cid:133):<>?(cid:146)
(cid:127)C9G(cid:133)D=EC<(cid:146)
@C(cid:134):(cid:4)(cid:131)(cid:139):<(cid:4):(cid:158):<A(cid:4)C>>(cid:133)9:(cid:145)(cid:146)
(cid:143)C(cid:133)A:(cid:146)
@=A:(cid:4)@(cid:154)B(cid:146)
@=A:(cid:4)(cid:143):(cid:134)A=9A:(cid:145)(cid:146)
(cid:160)(cid:157)(cid:4)@(cid:135)(cid:134)>C<E<(cid:133):(cid:145)¥(cid:4)(cid:145)(cid:135)(cid:145)(cid:4)A(cid:139):(cid:4):(cid:158):<A(cid:4)9:(cid:134)CD(cid:158):£ ⁄:(cid:134) (cid:155)C
(cid:160)(cid:157)(cid:4)(cid:143):(cid:134)A=9A:(cid:145)¥(cid:4)(cid:145)(cid:135)(cid:145)(cid:4)A(cid:139):(cid:4):(cid:158):<A(cid:4)C>>(cid:133)9£ ⁄:(cid:134) (cid:155)C
(cid:4)
j(cid:148)lƒmim§a(cid:4)viki(cid:4)wg‘‘l§k_gm(cid:4)o(cid:4)(cid:147)ikl(cid:148)mi‘
V0-Y5I5(cid:132)M(cid:4)H-1IKL6
(cid:155)=G:(cid:4)C9(cid:4)(cid:135)<(cid:135)E=D(cid:134)(cid:146)(cid:4)
@(cid:133):(cid:4)@=A:(cid:146)(cid:4)
@=A:(cid:4)C(cid:157)(cid:4)(cid:137)(cid:135)9A(cid:139)(cid:4)C9(cid:4)(cid:136);:(cid:146)(cid:4)
(cid:153)=(cid:134)A(cid:4)G:<(cid:134)A9(cid:133)=D(cid:4)(cid:144):9(cid:135)C(cid:145)(cid:146)(cid:4)
89:(cid:158)(cid:135)C(cid:133)(cid:134)(cid:4)(cid:144)9:;<=<>(cid:135):(cid:134)(cid:4)=<(cid:145)(cid:4)C(cid:133)A>CG:(cid:134)(cid:4)C(cid:157)(cid:4)A(cid:139):(cid:4)(cid:144)9:;<=<>(cid:135):(cid:134)(cid:4)(cid:156)(cid:144)D:=(cid:134):(cid:4)(cid:135)<(cid:145)(cid:135)>=A:(cid:4)(cid:135)(cid:157)(cid:4):¤(cid:144)C(cid:134):(cid:145)(cid:4)AC(cid:4)=(cid:4)(cid:153)(cid:135)DD?(cid:4)@9(cid:133);(cid:4)(cid:145)(cid:133)9(cid:135)<;(cid:4)(cid:144)9:;<=<>?(cid:4)C9(cid:4)(cid:141)9:=(cid:134)A(cid:4)(cid:157)::(cid:145)(cid:135)<;(cid:4)=<(cid:145)(cid:4)=<?(cid:4)>CG(cid:144)D(cid:135)>=EC<(cid:134)'(cid:159)
(cid:137)(cid:135)9A(cid:139)(cid:4)@=A:
(cid:128)=D:(cid:4)C9
(cid:127):G=D:
(cid:128)(cid:4)(cid:4)
(cid:127)
(cid:137)(cid:135)9A(cid:139)(cid:4)“:(cid:135);(cid:139)A
“::(cid:130)(cid:134)(cid:4)«:(cid:134)A=EC<
(cid:153)(cid:135)DD?(cid:4)@9(cid:133);(cid:4)(cid:129)(cid:134):(cid:145)
(cid:128)CA(cid:139):9(cid:4)C9(cid:4)(cid:141)=(cid:141)?
>CG(cid:144)D(cid:135)>=EC<(cid:134)£
‹I1-05IL(cid:4)T-2K(cid:132)IL(cid:4)|K61/0M[0K6›(cid:4)SI(cid:132)1/06(cid:4)(cid:156):';'¥(cid:4)(cid:139)?(cid:144):9A:<(cid:134)(cid:135)C<¥(cid:4)(cid:134):(cid:135)ﬁ(cid:133)9:(cid:4)(cid:145)(cid:135)(cid:134)C9(cid:145):9¥(cid:4)(cid:134)GC(cid:130)(cid:135)<;¥(cid:4)=D>C(cid:139)CD(cid:4)(cid:133)(cid:134):¥(cid:4)(cid:145)9(cid:133);(cid:4)=(cid:141)(cid:133)(cid:134):¥(cid:4)(cid:157)=G(cid:135)D?(cid:4)(cid:139)(cid:135)(cid:134)AC9?¥(cid:4):A>'(cid:159)
BC<A9=>:(cid:144)E(cid:158):(cid:4)G:A(cid:139)C(cid:145)(cid:146)(cid:4)
3]./6Z0-(cid:4)V-0K/2(cid:4)S/0(cid:4)JKLLM(cid:4)H0ZY(cid:4)ﬂ6-2(cid:4)HZ0K5Y(cid:4)NZ00-51(cid:4)V0-Y5I5(cid:132)M
(cid:176)¤(cid:144)C(cid:134)(cid:133)9:(cid:4)(cid:144):9(cid:135)C(cid:145)(cid:4)F(cid:4)“::(cid:130)(cid:134)(cid:4);:(cid:134)A=EC<(cid:146)
–F†‡(cid:4)(cid:131)::(cid:130)(cid:134)(cid:154)†(cid:134)A(cid:4)A9(cid:135)G:(cid:134)A:9 †·F‡(cid:181)(cid:4)(cid:131)::(cid:130)(cid:134)(cid:154)‡<(cid:145)(cid:4)A9(cid:135)G:(cid:134)A:9(cid:4) ‡¶(cid:4)(cid:144)D(cid:133)(cid:134)(cid:4)(cid:131)::(cid:130)(cid:134)(cid:154)·9(cid:145)(cid:4)A9(cid:135)G:(cid:134)A:9
‹I1-05IL(cid:4)N/5(cid:132)/TK1I51(cid:4)‹-2K(cid:132)IU/56[XZ•61I5(cid:132)-(cid:156)(cid:144)D:=(cid:134):(cid:4)(cid:135)<>D(cid:133)(cid:145):(cid:4)(cid:144)9:(cid:134)>9(cid:135)(cid:144)EC<¥(cid:4)(cid:138)‚B(cid:4)=<(cid:145)(cid:4)(cid:139):9(cid:141)=D(cid:159)
‹I1-05IL(cid:4)N/T.LK(cid:132)IU/56
„=(cid:134)(cid:4)A(cid:139):(cid:4)GCA(cid:139):9(cid:4):¤(cid:144):9(cid:135):<>:(cid:145)(cid:4)=<?(cid:4)>CG(cid:144)D(cid:135)>=EC<(cid:134)(cid:4)(cid:145)(cid:133)9(cid:135)<;(cid:4)A(cid:139)(cid:135)(cid:134)(cid:4)(cid:144)9:;<=<>?£ (cid:155)C ⁄:(cid:134)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:30)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:31)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4) !(cid:20)"(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4) #$$"(cid:4)$%%(cid:14)(cid:29)$&’(cid:4)((cid:10)(cid:4)%)(cid:30)’
*+,-+(cid:4)./0123.45/-67
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
89:;<=:><?
@/-5-A3-B7 C/ D+6
E;<:9>;F(cid:4)8:GH>I(cid:4)J:9KL9=:M(cid:4)N3O+OP(cid:4)40-3/.+-Q+636P(cid:4)A2QR46/A-SP(cid:4)+Q.OT
UMMVHL>;F(cid:4)WL><;X<(cid:4)Y>KL9=;HL>
Z+S3.42(cid:4)1R/[+663/-42(cid:4)R+61/-63\2+(cid:4)[/R(cid:4)0/-3Q/R3-B(cid:4)145+-Q]6(cid:4)1R+B-4-.^7
Z+S3.42(cid:4)1R/[+663/-42(cid:4)R+61/-63\2+(cid:4)[/R(cid:4)0/-3Q/R3-B(cid:4)Q_+(cid:4)3-[4-Q7
C40+7
‘SSR+667
a_/-+7
b4c7
C40+7
‘SSR+667
a_/-+7
b4c7
(cid:4)
d46(cid:4)Q_36(cid:4)+e+-Q(cid:4)R+24Q+S(cid:4)Q/(cid:4)4(cid:4)f322^(cid:4)SRABg
(cid:4)
(cid:4)
hijklmlno(cid:4)pmqm(cid:4)rsttjnquslv(cid:4)wmqjilmt
|e+-Q(cid:4)/AQ./0+
(cid:4)x
(cid:4)D+6(cid:4)(cid:4)(cid:4)(cid:4)(cid:4) (cid:4)C/
(cid:4)y-z-/{-
}+./e+R+S
C/Q(cid:4)}+./e+R+S
(cid:4)}+./e+R3-B
d/R6+-+S
(cid:4)y-z-/{-
}+./e+R+S(cid:4){3Q_(cid:4)~+(cid:127)A+224(cid:4)Na2+46+(cid:4)1R/e3S+(cid:4)S+Q4326T7
a2+46+(cid:4)1R/e3S+(cid:4)R45/-42+(cid:4)[/R(cid:4)R+24Q+S-+66(cid:4)466+660+-Q7
(cid:4)
(cid:4)
(cid:4)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:29)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:30)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:31) (cid:20)!(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4)(cid:31)"##!(cid:4)#$$(cid:14)%#&’(cid:4)((cid:10)(cid:4)$)(cid:29)’
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
,-./01-2(cid:4)34-5167(cid:4)89:;<=<>?(cid:4)@=A=(cid:4)>BCC:>DB<E(cid:4)F=A:9<=C
(cid:20)(cid:13)(cid:11)(cid:8)(cid:18)(cid:7)(cid:8)(cid:19)(cid:11)(cid:24)(cid:22)(cid:4)*(cid:11)(cid:2)(cid:2)(cid:11)+(cid:14)(cid:24)(cid:13)(cid:4)*(cid:11)(cid:25)(cid:12)
IJKKL(cid:4)MH6-(cid:4)N7
WJX5H1Y0-ZQ5JTHK67
(cid:4)
O
[H\7
]^__‘(cid:4)abcd(cid:4)e_fgh_(cid:4)ihj^klj(cid:4)chmkj‘(cid:4)n(cid:4)aoppd(cid:4)pqqnrpst(cid:4)uv(cid:4)qwxt
(cid:4)
,H(cid:131)-7
(cid:132)=(cid:133)>=(cid:134)(cid:135)=<
(cid:136)(cid:134)(cid:135)=<
(cid:140)-JX{17
(cid:137)C=>(cid:129)
(cid:138)A(cid:139):9
UHT-51y6(cid:4)VJ01{(cid:4)GH1-(cid:4)/0(cid:4)|X-7
O
(cid:142)-JX{17
C(cid:141)
(cid:129);
P
(cid:135)<
>(cid:143)
GH1-7(cid:4)
Q5R/0SHT/5(cid:4)U0/4J2-2(cid:4)VL7
(cid:4)
UHT-51y6(cid:4)zHS-(cid:4)/0(cid:4)Q5JTHK67
O
~(cid:4) (cid:127)(cid:4) (cid:128)<(cid:129)<B(cid:130)<
}-52-07(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:144):FB9A:(cid:145)(cid:4)@9(cid:133);(cid:146)(cid:4)
(cid:4)
(cid:4)
(cid:153)BA(cid:154)(cid:132)B<A9BC(cid:4)(cid:155)(cid:133)(cid:143)(cid:141):9(cid:156)(cid:135)(cid:157)(cid:4)=(cid:158)=(cid:135)C=(cid:141)C:(cid:159)(cid:146)
@B(cid:134):(cid:146)
(cid:147)^(cid:148)^(cid:149)^(cid:150)(cid:151)(cid:152)hg
¢A=9A(cid:4)@=A:(cid:146)
@9(cid:133);(cid:4)@(cid:154)(cid:132)£ (cid:155)B ⁄:(cid:134)
@9(cid:133);(cid:4)(cid:144):(cid:134)A=9A:(cid:145)£ (cid:155)B ⁄:(cid:134)
(cid:160)<(cid:145)(cid:135)>=DB<(cid:146)
~9:¡(cid:133):<>?(cid:146)
~B9(cid:143)(cid:133)C=DB<(cid:146)
@B(cid:134):(cid:4)(cid:130)(cid:139):<(cid:4):(cid:158):<A(cid:4)B>>(cid:133)9:(cid:145)(cid:146)
(cid:144)B(cid:133)A:(cid:146)
@=A:(cid:4)@(cid:154)(cid:132)(cid:146)
@=A:(cid:4)(cid:144):(cid:134)A=9A:(cid:145)(cid:146)
(cid:160)(cid:157)(cid:4)@(cid:135)(cid:134)>B<D<(cid:133):(cid:145)¥(cid:4)(cid:145)(cid:135)(cid:145)(cid:4)A(cid:139):(cid:4):(cid:158):<A(cid:4)9:(cid:134)BC(cid:158):£ ⁄:(cid:134) (cid:155)B
(cid:160)(cid:157)(cid:4)(cid:144):(cid:134)A=9A:(cid:145)¥(cid:4)(cid:145)(cid:135)(cid:145)(cid:4)A(cid:139):(cid:4):(cid:158):<A(cid:4)B>>(cid:133)9£ ⁄:(cid:134) (cid:155)B
(cid:4)
i(cid:148)kƒlhl§‘(cid:4)uhjh(cid:4)vf__k§j^fl(cid:4)n(cid:4)ihjk(cid:148)lh_
8=D:<A(cid:4)(cid:156)~=A(cid:139):9(cid:159)(cid:4)@:A=(cid:135)C(cid:134)
(cid:155)=(cid:143):(cid:4)B9(cid:4)(cid:135)<(cid:135)D=C(cid:134)(cid:146)(cid:4)
@=A:(cid:4)B(cid:157)(cid:4)(cid:137)(cid:135)9A(cid:139)(cid:4)B9(cid:4)(cid:136);:(cid:146)(cid:4)
~=A(cid:139):9¤(cid:134)(cid:4)(cid:143):(cid:145)(cid:135)>=C(cid:4)(cid:139)(cid:135)(cid:134)AB9?(cid:154)9(cid:135)(cid:134)(cid:129)(cid:4)(cid:157)=>AB9(cid:134)(cid:4)(cid:156):';'¥(cid:4)(cid:139)?F:9A:<(cid:134)(cid:135)B<¥(cid:4)(cid:134):(cid:135)“(cid:133)9:(cid:4)(cid:145)(cid:135)(cid:134)B9(cid:145):9¥(cid:4)(cid:134)(cid:143)B(cid:129)(cid:135)<;¥(cid:4)=C>B(cid:139)BC(cid:4)(cid:133)(cid:134):¥(cid:4)(cid:145)9(cid:133);(cid:4)=(cid:141)(cid:133)(cid:134):¥(cid:4)(cid:157)=(cid:143)(cid:135)C?(cid:4)(cid:139)(cid:135)(cid:134)AB9?¥(cid:4):A>'(cid:159)
U0-X5H5(cid:131)L(cid:4)G-1HJK6
(cid:155)=(cid:143):(cid:4)B9(cid:4)(cid:135)<(cid:135)D=C(cid:134)(cid:146)(cid:4)
@(cid:133):(cid:4)@=A:(cid:146)(cid:4)
@=A:(cid:4)B(cid:157)(cid:4)(cid:137)(cid:135)9A(cid:139)(cid:4)B9(cid:4)(cid:136);:(cid:146)(cid:4)
(cid:153)=(cid:134)A(cid:4)(cid:143):<(cid:134)A9(cid:133)=C(cid:4)F:9(cid:135)B(cid:145)(cid:146)(cid:4)
89:(cid:158)(cid:135)B(cid:133)(cid:134)(cid:4)F9:;<=<>(cid:135):(cid:134)(cid:4)=<(cid:145)(cid:4)B(cid:133)A>B(cid:143):(cid:134)(cid:4)B(cid:157)(cid:4)A(cid:139):(cid:4)F9:;<=<>(cid:135):(cid:134)(cid:4)(cid:156)FC:=(cid:134):(cid:4)(cid:135)<(cid:145)(cid:135)>=A:(cid:4)(cid:135)(cid:157)(cid:4):«FB(cid:134):(cid:145)(cid:4)AB(cid:4)=(cid:4)(cid:153)(cid:135)CC?(cid:4)@9(cid:133);(cid:4)(cid:145)(cid:133)9(cid:135)<;(cid:4)F9:;<=<>?(cid:4)B9(cid:4)(cid:141)9:=(cid:134)A(cid:4)(cid:157)::(cid:145)(cid:135)<;(cid:4)=<(cid:145)(cid:4)=<?(cid:4)>B(cid:143)FC(cid:135)>=DB<(cid:134)'(cid:159)
(cid:137)(cid:135)9A(cid:139)(cid:4)@=A:
(cid:127)=C:(cid:4)B9
~:(cid:143)=C:
(cid:127)(cid:4)(cid:4)
~
(cid:137)(cid:135)9A(cid:139)(cid:4)‹:(cid:135);(cid:139)A
‹::(cid:129)(cid:134)(cid:4)›:(cid:134)A=DB<
(cid:153)(cid:135)CC?(cid:4)@9(cid:133);(cid:4)(cid:128)(cid:134):(cid:145)
(cid:127)BA(cid:139):9(cid:4)B9(cid:4)(cid:141)=(cid:141)?
>B(cid:143)FC(cid:135)>=DB<(cid:134)£
ﬁH1-05HK(cid:4)S-2J(cid:131)HK(cid:4){J61/0LZ0J6ﬂ(cid:4)RH(cid:131)1/06(cid:4)(cid:156):';'¥(cid:4)(cid:139)?F:9A:<(cid:134)(cid:135)B<¥(cid:4)(cid:134):(cid:135)“(cid:133)9:(cid:4)(cid:145)(cid:135)(cid:134)B9(cid:145):9¥(cid:4)(cid:134)(cid:143)B(cid:129)(cid:135)<;¥(cid:4)=C>B(cid:139)BC(cid:4)(cid:133)(cid:134):¥(cid:4)(cid:145)9(cid:133);(cid:4)=(cid:141)(cid:133)(cid:134):¥(cid:4)(cid:157)=(cid:143)(cid:135)C?(cid:4)(cid:139)(cid:135)(cid:134)AB9?¥(cid:4):A>'(cid:159)
(cid:132)B<A9=>:FD(cid:158):(cid:4)(cid:143):A(cid:139)B(cid:145)(cid:146)(cid:4)
3\./6Y0-(cid:4)U-0J/2(cid:4)R/0(cid:4)IJKKL(cid:4)G0YX(cid:4)(cid:176)6-2(cid:4)GY0J5X(cid:4)MY00-51(cid:4)U0-X5H5(cid:131)L
–«FB(cid:134)(cid:133)9:(cid:4)F:9(cid:135)B(cid:145)(cid:4)E(cid:4)‹::(cid:129)(cid:134)(cid:4);:(cid:134)A=DB<(cid:146)
†E‡·(cid:4)(cid:130)::(cid:129)(cid:134)(cid:154)‡(cid:134)A(cid:4)A9(cid:135)(cid:143):(cid:134)A:9 ‡(cid:181)E·¶(cid:4)(cid:130)::(cid:129)(cid:134)(cid:154)·<(cid:145)(cid:4)A9(cid:135)(cid:143):(cid:134)A:9(cid:4) ·•(cid:4)FC(cid:133)(cid:134)(cid:4)(cid:130)::(cid:129)(cid:134)(cid:154)(cid:181)9(cid:145)(cid:4)A9(cid:135)(cid:143):(cid:134)A:9
8=A:9<=C(cid:4)(cid:132)B<>B(cid:143)(cid:135)A=<A(cid:4)(cid:127):(cid:145)(cid:135)>=DB<(cid:134)(cid:154)¢(cid:133)(cid:141)(cid:134)A=<>:(cid:4)(cid:156)FC:=(cid:134):(cid:4)(cid:135)<>C(cid:133)(cid:145):(cid:4)F9:(cid:134)>9(cid:135)FDB<¥(cid:4)(cid:138)‚(cid:132)(cid:4)=<(cid:145)(cid:4)(cid:139):9(cid:141)=C(cid:159)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:30)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:31)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4) !(cid:20)"(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4) #$$"(cid:4)$%%(cid:14)(cid:29)$&’(cid:4)((cid:10)(cid:4)%)(cid:30)’
*+,-./+0(cid:4)12/3245,+/,(cid:4)*-653+72/89:;<8,+/3-=>?@AB@(cid:4)CDE?FG@(cid:4)>H@BEHC>IJDK(cid:4)LMN(cid:4)ADG(cid:4)O@HPA?Q
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
*+,-./+0(cid:4)124R053+72/8
SAB(cid:4)TO@(cid:4)UJTO@H(cid:4)@V>@HC@DE@G(cid:4)ADW(cid:4)EJU>?CEAIJDB(cid:4)GFHCDX(cid:4)TOCB(cid:4)>H@XDADEWY ZJ [@B
\@]D@(cid:4)EJU>?CEAIJDB^
_.-+,4-/,‘
NJDIDFCDX^ ZJ [@B
*+,-./+0(cid:4)_-87/a(cid:4)b-.c2.4-6(cid:4)=Cd@dK(cid:4)AUDCJE@DT@BCBK(cid:4)F?THABJFDGK(cid:4)@TEdQ
e66572/+0(cid:4)12/,+3,(cid:4)f/c2.4+72/
g@GCEA?(cid:4)>HJh@BBCJDA?(cid:4)H@B>JDBCP?@(cid:4)hJH(cid:4)UJDCTJHCDX(cid:4)TO@(cid:4)hATO@H^
ZAU@^
g@GCEA?(cid:4)>HJh@BBCJDA?(cid:4)H@B>JDBCP?@(cid:4)hJH(cid:4)UJDCTJHCDX(cid:4)TO@(cid:4)UJTO@H^
ZAU@^
iGGH@BB^
jOJD@^
kAV^
iGGH@BB^
jOJD@^
kAV^
(cid:4)
lAB(cid:4)TOCB(cid:4)@m@DT(cid:4)H@?AT@G(cid:4)TJ(cid:4)A(cid:4)nC??W(cid:4)GHFXY
(cid:4)
(cid:4)
opqrstsuv(cid:4)wtxt(cid:4)uyzzqux{ys|(cid:4)}txqpstz
(cid:130)m@DT(cid:4)JFTEJU@
(cid:4)~
(cid:4)[@B(cid:4)(cid:4)(cid:4)(cid:4)(cid:4) (cid:4)ZJ
(cid:4)(cid:127)D(cid:128)DJ(cid:129)D
(cid:131)@EJm@H@G
ZJT(cid:4)(cid:131)@EJm@H@G
(cid:4)(cid:131)@EJm@HCDX
lJHB@D@G
(cid:4)(cid:127)D(cid:128)DJ(cid:129)D
(cid:131)@EJm@H@G(cid:4)(cid:129)CTO(cid:4)(cid:132)@(cid:133)F@??A(cid:4)=j?@AB@(cid:4)>HJmCG@(cid:4)G@TAC?BQ^
j?@AB@(cid:4)>HJmCG@(cid:4)HAIJDA?@(cid:4)hJH(cid:4)H@?AT@GD@BB(cid:4)ABB@BBU@DT^
(cid:4)
(cid:4)
(cid:4)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:29)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:30)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:31) (cid:20)!(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4)(cid:31)"##!(cid:4)#$$(cid:14)%#&’(cid:4)((cid:10)(cid:4)$)(cid:29)’
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
-./012.3(cid:4)45.6278(cid:4)9:;<=>=?@(cid:4)ABC?AD;E(cid:4)D>C;:=>F
(cid:20)(cid:13)(cid:11)(cid:8)(cid:18)(cid:7)(cid:8)(cid:19)(cid:11)(cid:24)(cid:22)(cid:4)+(cid:11)(cid:2)(cid:2)(cid:11),(cid:14)(cid:24)(cid:13)(cid:4)+(cid:11)(cid:25)(cid:12)
IJKKL(cid:4)MH7.(cid:4)N8
WJX6H2Y1.ZQ6JTHK78
(cid:4)
O
[H\8
]^__‘(cid:4)abcd(cid:4)e_fgh_(cid:4)ihj^klj(cid:4)chmkj‘(cid:4)n(cid:4)aoppd(cid:4)pqqnrpst(cid:4)uv(cid:4)qwxt
(cid:4)
-H(cid:131).8
(cid:132)>B?>(cid:133)(cid:134)>=
(cid:135)(cid:133)(cid:134)>=
(cid:139).JX{28
(cid:136)F>?(cid:129)
(cid:137)C(cid:138);:
UHT.62y7(cid:4)VJ12{(cid:4)GH2.(cid:4)01(cid:4)|X.8
O
(cid:141).JX{28
F(cid:140)
(cid:129)<
P
(cid:134)=
?D
GH2.8(cid:4)
Q6R01SHT06(cid:4)U105J3.3(cid:4)VL8
(cid:4)
UHT.62y7(cid:4)zHS.(cid:4)01(cid:4)Q6JTHK78
O
~(cid:4) (cid:127)(cid:4) (cid:128)=(cid:129)=A(cid:130)=
}.63.18(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:142);(cid:143)A:C;(cid:144)(cid:4)(cid:145):B<(cid:146)(cid:4)
(cid:4)
(cid:4)
(cid:153)AC(cid:154)(cid:132)A=C:AF(cid:4)(cid:155)BD(cid:140);:(cid:156)(cid:134)(cid:157)(cid:4)>(cid:158)>(cid:134)F>(cid:140)F;(cid:159)(cid:146)
(cid:145)A(cid:133);(cid:146)
(cid:147)^(cid:148)^(cid:149)^(cid:150)(cid:151)(cid:152)hg
£C>:C(cid:4)(cid:145)>C;(cid:146)
(cid:145):B<(cid:4)(cid:145)(cid:154)(cid:132)⁄ (cid:155)A ¥;(cid:133)
(cid:145):B<(cid:4)(cid:142);(cid:133)C>:C;(cid:144)⁄ (cid:155)A ¥;(cid:133)
(cid:4)
i(cid:148)k§lhl¤‘(cid:4)'(cid:151)j¤f(cid:152)k(cid:4)(cid:147)hjk(cid:148)lh_
U1.X6H6(cid:131)L(cid:4)G.2HJK7
(cid:155)>D;(cid:4)A:(cid:4)(cid:134)=(cid:134)¡>F(cid:133)(cid:146)(cid:4)
(cid:145)B;(cid:4)(cid:145)>C;(cid:146)(cid:4)
(cid:160)=(cid:144)(cid:134)?>¡A=(cid:146)
~:;¢B;=?@(cid:146)
~A:DBF>¡A=(cid:146)
(cid:145)A(cid:133);(cid:4)(cid:130)(cid:138);=(cid:4);(cid:158);=C(cid:4)A??B:;(cid:144)(cid:146)
(cid:142)ABC;(cid:146)
(cid:145)>C;(cid:4)(cid:145)(cid:154)(cid:132)(cid:146)
(cid:145)>C;(cid:4)(cid:142);(cid:133)C>:C;(cid:144)(cid:146)
(cid:160)(cid:157)(cid:4)(cid:145)(cid:134)(cid:133)?A=¡=B;(cid:144)ƒ(cid:4)(cid:144)(cid:134)(cid:144)(cid:4)C(cid:138);(cid:4);(cid:158);=C(cid:4):;(cid:133)AF(cid:158);⁄ ¥;(cid:133) (cid:155)A
(cid:160)(cid:157)(cid:4)(cid:142);(cid:133)C>:C;(cid:144)ƒ(cid:4)(cid:144)(cid:134)(cid:144)(cid:4)C(cid:138);(cid:4);(cid:158);=C(cid:4)A??B:⁄ ¥;(cid:133) (cid:155)A
(cid:145)>C;(cid:4)A(cid:157)(cid:4)(cid:136)(cid:134):C(cid:138)(cid:4)A:(cid:4)(cid:135)<;(cid:146)(cid:4)
(cid:153)>(cid:133)C(cid:4)D;=(cid:133)C:B>F(cid:4)(cid:143);:(cid:134)A(cid:144)(cid:146)(cid:4)
9:;(cid:158)(cid:134)AB(cid:133)(cid:4)(cid:143):;<=>=?(cid:134);(cid:133)(cid:4)>=(cid:144)(cid:4)ABC?AD;(cid:133)(cid:4)A(cid:157)(cid:4)C(cid:138);(cid:4)(cid:143):;<=>=?(cid:134);(cid:133)(cid:4)(cid:156)(cid:143)F;>(cid:133);(cid:4)(cid:134)=(cid:144)(cid:134)?>C;(cid:4)(cid:134)(cid:157)(cid:4);“(cid:143)A(cid:133);(cid:144)(cid:4)CA(cid:4)>(cid:4)(cid:153)(cid:134)FF@(cid:4)(cid:145):B<(cid:4)(cid:144)B:(cid:134)=<(cid:4)(cid:143):;<=>=?@(cid:4)A:(cid:4)(cid:140):;>(cid:133)C(cid:4)(cid:157);;(cid:144)(cid:134)=<(cid:4)>=(cid:144)(cid:4)>=@(cid:4)?AD(cid:143)F(cid:134)?>¡A=(cid:133)«(cid:159)
(cid:136)(cid:134):C(cid:138)(cid:4)(cid:145)>C;
(cid:127)>F;(cid:4)A:
~;D>F;
(cid:127)(cid:4)(cid:4)
~
(cid:136)(cid:134):C(cid:138)(cid:4)‹;(cid:134)<(cid:138)C
‹;;(cid:129)(cid:133)(cid:4)›;(cid:133)C>¡A=
(cid:153)(cid:134)FF@(cid:4)(cid:145):B<(cid:4)(cid:128)(cid:133);(cid:144)
(cid:127)AC(cid:138);:(cid:4)A:(cid:4)(cid:140)>(cid:140)@
?AD(cid:143)F(cid:134)?>¡A=(cid:133)⁄
ﬁH2.16HK(cid:4)S.3J(cid:131)HK(cid:4){J7201LZ1J7ﬂ(cid:4)RH(cid:131)2017(cid:4)(cid:156);«<«ƒ(cid:4)(cid:138)@(cid:143);:C;=(cid:133)(cid:134)A=ƒ(cid:4)(cid:133);(cid:134)(cid:176)B:;(cid:4)(cid:144)(cid:134)(cid:133)A:(cid:144);:ƒ(cid:4)(cid:133)DA(cid:129)(cid:134)=<ƒ(cid:4)>F?A(cid:138)AF(cid:4)B(cid:133);ƒ(cid:4)(cid:144):B<(cid:4)>(cid:140)B(cid:133);ƒ(cid:4)(cid:157)>D(cid:134)F@(cid:4)(cid:138)(cid:134)(cid:133)CA:@ƒ(cid:4);C?«(cid:159)
(cid:132)A=C:>?;(cid:143)¡(cid:158);(cid:4)D;C(cid:138)A(cid:144)(cid:146)(cid:4)
4\/07Y1.(cid:4)U.1J03(cid:4)R01(cid:4)IJKKL(cid:4)G1YX(cid:4)–7.3(cid:4)GY1J6X(cid:4)MY11.62(cid:4)U1.X6H6(cid:131)L
†“(cid:143)A(cid:133)B:;(cid:4)(cid:143);:(cid:134)A(cid:144)(cid:4)E(cid:4)‹;;(cid:129)(cid:133)(cid:4)<;(cid:133)C>¡A=(cid:146)
‡E·(cid:181)(cid:4)(cid:130);;(cid:129)(cid:133)(cid:154)·(cid:133)C(cid:4)C:(cid:134)D;(cid:133)C;: ·¶E(cid:181)•(cid:4)(cid:130);;(cid:129)(cid:133)(cid:154)(cid:181)=(cid:144)(cid:4)C:(cid:134)D;(cid:133)C;:(cid:4) (cid:181)‚(cid:4)(cid:143)FB(cid:133)(cid:4)(cid:130);;(cid:129)(cid:133)(cid:154)¶:(cid:144)(cid:4)C:(cid:134)D;(cid:133)C;:
ﬁH2.16HK(cid:4)M06(cid:131)0SJ2H62(cid:4)ﬁ.3J(cid:131)HT067ZWY„72H6(cid:131).(cid:156)(cid:143)F;>(cid:133);(cid:4)(cid:134)=?FB(cid:144);(cid:4)(cid:143):;(cid:133)?:(cid:134)(cid:143)¡A=ƒ(cid:4)(cid:137)”(cid:132)(cid:4)>=(cid:144)(cid:4)(cid:138);:(cid:140)>F(cid:159)
ﬁH2.16HK(cid:4)M0S/KJ(cid:131)HT067
»>(cid:133)(cid:4)C(cid:138);(cid:4)DAC(cid:138);:(cid:4);“(cid:143);:(cid:134);=?;(cid:144)(cid:4)>=@(cid:4)?AD(cid:143)F(cid:134)?>¡A=(cid:133)(cid:4)(cid:144)B:(cid:134)=<(cid:4)C(cid:138)(cid:134)(cid:133)(cid:4)(cid:143):;<=>=?@⁄ (cid:155)A ¥;(cid:133)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:30)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:31)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4) !(cid:20)"(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4) #$$"(cid:4)$%%(cid:14)(cid:29)$&’(cid:4)((cid:10)(cid:4)%)*’
+,-.,(cid:4)/01234/560.78
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
9:;<=>;?=@
A0.6.B4.C8 D0 E,7
F<=;:?<G(cid:4)9;HI?J(cid:4)K;:LM:>;N(cid:4)O4P,PQ(cid:4)51.40/,.R,747Q(cid:4)B3RS570B.TQ(cid:4),R/PU
K:;J?<?VWXY;=<G(cid:4)Z[=VM>;
(cid:4)
(cid:4)\4],(cid:4)^4SR_‘aB33(cid:4)R,S1
(cid:4)g20.R5.,0B7‘1477,T(cid:4)5^0S60.
(cid:4)\4],(cid:4)^4SR_(cid:4)e4R_(cid:4).,0.5R53(cid:4)T,5R_
i,S,(cid:4)/0.C,.4R53(cid:4)0S(cid:4)/_S01070153(cid:4)5^.0S15346,7(cid:4)T,R,/R,Tj D0 E,7
b3,57,(cid:4)T,-.,8
(cid:4)bS,15RBS,(cid:4)^4SR_(cid:4)O3,77(cid:4)R_5.(cid:4)cd(cid:4)e,,f7U
(cid:4)h,R53(cid:4)T,5R_(cid:4)4.(cid:4)BR,S0‘7633^4SR_
(cid:4)b07R(cid:4).5R53(cid:4)T,5R_
k;M?<=<GXl?L<?=(cid:4)m<=<
n.a5.R(cid:4).51,(cid:4)0S(cid:4)4.465378(cid:4)
q,7R560.53(cid:4)5C,8(cid:4)
t2C5S(cid:4)7/0S,78(cid:4)5R(cid:4)u(cid:4)14.BR,(cid:4)
i,4C_R8
n.a5.Rw7(cid:4)0],S533(cid:4)_,53R_p(cid:4)7R5RB7j
(cid:4)
o+A(cid:4)O+B,(cid:4)+5R,U8(cid:4)
+5R,(cid:4)0a(cid:4)+,34],Sp8(cid:4)
q,.T,S(cid:4)8(cid:4) r.T,R,S14.,T‘B.f.0e. s53,(cid:4) h,153,
5R(cid:4)v(cid:4)14.BR,7
CS517 20B.T7
\,.CR_8
/1 4./_,7
l?L<?=(cid:4)xNy;:H;(cid:4)zy;?=HX{M>|G}V<IM?H
+4T(cid:4)R_,(cid:4)4.a5.R(cid:4),~2,S4,./,(cid:4)5.p(cid:4)2S0^3,17(cid:4)e_43,(cid:4)^S,57R(cid:4)a,,T4.Cj D0 E,7
b3,57,(cid:4)T,7/S4^,8
9:;<=>;?=@
A0.6.B4.C8 D0 E,7
n.a5.Rw7(cid:4)0],S533(cid:4)_,53R_(cid:4)7R5RB78(cid:4)
xNN}IM?<G(cid:4){M?=<V=(cid:4)l?LM:><IM?
s,T4/53(cid:4)2S0a,7740.53(cid:4)S,720.74^3,(cid:4)a0S(cid:4)10.4R0S4.C(cid:4)256,.Rw7(cid:4)2S,C.5./p8
s,T4/53(cid:4)2S0a,7740.53(cid:4)S,720.74^3,(cid:4)a0S(cid:4)10.4R0S4.C(cid:4)R_,(cid:4)4.a5.R8
D51,8
tTTS,778
b_0.,8
h5~8
(cid:4)
i57(cid:4)R_47(cid:4),],.R(cid:4)S,35R,T(cid:4)R0(cid:4)5(cid:4)\433p(cid:4)TSBCj
(cid:4)
(cid:4)
(cid:127)(cid:128)(cid:129)(cid:130)(cid:131)(cid:132)(cid:131)(cid:133)(cid:134)(cid:4)(cid:135)(cid:136)(cid:137)(cid:133)(cid:135)(cid:138)(cid:129)(cid:139)(cid:4)(cid:138)(cid:132)(cid:137)(cid:129)(cid:128)(cid:131)(cid:132)(cid:140)
o],.R(cid:4)0BR/01,
D51,8
tTTS,778
b_0.,8
h5~8
(cid:4)(cid:141)
(cid:4)E,7(cid:4)(cid:4)(cid:4)(cid:4)(cid:4) (cid:4)D0
(cid:4)r.f.0e.
(cid:142),/0],S,T
D0R(cid:4)(cid:142),/0],S,T
(cid:4)(cid:142),/0],S4.C
i0S7,.,T
(cid:4)r.f.0e.
(cid:142),/0],S,T(cid:4)e4R_(cid:4)g,(cid:143)B,335(cid:4)Ob3,57,(cid:4)2S0]4T,(cid:4)T,R5437U8
(cid:4)
(cid:4)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:30)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:31)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4) !(cid:20)"(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4) #$$"(cid:4)$%%(cid:14)&$’((cid:4))(cid:10)(cid:4)%*(cid:29)(
+,-./-(cid:4)012345-(cid:4)1.627.,-(cid:4)821(cid:4)1-,.9-57-//(cid:4).//-//:-79;
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:4)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:29)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:30)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:31) (cid:20)!(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4)(cid:31)"##!(cid:4)#$$(cid:14)%#&’(cid:4)((cid:10)(cid:4)$)*’
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
-./012.3(cid:4)45.6278(cid:4)9:;<=>=?@(cid:4)ABC?DE;F(cid:4)G>C;:=>H
(cid:20)(cid:13)(cid:11)(cid:8)(cid:18)(cid:7)(cid:8)(cid:19)(cid:11)(cid:24)(cid:22)(cid:4)+(cid:11)(cid:2)(cid:2)(cid:11),(cid:14)(cid:24)(cid:13)(cid:4)+(cid:11)(cid:25)(cid:12)
KLMMN(cid:4)OJ7.(cid:4)P8
YLZ6J2[1.\S6LVJM78
(cid:4)
Q
]J^8
_‘aab(cid:4)cdef(cid:4)gahija(cid:4)kjl‘mnl(cid:4)ejomlb(cid:4)p(cid:4)cqrrf(cid:4)rssptruv(cid:4)wx(cid:4)syzv
(cid:4)
-J(cid:133).8
(cid:134)>B?>(cid:135)(cid:136)>=
(cid:137)(cid:135)(cid:136)>=
(cid:140).LZ}28
(cid:138)H>?(cid:131)
AC(cid:139);:
WJV.62{7(cid:4)XL12}(cid:4)IJ2.(cid:4)01(cid:4)~Z.8
Q
(cid:142).LZ}28
H(cid:141)
(cid:131)<
R
(cid:136)=
?E
IJ2.8(cid:4)
S6T01UJV06(cid:4)W105L3.3(cid:4)XN8
(cid:4)
WJV.62{7(cid:4)|JU.(cid:4)01(cid:4)S6LVJM78
Q
(cid:128)(cid:4) (cid:129)(cid:4) (cid:130)=(cid:131)=D(cid:132)=
(cid:127).63.18(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:143);GD:C;(cid:144)(cid:4)(cid:145):B<(cid:146)(cid:4)
(cid:4)
(cid:4)
(cid:153)DC(cid:154)(cid:134)D=C:DH(cid:4)(cid:155)BE(cid:141);:(cid:156)(cid:136)(cid:157)(cid:4)>(cid:158)>(cid:136)H>(cid:141)H;(cid:159)(cid:146)
(cid:145)D(cid:135);(cid:146)
(cid:147)‘(cid:148)‘(cid:149)‘(cid:150)(cid:151)(cid:152)ji
£C>:C(cid:4)(cid:145)>C;(cid:146)
(cid:145):B<(cid:4)(cid:145)(cid:154)(cid:134)⁄ (cid:155)D ¥;(cid:135)
(cid:145):B<(cid:4)(cid:143);(cid:135)C>:C;(cid:144)⁄ (cid:155)D ¥;(cid:135)
(cid:4)
k(cid:148)m§njn¤b(cid:4)'(cid:151)l¤h(cid:152)m(cid:4)kjlm(cid:148)nja
9>¡;=C(cid:4)(cid:156)(cid:128)>C(cid:139);:(cid:159)(cid:4)(cid:145);C>(cid:136)H(cid:135)
(cid:155)>E;(cid:4)D:(cid:4)(cid:136)=(cid:136)¡>H(cid:135)(cid:146)(cid:4)
(cid:160)=(cid:144)(cid:136)?>¡D=(cid:146)
(cid:128):;¢B;=?@(cid:146)
(cid:128)D:EBH>¡D=(cid:146)
(cid:145)D(cid:135);(cid:4)(cid:132)(cid:139);=(cid:4);(cid:158);=C(cid:4)D??B:;(cid:144)(cid:146)
(cid:143)DBC;(cid:146)
(cid:145)>C;(cid:4)(cid:145)(cid:154)(cid:134)(cid:146)
(cid:145)>C;(cid:4)(cid:143);(cid:135)C>:C;(cid:144)(cid:146)
(cid:160)(cid:157)(cid:4)(cid:145)(cid:136)(cid:135)?D=¡=B;(cid:144)ƒ(cid:4)(cid:144)(cid:136)(cid:144)(cid:4)C(cid:139);(cid:4);(cid:158);=C(cid:4):;(cid:135)DH(cid:158);⁄ ¥;(cid:135) (cid:155)D
(cid:160)(cid:157)(cid:4)(cid:143);(cid:135)C>:C;(cid:144)ƒ(cid:4)(cid:144)(cid:136)(cid:144)(cid:4)C(cid:139);(cid:4);(cid:158);=C(cid:4)D??B:⁄ ¥;(cid:135) (cid:155)D
(cid:145)>C;(cid:4)D(cid:157)(cid:4)(cid:138)(cid:136):C(cid:139)(cid:4)D:(cid:4)(cid:137)<;(cid:146)(cid:4)
(cid:128)>C(cid:139);:“(cid:135)(cid:4)E;(cid:144)(cid:136)?>H(cid:4)(cid:139)(cid:136)(cid:135)CD:@(cid:154):(cid:136)(cid:135)(cid:131)(cid:4)(cid:157)>?CD:(cid:135)(cid:4)(cid:156);«<«ƒ(cid:4)(cid:139)@G;:C;=(cid:135)(cid:136)D=ƒ(cid:4)(cid:135);(cid:136)‹B:;(cid:4)(cid:144)(cid:136)(cid:135)D:(cid:144);:ƒ(cid:4)(cid:135)ED(cid:131)(cid:136)=<ƒ(cid:4)>H?D(cid:139)DH(cid:4)B(cid:135);ƒ(cid:4)(cid:144):B<(cid:4)>(cid:141)B(cid:135);ƒ(cid:4)(cid:157)>E(cid:136)H@(cid:4)(cid:139)(cid:136)(cid:135)CD:@ƒ(cid:4);C?«(cid:159)
W1.Z6J6(cid:133)N(cid:4)I.2JLM7
(cid:155)>E;(cid:4)D:(cid:4)(cid:136)=(cid:136)¡>H(cid:135)(cid:146)(cid:4)
(cid:145)B;(cid:4)(cid:145)>C;(cid:146)(cid:4)
(cid:145)>C;(cid:4)D(cid:157)(cid:4)(cid:138)(cid:136):C(cid:139)(cid:4)D:(cid:4)(cid:137)<;(cid:146)(cid:4)
(cid:153)>(cid:135)C(cid:4)E;=(cid:135)C:B>H(cid:4)G;:(cid:136)D(cid:144)(cid:146)(cid:4)
9:;(cid:158)(cid:136)DB(cid:135)(cid:4)G:;<=>=?(cid:136);(cid:135)(cid:4)>=(cid:144)(cid:4)DBC?DE;(cid:135)(cid:4)D(cid:157)(cid:4)C(cid:139);(cid:4)G:;<=>=?(cid:136);(cid:135)(cid:4)(cid:156)GH;>(cid:135);(cid:4)(cid:136)=(cid:144)(cid:136)?>C;(cid:4)(cid:136)(cid:157)(cid:4);›GD(cid:135);(cid:144)(cid:4)CD(cid:4)>(cid:4)(cid:153)(cid:136)HH@(cid:4)(cid:145):B<(cid:4)(cid:144)B:(cid:136)=<(cid:4)G:;<=>=?@(cid:4)D:(cid:4)(cid:141):;>(cid:135)C(cid:4)(cid:157);;(cid:144)(cid:136)=<(cid:4)>=(cid:144)(cid:4)>=@(cid:4)?DEGH(cid:136)?>¡D=(cid:135)«(cid:159)
(cid:138)(cid:136):C(cid:139)(cid:4)(cid:145)>C;
(cid:129)>H;(cid:4)D:
(cid:128);E>H;
(cid:129)(cid:4)(cid:4)
(cid:128)
(cid:138)(cid:136):C(cid:139)(cid:4)ﬁ;(cid:136)<(cid:139)C
ﬁ;;(cid:131)(cid:135)(cid:4)ﬂ;(cid:135)C>¡D=
(cid:153)(cid:136)HH@(cid:4)(cid:145):B<(cid:4)(cid:130)(cid:135);(cid:144)
(cid:129)DC(cid:139);:(cid:4)D:(cid:4)(cid:141)>(cid:141)@
?DEGH(cid:136)?>¡D=(cid:135)⁄
(cid:176)J2.16JM(cid:4)U.3L(cid:133)JM(cid:4)}L7201N\1L7–(cid:4)TJ(cid:133)2017(cid:4)(cid:156);«<«ƒ(cid:4)(cid:139)@G;:C;=(cid:135)(cid:136)D=ƒ(cid:4)(cid:135);(cid:136)‹B:;(cid:4)(cid:144)(cid:136)(cid:135)D:(cid:144);:ƒ(cid:4)(cid:135)ED(cid:131)(cid:136)=<ƒ(cid:4)>H?D(cid:139)DH(cid:4)B(cid:135);ƒ(cid:4)(cid:144):B<(cid:4)>(cid:141)B(cid:135);ƒ(cid:4)(cid:157)>E(cid:136)H@(cid:4)(cid:139)(cid:136)(cid:135)CD:@ƒ(cid:4);C?«(cid:159)
(cid:134)D=C:>?;G¡(cid:158);(cid:4)E;C(cid:139)D(cid:144)(cid:146)(cid:4)
4^/07[1.(cid:4)W.1L03(cid:4)T01(cid:4)KLMMN(cid:4)I1[Z(cid:4)†7.3(cid:4)I[1L6Z(cid:4)O[11.62(cid:4)W1.Z6J6(cid:133)N
‡›GD(cid:135)B:;(cid:4)G;:(cid:136)D(cid:144)(cid:4)F(cid:4)ﬁ;;(cid:131)(cid:135)(cid:4)<;(cid:135)C>¡D=(cid:146)
·F(cid:181)¶(cid:4)(cid:132);;(cid:131)(cid:135)(cid:154)(cid:181)(cid:135)C(cid:4)C:(cid:136)E;(cid:135)C;: (cid:181)•F¶‚(cid:4)(cid:132);;(cid:131)(cid:135)(cid:154)¶=(cid:144)(cid:4)C:(cid:136)E;(cid:135)C;:(cid:4) ¶„(cid:4)GHB(cid:135)(cid:4)(cid:132);;(cid:131)(cid:135)(cid:154)•:(cid:144)(cid:4)C:(cid:136)E;(cid:135)C;:
9>C;:=>H(cid:4)(cid:134)D=?DE(cid:136)C>=C(cid:4)(cid:129);(cid:144)(cid:136)?>¡D=(cid:135)(cid:154)£B(cid:141)(cid:135)C>=?;(cid:4)(cid:156)GH;>(cid:135);(cid:4)(cid:136)=?HB(cid:144);(cid:4)G:;(cid:135)?:(cid:136)G¡D=ƒ(cid:4)A”(cid:134)(cid:4)>=(cid:144)(cid:4)(cid:139);:(cid:141)>H(cid:159)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:30)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:31)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4) !(cid:20)"(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4) #$$"(cid:4)$%%(cid:14)(cid:29)$&’(cid:4)((cid:10)(cid:4)%)*’
+,-./0,1(cid:4)2304356-,0-(cid:4)+.764,8309:;<=9-,04.>?@ABCA(cid:4)DEF@GHA(cid:4)?IACFID?JKEL(cid:4)MNO(cid:4)BEH(cid:4)PAIQB@R
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
+,-./0,1(cid:4)235S164,8309
TBC(cid:4)UPA(cid:4)VKUPAI(cid:4)AW?AIDAEFAH(cid:4)BEX(cid:4)FKV?@DFBJKEC(cid:4)HGIDEY(cid:4)UPDC(cid:4)?IAYEBEFXZ [K \AC
]A^EA(cid:4)FKV?@DFBJKEC_
‘/.,-5.0-a
OKEJEGDEY_ [K \AC
+,-./0,1(cid:4)‘.980b(cid:4)c./d3/5.7(cid:4)>DeAeL(cid:4)BVEDKFAEUACDCL(cid:4)G@UIBCKGEHL(cid:4)AUFeR
c/.b0,04f:g.-,1(cid:4)h<-435.
(cid:4)iDjA(cid:4)QDIUPklG@@(cid:4)UAIV
(cid:4)r?KEUBEAKGCkVDCCAH(cid:4)BQKIJKE
(cid:4)iDjA(cid:4)QDIUP(cid:4)pDUP(cid:4)EAKEBUB@(cid:4)HABUP
tAIA(cid:4)FKEYAEDUB@(cid:4)KI(cid:4)FPIKVKCKVB@(cid:4)BQEKIVB@DJAC(cid:4)HAUAFUAHZ [K \AC
m@ABCA(cid:4)HA^EA_
(cid:4)mIAVBUGIA(cid:4)QDIUP(cid:4)>@ACC(cid:4)UPBE(cid:4)no(cid:4)pAAqCR
(cid:4)sAUB@(cid:4)HABUP(cid:4)DE(cid:4)GUAIKkCJ@@QDIUP
(cid:4)mKCU(cid:4)EBUB@(cid:4)HABUP
u.30,-,1:v0d,0-(cid:4)w,-,
xElBEU(cid:4)EBVA(cid:4)KI(cid:4)DEDJB@C_(cid:4)
zACUBJKEB@(cid:4)BYA_(cid:4)
}?YBI(cid:4)CFKIAC_(cid:4)BU(cid:4)~(cid:4)VDEGUA(cid:4)
tADYPU_
xElBEU(cid:128)C(cid:4)KjAIB@@(cid:4)PAB@UPX(cid:4)CUBUGCZ
(cid:4)
v0d,0-(cid:4)(cid:129)7(cid:130)./9.(cid:4)(cid:131)(cid:130).0-9:235S164,8309
y]O(cid:4)>]GA(cid:4)]BUAR_(cid:4)
]BUA(cid:4)Kl(cid:4)]A@DjAIX_(cid:4)
zAEHAI(cid:4)_(cid:4) {EHAUAIVDEAHkGEqEKpE |B@A(cid:4) sAVB@A
BU(cid:4)(cid:127)(cid:4)VDEGUAC
YIBVC ?KGEHC
iAEYUP_
FV DEFPAC
]DH(cid:4)UPA(cid:4)DElBEU(cid:4)AW?AIDAEFA(cid:4)BEX(cid:4)?IKQ@AVC(cid:4)pPD@A(cid:4)QIABCU(cid:4)lAAHDEYZ [K \AC
m@ABCA(cid:4)HACFIDQA_
‘/.,-5.0-a
OKEJEGDEY_ [K \AC
xElBEU(cid:128)C(cid:4)KjAIB@@(cid:4)PAB@UP(cid:4)CUBUGC_(cid:4)
(cid:129)776830,1(cid:4)230-,4-(cid:4)v0d3/5,830
|AHDFB@(cid:4)?IKlACCDKEB@(cid:4)IAC?KECDQ@A(cid:4)lKI(cid:4)VKEDUKIDEY(cid:4)UPA(cid:4)lBUPAI_
[BVA_
}HHIACC_
mPKEA_
sBW_
(cid:4)
tBC(cid:4)UPDC(cid:4)AjAEU(cid:4)IA@BUAH(cid:4)UK(cid:4)B(cid:4)iD@@X(cid:4)HIGYZ
(cid:4)
(cid:4)
(cid:132)(cid:133)(cid:134)(cid:135)(cid:136)(cid:137)(cid:136)(cid:138)(cid:139)(cid:4)(cid:140)(cid:141)(cid:142)(cid:138)(cid:143)(cid:144)(cid:134)(cid:145)(cid:4)(cid:146)(cid:137)(cid:142)(cid:134)(cid:133)(cid:136)(cid:137)(cid:147)
yjAEU(cid:4)KGUFKVA
|AHDFB@(cid:4)?IKlACCDKEB@(cid:4)IAC?KECDQ@A(cid:4)lKI(cid:4)VKEDUKIDEY(cid:4)UPA(cid:4)VKUPAI_
[BVA_
}HHIACC_
mPKEA_
sBW_
(cid:4)(cid:148)
(cid:4)\AC(cid:4)(cid:4)(cid:4)(cid:4)(cid:4) (cid:4)[K
(cid:4){EqEKpE
(cid:149)AFKjAIAH
[KU(cid:4)(cid:149)AFKjAIAH
(cid:4)(cid:149)AFKjAIDEY
tKICAEAH
(cid:4){EqEKpE
(cid:149)AFKjAIAH(cid:4)pDUP(cid:4)rA(cid:150)GA@@B(cid:4)>m@ABCA(cid:4)?IKjDHA(cid:4)HAUBD@CR_
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:30)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:31)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4) !(cid:20)"(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4) #$$"(cid:4)$%%(cid:14)&$’((cid:4))(cid:10)(cid:4)%*(cid:29)(
+,-./-(cid:4)012345-(cid:4)1.627.,-(cid:4)821(cid:4)1-,.9-57-//(cid:4).//-//:-79;
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
(cid:4)
(cid:4)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:29)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:30)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:31) (cid:20)!(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4)(cid:31)"##!(cid:4)#$$(cid:14)%#&’(cid:4)((cid:10)(cid:4)$)*’
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
,-./01-2(cid:4)34-5167(cid:4)89:;<=::>?@A
BC1-7(cid:4)
L5M/0NCO/5(cid:4)P0/4E2-2(cid:4)QG7
(cid:4)
PCO-51t6(cid:4)uCN-(cid:4)/0(cid:4)L5EOCF67
J
y(cid:4) z(cid:4) {@|@}~@
x-52-07(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:20)(cid:13)(cid:11)(cid:8)(cid:18)(cid:7)(cid:8)(cid:19)(cid:11)(cid:24)(cid:22)(cid:4)*(cid:11)(cid:2)(cid:2)(cid:11)+(cid:14)(cid:24)(cid:13)(cid:4)*(cid:11)(cid:25)(cid:12)
DEFFG(cid:4)HC6-(cid:4)I7
RES5C1T0-UL5EOCF67
(cid:4)
J
VCW7
XYZZ[(cid:4)\]^_(cid:4)‘ZabcZ(cid:4)dceYfge(cid:4)^chfe[(cid:4)i(cid:4)\jkk_(cid:4)kllimkno(cid:4)pq(cid:4)lrso
(cid:4)
,C(cid:127)-7
(cid:128);(cid:129)(cid:130);<?;@
(cid:131)<?;@
(cid:136)-ESv17
8(cid:132);(cid:130)|
(cid:133)(cid:134)(cid:135):9
PCO-51t6(cid:4)QE01v(cid:4)BC1-(cid:4)/0(cid:4)wS-7
J
(cid:138)-ESv17
(cid:132)(cid:137)
|A
K
?@
(cid:130)(cid:139)
(cid:140):(cid:141)}9(cid:134):>(cid:4)(cid:142)9(cid:129)A(cid:143)(cid:4)
(cid:4)
(cid:4)
(cid:150)}(cid:134)(cid:151)(cid:128)}@(cid:134)9}(cid:132)(cid:4)(cid:152)(cid:129)(cid:139)(cid:137):9(cid:153)?(cid:154)(cid:4);(cid:155);?(cid:132);(cid:137)(cid:132):(cid:156)(cid:143)
(cid:142)}<:(cid:143)
(cid:144)Y(cid:145)Y(cid:146)Y(cid:147)(cid:148)(cid:149)cb
¡(cid:134);9(cid:134)(cid:4)(cid:142);(cid:134):(cid:143)
(cid:142)9(cid:129)A(cid:4)(cid:142)(cid:151)(cid:128)¢ (cid:152)} £:<
(cid:142)9(cid:129)A(cid:4)(cid:140):<(cid:134);9(cid:134):>¢ (cid:152)} £:<
(cid:4)
¥(cid:145)fcƒe(cid:4)§ff¤Yg'
P0-S5C5(cid:127)G(cid:4)B-1CEF6
(cid:152);(cid:139):(cid:4)}9(cid:4)?@?(cid:158);(cid:132)<(cid:143)(cid:4)
(cid:142)(cid:129):(cid:4)(cid:142);(cid:134):(cid:143)(cid:4)
(cid:157)@>?(cid:130);(cid:158)}@(cid:143)
y9:(cid:159)(cid:129):@(cid:130)(cid:160)(cid:143)
y}9(cid:139)(cid:129)(cid:132);(cid:158)}@(cid:143)
(cid:142)}<:(cid:4)~(cid:135):@(cid:4):(cid:155):@(cid:134)(cid:4)}(cid:130)(cid:130)(cid:129)9:>(cid:143)
(cid:140)}(cid:129)(cid:134):(cid:143)
(cid:142);(cid:134):(cid:4)(cid:142)(cid:151)(cid:128)(cid:143)
(cid:142);(cid:134):(cid:4)(cid:140):<(cid:134);9(cid:134):>(cid:143)
(cid:157)(cid:154)(cid:4)(cid:142)?<(cid:130)}@(cid:158)@(cid:129):>⁄(cid:4)>?>(cid:4)(cid:134)(cid:135):(cid:4):(cid:155):@(cid:134)(cid:4)9:<}(cid:132)(cid:155):¢ £:< (cid:152)}
(cid:157)(cid:154)(cid:4)(cid:140):<(cid:134);9(cid:134):>⁄(cid:4)>?>(cid:4)(cid:134)(cid:135):(cid:4):(cid:155):@(cid:134)(cid:4)}(cid:130)(cid:130)(cid:129)9¢ £:< (cid:152)}
(cid:142);(cid:134):(cid:4)}(cid:154)(cid:4)8?9(cid:134)(cid:135)(cid:4)}9(cid:4)(cid:131)A:(cid:143)(cid:4)
(cid:150);<(cid:134)(cid:4)(cid:139):@<(cid:134)9(cid:129);(cid:132)(cid:4)(cid:141):9?}>(cid:143)(cid:4)
ﬁ9:(cid:155)?}(cid:129)<(cid:4)(cid:141)9:A@;@(cid:130)?:<(cid:4);@>(cid:4)}(cid:129)(cid:134)(cid:130)}(cid:139):<(cid:4)}(cid:154)(cid:4)(cid:134)(cid:135):(cid:4)(cid:141)9:A@;@(cid:130)?:<(cid:4)(cid:153)(cid:141)(cid:132):;<:(cid:4)?@>?(cid:130);(cid:134):(cid:4)?(cid:154)(cid:4):ﬂ(cid:141)}<:>(cid:4)(cid:134)}(cid:4);(cid:4)(cid:150)?(cid:132)(cid:132)(cid:160)(cid:4)(cid:142)9(cid:129)A(cid:4)>(cid:129)9?@A(cid:4)(cid:141)9:A@;@(cid:130)(cid:160)(cid:4)}9(cid:4)(cid:137)9:;<(cid:134)(cid:4)(cid:154)::>?@A(cid:4);@>(cid:4);@(cid:160)(cid:4)(cid:130)}(cid:139)(cid:141)(cid:132)?(cid:130);(cid:158)}@<(cid:176)(cid:156)
““«‹‹«››››
8?9(cid:134)(cid:135)(cid:4)(cid:142);(cid:134):
8?9(cid:134)(cid:135)(cid:4)–:?A(cid:135)(cid:134)
–::|<(cid:4)†:<(cid:134);(cid:158)}@
z;(cid:132):(cid:4)}9
y:(cid:139);(cid:132):
z(cid:4)(cid:4)
y
““«‹‹«››››
(cid:150)?(cid:132)(cid:132)(cid:160)(cid:4)(cid:142)9(cid:129)A(cid:4){<:>
z}(cid:134)(cid:135):9(cid:4)}9(cid:4)(cid:137);(cid:137)(cid:160)
(cid:130)}(cid:139)(cid:141)(cid:132)?(cid:130);(cid:158)}@<¢
‡C1-05CF(cid:4)N-2E(cid:127)CF(cid:4)vE61/0GU0E6·(cid:4)MC(cid:127)1/06(cid:4)(cid:153):(cid:176)A(cid:176)⁄(cid:4)(cid:135)(cid:160)(cid:141):9(cid:134):@<?}@⁄(cid:4)<:?(cid:181)(cid:129)9:(cid:4)>?<}9>:9⁄(cid:4)<(cid:139)}|?@A⁄(cid:4);(cid:132)(cid:130)}(cid:135)}(cid:132)(cid:4)(cid:129)<:⁄(cid:4)>9(cid:129)A(cid:4);(cid:137)(cid:129)<:⁄(cid:4)(cid:154);(cid:139)?(cid:132)(cid:160)(cid:4)(cid:135)?<(cid:134)}9(cid:160)⁄(cid:4):(cid:134)(cid:130)(cid:176)(cid:156)
(cid:128)}@(cid:134)9;(cid:130):(cid:141)(cid:158)(cid:155):(cid:4)(cid:139):(cid:134)(cid:135)}>(cid:143)(cid:4)
‡C1-05CF(cid:4)DEFFG(cid:4)B0TS(cid:4)L5M/0NCO/5
(cid:142)9(cid:129)A(cid:4)@;(cid:139):(cid:143)
(cid:157)@(cid:154);@(cid:134)•<(cid:4);A:(cid:4);(cid:134)(cid:4)¶9<(cid:134)(cid:4)(cid:129)<:(cid:143)
(cid:157)@(cid:154);@(cid:134)•<(cid:4);A:(cid:4);(cid:134)(cid:4)(cid:132);<(cid:134)(cid:4)(cid:129)<:(cid:143)
(cid:142);(cid:134):(cid:4)}(cid:154)(cid:4)¶9<(cid:134)(cid:4)(cid:129)<:(cid:4)
(cid:142);(cid:134):(cid:4)}(cid:154)(cid:4)(cid:132);<(cid:134)(cid:4)(cid:129)<:(cid:143)(cid:4)
““«‹‹«››››
““«‹‹«››››
z;(cid:134):9@;(cid:132)(cid:4)(cid:128)}@(cid:130)}(cid:139)?(cid:134);@(cid:134)(cid:4)z:>?(cid:130);(cid:158)}@<(cid:151)¡(cid:129)(cid:137)<(cid:134);@(cid:130):(cid:4)(cid:153)(cid:141)(cid:132):;<:(cid:4)?@(cid:130)(cid:132)(cid:129)>:(cid:4)(cid:141)9:<(cid:130)9?(cid:141)(cid:158)}@⁄(cid:4)(cid:133)‚(cid:128)(cid:4);@>(cid:4)(cid:135):9(cid:137);(cid:132)(cid:156)
Q0-C61(cid:4)V--2E5S(cid:4)L5M/0NCO/5
(cid:142);(cid:134):(cid:4)(cid:134)(cid:135):(cid:4)(cid:137)9:;<(cid:134)(cid:4)(cid:154)::>?@A(cid:4)<(cid:134);9(cid:134):>(cid:143)
(cid:142);(cid:134):(cid:4)(cid:137)9:;<(cid:134)(cid:4)(cid:154)::>?@A(cid:4)<(cid:134)}(cid:141)(cid:141):>(cid:143)(cid:4)
89:;<(cid:134)(cid:4)(cid:154)::>?@A(cid:4)(cid:130)}@(cid:158)@(cid:129):>¢(cid:4) (cid:152)} £:<
““«‹‹«››››
““«‹‹«››››
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:30)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:31)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4) !(cid:20)"(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4) #$$"(cid:4)$%%(cid:14)(cid:29)$&’(cid:4)((cid:10)(cid:4)%)(cid:30)’
*+,-+.(cid:4)/012342(cid:4)512+.46789:;<=->8+4
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
?@A(cid:4)BCD(cid:4)@EFGEB(cid:4)DHIDJ@DEKD(cid:4)GEL(cid:4)IJMNODPQ(cid:4)RC@OD(cid:4)NJDGQB(cid:4)FDDA@EST(cid:4) UM(cid:4) VDQ
WODGQD(cid:4)ADQKJ@NDX
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
Y32-.92+.Z
[ME\E]@ESX UM(cid:4) VDQ
^EFGEB_Q(cid:4)M‘DJGOO(cid:4)CDGOBC(cid:4)QBGB]QX(cid:4)
(cid:4)
aAA@\MEGO(cid:4)[MEBGKB(cid:4)^EFMJPG\ME
bDA@KGO(cid:4)IJMFDQQ@MEGO(cid:4)JDQIMEQ@NOD(cid:4)FMJ(cid:4)PME@BMJ@ES(cid:4)BCD(cid:4)PMBCDJX
bDA@KGO(cid:4)IJMFDQQ@MEGO(cid:4)JDQIMEQ@NOD(cid:4)FMJ(cid:4)PME@BMJ@ES(cid:4)BCD(cid:4)@EFGEBX
UGPDX
aAAJDQQX
WCMEDX
cGHX
(cid:4)
dGQ(cid:4)BC@Q(cid:4)D‘DEB(cid:4)JDOGBDA(cid:4)BM(cid:4)G(cid:4)e@OOL(cid:4)AJ]ST
(cid:4)
(cid:4)
fghijklhhmnop
t‘DEB(cid:4)M]BKMPD
UGPDX
aAAJDQQX
WCMEDX
cGHX
(cid:4)q
(cid:4)VDQ(cid:4)(cid:4)(cid:4)(cid:4)(cid:4) (cid:4)UM
(cid:4)rEsEMRE
uDKM‘DJDA
UMB(cid:4)uDKM‘DJDA
(cid:4)uDKM‘DJ@ES
dMJQDEDA
(cid:4)rEsEMRE
uDKM‘DJDA(cid:4)R@BC(cid:4)vDw]DOOG(cid:4)xWODGQD(cid:4)IJM‘@AD(cid:4)ADBG@OQyX
WODGQD(cid:4)IJM‘@AD(cid:4)JG\MEGOD(cid:4)FMJ(cid:4)JDOGBDAEDQQ(cid:4)GQQDQQPDEBX
(cid:4)
(cid:4)
(cid:4)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:29)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:30)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:31) (cid:20)!(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4)(cid:31)"##!(cid:4)#$$(cid:14)%#&’(cid:4)((cid:10)(cid:4)$)(cid:29)’
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
-./012.3(cid:4)45.6278(cid:4)9:;<=>(cid:4)?@ABCD:CA
EF2.8(cid:4)
O6P01QFR06(cid:4)S105H3.3(cid:4)TJ8
(cid:4)
SFR.62w7(cid:4)xFQ.(cid:4)01(cid:4)O6HRFI78
M
(cid:20)(cid:13)(cid:11)(cid:8)(cid:18)(cid:7)(cid:8)(cid:19)(cid:11)(cid:24)(cid:22)(cid:4)+(cid:11)(cid:2)(cid:2)(cid:11),(cid:14)(cid:24)(cid:13)(cid:4)+(cid:11)(cid:25)(cid:12)
GHIIJ(cid:4)KF7.(cid:4)L8
UHV6F2W1.XO6HRFI78
(cid:4)
M
YFZ8
[\]]^(cid:4)_‘ab(cid:4)c]def](cid:4)gfh\ijh(cid:4)afkih^(cid:4)l(cid:4)_mnnb(cid:4)noolpnqr(cid:4)st(cid:4)ouvr
(cid:4)
|(cid:4) }(cid:4) ~(cid:127)(cid:128)(cid:127)B(cid:129)(cid:127)
{.63.18(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:4)
-F(cid:130).8
(cid:131)<(cid:132)><A@<(cid:127)
(cid:133)A@<(cid:127)
(cid:139).HVy28
(cid:134)(cid:135)<>(cid:128)
(cid:136)(cid:137)(cid:138):C
SFR.62w7(cid:4)TH12y(cid:4)EF2.(cid:4)01(cid:4)zV.8
M
(cid:142).HVy28
(cid:135)(cid:140)
(cid:128)(cid:141)
N
@(cid:127)
>(cid:143)
(cid:144):;BC(cid:137):D(cid:4)?C(cid:132)(cid:141)(cid:145)(cid:4)
(cid:4)
(cid:4)
(cid:152)B(cid:137)(cid:153)(cid:131)B(cid:127)(cid:137)CB(cid:135)(cid:4)(cid:154)(cid:132)(cid:143)(cid:140):C(cid:155)@(cid:156)(cid:4)<(cid:157)<@(cid:135)<(cid:140)(cid:135):(cid:158)(cid:145)
?BA:(cid:145)
(cid:146)\(cid:147)\(cid:148)\(cid:149)(cid:150)(cid:151)fe
¢(cid:137)<C(cid:137)(cid:4)?<(cid:137):(cid:145)
?C(cid:132)(cid:141)(cid:4)?(cid:153)(cid:131)£ (cid:154)B ⁄:A
?C(cid:132)(cid:141)(cid:4)(cid:144):A(cid:137)<C(cid:137):D£ (cid:154)B ⁄:A
(cid:4)
(cid:4)
S1HQF1J(cid:4)3HFV607H7(cid:4)P01(cid:4)2y.(cid:4)1./012.3(cid:4).5.62¤7'8
ƒ(cid:19)(cid:13)(cid:7)(cid:18)(cid:3)§(cid:4)((cid:3)(cid:22)(cid:11)(cid:25)(cid:9)(cid:19)(cid:25)(cid:22)
9BA;@(cid:137)<(cid:135)@“<=B(cid:127)(cid:4)(cid:156)BC(cid:4)(cid:137)(cid:138)@A(cid:4):(cid:157):(cid:127)(cid:137)£ ⁄:A(cid:4) (cid:154)B
(cid:4)
S1.7.6R6V(cid:4)UHV67XUJQ/20Q7
|:(cid:157):C
(cid:144)<A(cid:138)
«B@(cid:127)(cid:137)(cid:4)›ﬁ(cid:132)A@B(cid:127)A
~C=><C@<
(cid:133)C(cid:137)(cid:138)C<(cid:135)(cid:141)@<A
(cid:4)
K06(cid:130)W11.62(cid:4)45.627(cid:4)F63(cid:4)EH7.F7.¤7'
¢:;A@A
9¡;B(cid:137):(cid:127)A@B(cid:127)
(cid:4)
K06(cid:130)W11.62(cid:4)EH7.F7.¤7'
9(cid:159)–
†(cid:132)(cid:140):C>(cid:132)(cid:135)BA@A
«<(cid:132)(cid:127)D@>:
›D:(cid:143)<
(cid:154)<(cid:132)A:<
(cid:131)B(cid:127)(cid:156)(cid:132)A@B(cid:127)
(cid:136)(cid:137)(cid:138):C(cid:145)
(cid:176)@D(cid:127):¡(cid:4)|<@(cid:135)(cid:132)C:
(cid:136)(cid:137)(cid:138):C(cid:145)
(cid:131)BC(cid:4);(cid:132)(cid:135)(cid:143)B(cid:127)<(cid:135):
(cid:133)(cid:132)(cid:137)B@(cid:143)(cid:143)(cid:132)(cid:127):(cid:4)D@A:<A:
(cid:131)B(cid:127)(cid:141):A=(cid:157):(cid:4)(cid:138):<C(cid:137)(cid:4)(cid:156)<@(cid:135)(cid:132)C:
?@<(cid:140):(cid:137):A
(cid:4)
-.I.5F62(cid:4)SF72(cid:4)·.3H(cid:130)FI(cid:4)(cid:142)H7201J
(cid:159)(cid:127)D@><=B(cid:127)(cid:145)
|C:(cid:160)(cid:132):(cid:127)>¡(cid:145)
|BC(cid:143)(cid:132)(cid:135)<=B(cid:127)(cid:145)
?BA:(cid:4)(cid:129)(cid:138):(cid:127)(cid:4):(cid:157):(cid:127)(cid:137)(cid:4)B>>(cid:132)C:D(cid:145)
(cid:144)B(cid:132)(cid:137):(cid:145)
?<(cid:137):(cid:4)?(cid:153)(cid:131)(cid:145)
?<(cid:137):(cid:4)(cid:144):A(cid:137)<C(cid:137):D(cid:145)
(cid:159)(cid:156)(cid:4)?@A>B(cid:127)=(cid:127)(cid:132):D¥(cid:4)D@D(cid:4)(cid:137)(cid:138):(cid:4):(cid:157):(cid:127)(cid:137)(cid:4)C:AB(cid:135)(cid:157):£ ⁄:A (cid:154)B
(cid:159)(cid:156)(cid:4)(cid:144):A(cid:137)<C(cid:137):D¥(cid:4)D@D(cid:4)(cid:137)(cid:138):(cid:4):(cid:157):(cid:127)(cid:137)(cid:4)B>>(cid:132)C£ ⁄:A (cid:154)B
(cid:133)(cid:140)DB(cid:143)@(cid:127)<(cid:135)(cid:4)‹<@(cid:127)
(cid:133)A>@(cid:137):A
‹<(cid:135)(cid:143)<C(cid:4)›C¡(cid:137)(cid:138):(cid:143)<
(cid:133)A(cid:137):C@ﬂ@A
(cid:4)
(cid:4)
(cid:134)(cid:135)::D@(cid:127)(cid:141)
}<(cid:135)@(cid:141)(cid:127)<(cid:127)>¡
(cid:159)(cid:127)‡<(cid:143)(cid:143)<(cid:137)BC¡(cid:4)(cid:140)B(cid:129):(cid:135)(cid:4)D@A:<A:
(cid:136)(cid:137)(cid:138):C(cid:145)
(cid:154)B(cid:127):
9:;<==A(cid:4)(cid:133)
(cid:152)@(cid:157):C(cid:4)(cid:137)Bﬂ@(cid:127)(cid:4):ﬂ;BA(cid:132)C:
(cid:131)@CC(cid:138)BA@A(cid:4)(cid:131)(cid:138)@(cid:135)D(cid:4)‹(cid:132)(cid:141)(cid:138)(cid:4)(cid:134)(cid:4)BC(cid:4)(cid:131)
(cid:134)(cid:132)DD(cid:181)(cid:131)(cid:138)@<C@(cid:4)A¡(cid:127)DCB(cid:143):
9:;<=>(cid:4):(cid:127)>:;(cid:138)<(cid:135)B;<(cid:137)(cid:138)¡
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:30)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:31)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4) !(cid:20)"(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4) #$$"(cid:4)$%%(cid:14)(cid:29)$&’(cid:4)((cid:10)(cid:4)%)*’
+,-.//0(cid:4)1
234567738,(cid:4)9,-.//0
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
+<-,:?6;6:3?68,76.@A.38=6B,
>.;;(cid:4)?;.==,:(cid:4)=60,.0,
+,-.45:,8.;(cid:4)0<8=:57,
C5:4.;(cid:4)+<-,:4,80658
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
D.E<(cid:4);6F,:
2?85:7.;(cid:4);6F,:(cid:4);.?5:.45:<(cid:4):,03;40
G49,:H
(cid:4)
IJKLJMNOPKO(cid:4)QRSTUVWXTOPKLRT(cid:4)YNKLZWSR(cid:4)[\RTL\N[]JK^(cid:4)_‘I(cid:4)PKS(cid:4)aR\XPZbc
13::,84(cid:4)2;B595;
13::,84(cid:4)d5?.BB5
C.04(cid:4)d5?.BB5
13::,84(cid:4)15B.68,@e,49.7-9,4.768,
C.04(cid:4)15B.68,@e,49.7-9,4.768,
h5:7.;(cid:4)f.8i,(cid:4)j5:(cid:4)k53:
l80/43/58
m.0,;68,(cid:4)n.;3,(cid:4)j5:(cid:4)C./,84
2?85:7.;(cid:4)n.;3,
l7-:5F,7,84(cid:4)n.;3,
o.4,H
o.4,H
o.4,H
C.04(cid:4)2;B595;
G49,:H
f,;,F.84(cid:4)g.?5:.45:<
d,040
(cid:4)
(cid:4)
2pd(cid:4)qp>Gdr
(cid:4)
2gd(cid:4)qp>Cdr
d54.;(cid:4)m6;6:3?68
o6:,B4(cid:4)m6;6:3?68
2;st(cid:4)C950t
>>d
Cdulhf
Cd
277586.
2;?3768
1Cv
1:,./868,
wm1
+,75i;5?68
C;.4,;,4(cid:4)15384
(cid:4)
VR\JZJxNL(cid:4)VOWSNRT(cid:4)YLaRLy(cid:4)[JTN]zRb
28/u83B;,.:(cid:4)28/?5=<(cid:4)q2h2r
+,-.//0(cid:4)2(cid:4)n6:30(cid:4)28/?5=<(cid:4)lie(cid:4)q.8/u+2n(cid:4)lier
28/u;6F,:(cid:4)v6=8,<(cid:4)e6B:5057.;(cid:4)q.8/gver
+,-.//0(cid:4)2(cid:4)n6:30(cid:4)28/?5=<(cid:4)li>(cid:4)q.8/u+2n(cid:4)li>r
28/u.B/8
28/u075549(cid:4)e30B;,(cid:4)28/?5=<(cid:4)q2pe2r
1<457,i.;5F6:30(cid:4)q1enr(cid:4)28/?5=<(cid:4)lie
{?04,68(cid:4)m.::(cid:4)q{mnr(cid:4)p,:5;5i<
G49,:H
+,-.//0(cid:4)m(cid:4)n6:30(cid:4)15:,(cid:4)28/?5=<(cid:4)lie(cid:4)q.8/u+mB(cid:4)lier
+,-.//0(cid:4)m(cid:4)n6:30(cid:4)p3:j.B,(cid:4)28/?5=<(cid:4)q.8/u+m0r
+,-.//0(cid:4)m(cid:4)n6:30(cid:4)p3:j.B,(cid:4)28/i,8(cid:4)q+m0(cid:4)2ir
+,-.//0(cid:4)1(cid:4)n6:30(cid:4)28/?5=<(cid:4)q.8/u+1nr
+,-.//0(cid:4)1(cid:4)n6:30(cid:4)fh2(cid:4)q+1n(cid:4)fh2r
G49,:(cid:4)p43=<
f,03;40
g6F,:(cid:4)m65-0<
(cid:4)
+,-./B(cid:4)|;4:.0538=
efl
1d(cid:4)pB.8
G49,:H
‘\RPOMRKO(cid:4)[\JzNSRS(cid:4)Y[ZRPTR(cid:4)SRTL\NXRb
(cid:4)
w.0(cid:4)4960(cid:4),F,84(cid:4):,;.4,=(cid:4)45(cid:4).(cid:4)g6;;<(cid:4)=:3i}
(cid:4)
(cid:4)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:30)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:31)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4) !(cid:20)"(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4) #$$"(cid:4)$%%(cid:14)&$’((cid:4))(cid:10)(cid:4)%*(cid:29)(
+,-./(cid:4)01/203-
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
70/(cid:4)4-20,-5-6
4-20,-5-6
(cid:4)4-20,-58.9
:05;-.-6
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
(cid:4)<.=.0>.
4-20,-5-6(cid:4)>8/?(cid:4)@-A1-BBC(cid:4)DEB-C;-(cid:4)F50,86-(cid:4)6-/C8B;GH
EB-C;-(cid:4)F50,86-(cid:4)5CI0.CB-(cid:4)J05(cid:4)5-BC/-6.-;;(cid:4)C;;-;;3-./H
(cid:4)
(cid:4)
(cid:4)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:29)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:30)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:31) (cid:20)!(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4)(cid:31)"##!(cid:4)#$$(cid:14)%#&’(cid:4)((cid:10)(cid:4)$)*’
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
,-./01-2(cid:4)34-5167(cid:4)89:;<=
>?1-7(cid:4)
H5I/0J?K/5(cid:4)L0/4A2-2(cid:4)MC7
(cid:4)
L?K-51p6(cid:4)q?J-(cid:4)/0(cid:4)H5AK?B67
F
u(cid:4) v(cid:4) w:x:yz:
t-52-07(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:20)(cid:13)(cid:11)(cid:8)(cid:18)(cid:7)(cid:8)(cid:19)(cid:11)(cid:24)(cid:22)(cid:4)*(cid:11)(cid:2)(cid:2)(cid:11)+(cid:14)(cid:24)(cid:13)(cid:4)*(cid:11)(cid:25)(cid:12)
@ABBC(cid:4)D?6-(cid:4)E7
NAO5?1P0-QH5AK?B67
(cid:4)
F
R?S7
TUVVW(cid:4)XYZ[(cid:4)\V]^_V(cid:4)‘_aUbca(cid:4)Z_dbaW(cid:4)e(cid:4)Xfgg[(cid:4)ghheigjk(cid:4)lm(cid:4)hnok
(cid:4)
,?{-7
89|;9}~9:
(cid:127)}~9:
(cid:133)-AOr17
(cid:128)(cid:129)9;x
(cid:130)(cid:131)(cid:132)<=
L?K-51p6(cid:4)MA01r(cid:4)>?1-(cid:4)/0(cid:4)sO-7
F
(cid:136)-AOr17
(cid:129)(cid:134)
x(cid:135)
G
~:
;(cid:137)
(cid:156):(cid:140)~;9(cid:157)y:(cid:142)
u=<(cid:158)|<:;(cid:159)(cid:142)
uy=(cid:137)|(cid:129)9(cid:157)y:(cid:142)
(cid:141)y}<(cid:4)z(cid:132)<:(cid:4)<(cid:154)<:(cid:131)(cid:4)y;;|=<(cid:140)(cid:142)
(cid:138)y|(cid:131)<(cid:142)
(cid:141)9(cid:131)<(cid:4)(cid:141)(cid:150)8(cid:142)
(cid:141)9(cid:131)<(cid:4)(cid:138)<}(cid:131)9=(cid:131)<(cid:140)(cid:142)
(cid:156)(cid:153)(cid:4)(cid:141)~};y:(cid:157):|<(cid:140)£(cid:4)(cid:140)~(cid:140)(cid:4)(cid:131)(cid:132)<(cid:4)<(cid:154)<:(cid:131)(cid:4)=<}y(cid:129)(cid:154)<¡ ¢<} (cid:151)y
(cid:156)(cid:153)(cid:4)(cid:138)<}(cid:131)9=(cid:131)<(cid:140)£(cid:4)(cid:140)~(cid:140)(cid:4)(cid:131)(cid:132)<(cid:4)<(cid:154)<:(cid:131)(cid:4)y;;|=¡ ¢<} (cid:151)y
(cid:138)<(cid:139)y=(cid:131)<(cid:140)(cid:4)(cid:141)=|(cid:135)(cid:142)(cid:4)
(cid:4)
(cid:4)
(cid:149)y(cid:131)(cid:150)8y:(cid:131)=y(cid:129)(cid:4)(cid:151)|(cid:137)(cid:134)<=(cid:152)~(cid:153)(cid:4)9(cid:154)9~(cid:129)9(cid:134)(cid:129)<(cid:155)(cid:142)
(cid:141)y}<(cid:142)
(cid:143)U(cid:144)U(cid:145)U(cid:146)(cid:147)(cid:148)_^
(cid:160)(cid:131)9=(cid:131)(cid:4)(cid:141)9(cid:131)<(cid:142)
(cid:141)=|(cid:135)(cid:4)(cid:141)(cid:150)8¡ (cid:151)y ¢<}
(cid:141)=|(cid:135)(cid:4)(cid:138)<}(cid:131)9=(cid:131)<(cid:140)¡ (cid:151)y ¢<}
(cid:4)
L0AJ?0C(cid:4)2A?O5/6A6(cid:4)I/0(cid:4)1r-(cid:4)0-./01-2(cid:4)-4-51ƒ6§7
¤y}(cid:139)~(cid:131)9(cid:129)~'9(cid:157)y:(cid:4)(cid:153)y=(cid:4)(cid:131)(cid:132)~}(cid:4)<(cid:154)<:(cid:131)¡ ¢<}(cid:4) (cid:151)y
(cid:10)(cid:7)(cid:8)⁄(cid:19)(cid:25)(cid:4)¥(cid:4)(cid:23)(cid:19)(cid:11)(cid:13)(cid:2)(cid:7)(cid:22)(cid:12)
(cid:4)
“(cid:129)<9}<(cid:4)}(cid:139)<;~(cid:153)(cid:159)(cid:4)(cid:139)=~(cid:137)9=(cid:159)(cid:4)}~(cid:131)<(cid:142)(cid:4)
(cid:151)<y(cid:139)(cid:129)9}(cid:137)(cid:4)(cid:152)(cid:134)<:~(cid:135):(cid:4)(cid:137)9}}(cid:150)(cid:129)<}~y:}(cid:155)
“y}}~(cid:134)(cid:129)<(cid:4)(cid:137)9(cid:129)~(cid:135):9:(cid:131)(cid:4)(cid:131)|(cid:137)y=(cid:4)«(cid:4):y(cid:131)(cid:4)(cid:159)<(cid:131)(cid:4);y:‹=(cid:137)<(cid:140)
v9(cid:129)~(cid:135):9:(cid:131)(cid:4)(cid:131)|(cid:137)y=(cid:4)(cid:152)(cid:139)(cid:129)<9}<(cid:4)9›9;(cid:132)(cid:4);y(cid:139)(cid:159)(cid:4)y(cid:153)(cid:4)(cid:139)9(cid:131)(cid:132)y(cid:129)y(cid:135)(cid:159)(cid:4)=<(cid:139)y=(cid:131)(cid:4)y=(cid:4)(cid:139)=y(cid:154)~(cid:140)<(cid:4)(cid:131)(cid:132)<(cid:4)~:(cid:153)y=(cid:137)9(cid:157)y:(cid:4)y(cid:153)(cid:4)(cid:160)(cid:131)9(cid:135)<(cid:150)ﬁ=9(cid:140)<£(cid:4)(cid:160)(cid:131)9(cid:135)~:(cid:135)(cid:4);(cid:129)9}}~‹;9(cid:157)y:(cid:4)9:(cid:140)(cid:4)(cid:157)}}|<(cid:4)}y|=;<(cid:155)(cid:142)
D/5{/JA1?51(cid:4)ﬂ-2A{?K/56QNP(cid:176)61?5{-6(cid:4)ƒ.B-?6-(cid:4)A5{BP2-(cid:4).0-6{0A.K/5–(cid:4)†‡D(cid:4)?52(cid:4)r-0(cid:176)?B§
,-B-4?51(cid:4)‡-616QN1P2A-6(cid:4)ƒ.B-?6-(cid:4)?·?{r(cid:4){/.C(cid:4)/I(cid:4).?1r/B/OC(cid:4)0-./01(cid:4)AI(cid:4)?4?AB?(cid:176)B-§
(cid:160)(cid:131)|(cid:140)(cid:159)
(cid:138)<}|(cid:129)(cid:131)
¤~}(cid:131)y(cid:139)9(cid:131)(cid:132)y(cid:129)y(cid:135)(cid:159)(cid:4)(cid:152)(cid:139)(cid:129)<9}<(cid:4)~:(cid:140)~;9(cid:131)<(cid:4)}(cid:131)9(cid:135)<(cid:150)(cid:135)=9(cid:140)<£(cid:4)}(cid:131)9(cid:135)~:(cid:135)(cid:4);(cid:129)9}}~‹;9(cid:157)y:(cid:4)9:(cid:140)(cid:4)(cid:157)}}|<
}y|=;<(cid:155)
w(cid:129)(cid:131)=9}y|:(cid:140)
8(cid:127)(cid:181)(cid:4)(cid:160);9:
v(cid:138)(cid:156)
(cid:130)(cid:131)(cid:132)<=(cid:142)
(cid:4)
ﬂ-2A{?B(cid:4)(cid:136)A61/0CQ,A6¶(cid:4)R?{1/06
(cid:4)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:30)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:31)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4) !(cid:20)"(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4) #$$"(cid:4)$%%(cid:14)(cid:29)$&’(cid:4)((cid:10)(cid:4)%)(cid:30)’
*+,-./0(cid:4)
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
*6.2986./+;50
(cid:4)5.+/7
?78/9@.,(cid:4)A7.(cid:4)
D3+C.8.7(cid:4)2.4438A7
F4-9694
J22A,97A;;/.7739,0(cid:4)
(cid:4)E86./(cid:4)L;4.+7.(cid:4)=.7-/3C.M0
(cid:4)
NOPQRSPTR(cid:4)UOVWXYPY(cid:4)ZU[PQ\P(cid:4)YP\]OX^P_(cid:4)
1+2345(cid:4)63789/5(cid:4)9:(cid:4)-+,-./0(cid:4)
<+=3+>9,(cid:4)86./+;5
B9C+--9(cid:4)A7.
EC.7385
G9(cid:4)H,9I,(cid:4);/.=37;973,@(cid:4):+-89/7
?,K3/9,2.,8+4(cid:4)/37H0(cid:4)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
(cid:4)
‘+7(cid:4)8637(cid:4).K.,8(cid:4)/.4+8.=(cid:4)89(cid:4)+(cid:4)a3445(cid:4)=/A@b
(cid:4)
(cid:4)
cdefgh
?K.,8(cid:4)9A8-92.
(cid:4)i
(cid:4)j.7(cid:4)(cid:4)(cid:4)(cid:4)(cid:4) (cid:4)G9
(cid:4)k,H,9I,
<.-9K./.=
G98(cid:4)<.-9K./.=
(cid:4)<.-9K./3,@
‘9/7.,.=
(cid:4)k,H,9I,
<.-9K./.=(cid:4)I386(cid:4)l.mA.44+(cid:4)Ln4.+7.(cid:4);/9K3=.(cid:4)=.8+347M0
n4.+7.(cid:4);/9K3=.(cid:4)/+>9,+4.(cid:4):9/(cid:4)/.4+8.=,.77(cid:4)+77.772.,80
(cid:4)
(cid:4)
(cid:4)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:29)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:30)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:31) (cid:20)!(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4)(cid:31)"##!(cid:4)#$$(cid:14)%#&’(cid:4)((cid:10)(cid:4)$)(cid:29)’
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
-./012.3(cid:4)45.6278(cid:4)9:;<=:>(cid:4)?=@A;<B;@
CD2.8(cid:4)
M6N01ODP06(cid:4)Q105F3.3(cid:4)RH8
(cid:4)
QDP.62u7(cid:4)vDO.(cid:4)01(cid:4)M6FPDG78
K
(cid:20)(cid:13)(cid:11)(cid:8)(cid:18)(cid:7)(cid:8)(cid:19)(cid:11)(cid:24)(cid:22)(cid:4)+(cid:11)(cid:2)(cid:2)(cid:11),(cid:14)(cid:24)(cid:13)(cid:4)+(cid:11)(cid:25)(cid:12)
EFGGH(cid:4)ID7.(cid:4)J8
SFT6D2U1.VM6FPDG78
(cid:4)
K
WDX8
YZ[[\(cid:4)]^_‘(cid:4)a[bcd[(cid:4)edfZghf(cid:4)_digf\(cid:4)j(cid:4)]kll‘(cid:4)lmmjnlop(cid:4)qr(cid:4)mstp
(cid:4)
z(cid:4) {(cid:4) |}~}A(cid:127)}
y.63.18(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:4)
-D(cid:128).8
9:(cid:129)>:@=:}
(cid:130)@=:}
(cid:136).FTw28
(cid:131)(cid:132):>~
(cid:133)(cid:134)(cid:135)B;
QDP.62u7(cid:4)RF12w(cid:4)CD2.(cid:4)01(cid:4)xT.8
K
(cid:139).FTw28
(cid:132)(cid:137)
~(cid:138)
L
=}
>(cid:140)
(cid:141)B(cid:142)A;(cid:134)B<(cid:4)?;(cid:129)(cid:138)(cid:143)(cid:4)
(cid:4)
(cid:4)
(cid:150)A(cid:134)(cid:151)9A}(cid:134);A(cid:132)(cid:4)(cid:152)(cid:129)(cid:140)(cid:137)B;(cid:153)=(cid:154)(cid:4):(cid:155):=(cid:132):(cid:137)(cid:132)B(cid:156)(cid:143)
?A@B(cid:143)
(cid:144)Z(cid:145)Z(cid:146)Z(cid:147)(cid:148)(cid:149)dc
¡(cid:134):;(cid:134)(cid:4)?:(cid:134)B(cid:143)
?;(cid:129)(cid:138)(cid:4)?(cid:151)9¢ (cid:152)A £B@
?;(cid:129)(cid:138)(cid:4)(cid:141)B@(cid:134):;(cid:134)B<¢ (cid:152)A £B@
(cid:157)}<=>:(cid:158)A}(cid:143)
z;B(cid:159)(cid:129)B}>(cid:160)(cid:143)
zA;(cid:140)(cid:129)(cid:132):(cid:158)A}(cid:143)
?A@B(cid:4)(cid:127)(cid:135)B}(cid:4)B(cid:155)B}(cid:134)(cid:4)A>>(cid:129);B<(cid:143)
(cid:141)A(cid:129)(cid:134)B(cid:143)
?:(cid:134)B(cid:4)?(cid:151)9(cid:143)
?:(cid:134)B(cid:4)(cid:141)B@(cid:134):;(cid:134)B<(cid:143)
(cid:157)(cid:154)(cid:4)?=@>A}(cid:158)}(cid:129)B<⁄(cid:4)<=<(cid:4)(cid:134)(cid:135)B(cid:4)B(cid:155)B}(cid:134)(cid:4);B@A(cid:132)(cid:155)B¢ £B@ (cid:152)A
(cid:157)(cid:154)(cid:4)(cid:141)B@(cid:134):;(cid:134)B<⁄(cid:4)<=<(cid:4)(cid:134)(cid:135)B(cid:4)B(cid:155)B}(cid:134)(cid:4)A>>(cid:129);¢ £B@ (cid:152)A
(cid:4)
(cid:4)
Q1FOD1H(cid:4)3FDT607F7(cid:4)N01(cid:4)2w.(cid:4)1./012.3(cid:4).5.62ƒ7§
9(cid:135)B@(cid:134)(cid:4)¤:=}(cid:151)(cid:130)}(cid:138)=}:
{(cid:160)A>:;<=:(cid:132)(cid:4)(cid:157)}(cid:154):;>(cid:158)A}
(cid:130);;(cid:135)(cid:160)(cid:134)(cid:135)(cid:140)=:
(cid:133)(cid:134)(cid:135)B;(cid:4)'(cid:4)(cid:142)(cid:132)B:@B(cid:4)<B@>;=(cid:137)B(cid:143)(cid:4)
(cid:10)(cid:7)(cid:25)(cid:9)(cid:3)(cid:7)¥(cid:4)((cid:3)(cid:22)(cid:11)(cid:25)(cid:9)(cid:19)(cid:25)(cid:22)
(cid:139)07/F2DGF“DP06(cid:4)N01(cid:4)2wF7(cid:4).5.62« £B@(cid:4) (cid:152)A
Q1.7.6P6T(cid:4)SFT67VSHO/20O7
‹B:;(cid:134)(cid:4)(cid:141):(cid:134)B(cid:143)
¤:(cid:132)(cid:142)=(cid:134):(cid:158)A}@
¡(cid:160)}>A(cid:142)B
9:;<=:>(cid:4)B›:(cid:140)(cid:143)
¤(cid:129)(cid:132)(cid:140)A}:;(cid:160)(cid:4)B›:(cid:140)(cid:143)
(cid:133)(cid:134)(cid:135)B;(cid:4)(cid:153)(cid:142)(cid:132)B:@B(cid:4)@(cid:142)B>=(cid:154)(cid:160)(cid:156)(cid:143)
(cid:4)
-.G.5D62(cid:4)ﬁ.3F(cid:128)DG(cid:4)(cid:139)F7201H(cid:4)ƒ/G.D7.(cid:4)7/.(cid:128)FNH(cid:4)FN(cid:4)6..3.3§
(cid:130)(cid:134);=:(cid:132)(cid:4)(cid:130);;(cid:135)(cid:160)(cid:134)(cid:135)(cid:140)=:
9A}<(cid:129)>(cid:158)A}(cid:4)?=@A;<B;@
9:;<=A(cid:155):@>(cid:129)(cid:132):;(cid:4)?=@B:@B
9:;<=A(cid:155):@>(cid:129)(cid:132):;(cid:4)(cid:157)}(cid:154)B>(cid:158)A}
¤(cid:129)(cid:132)(cid:140)A}:;(cid:160)(cid:4)?=@B:@B
{B(cid:134):(cid:137)A(cid:132)=>(cid:4)?=@A;<B;@
¤B;=>:;<=(cid:158)@
¤AA;(cid:4)9A(cid:140)(cid:142)(cid:132)=:}>B(cid:4)(cid:127)=(cid:134)(cid:135)(cid:4)(cid:131)¤(cid:151)9:;<=:>(cid:4){B<@
(cid:4)
(cid:131)(cid:132)AA<(cid:4)¤;B@@(cid:129);B(cid:143)(cid:4)
¡(cid:135)A;(cid:134)}B@@(cid:4)A(cid:154)(cid:4)(cid:131);B:(cid:134)(cid:135)
9(cid:135)B@(cid:134)(cid:4)(cid:142):=}(cid:4)(cid:153)(cid:142)(cid:132)B:@B(cid:4)@(cid:142)B>=(cid:154)(cid:160)(cid:156)(cid:143)
ﬂB}(cid:134);=>(cid:129)(cid:132):;(cid:4)(cid:130);;(cid:135)(cid:160)(cid:134)(cid:135)(cid:140)=:
9A}(cid:138)B}=(cid:134):(cid:132)(cid:4)‹B:;(cid:134)(cid:4)(cid:130)(cid:137)}A;(cid:140):(cid:132)=(cid:158)B@
‹(cid:160)(cid:142)B;(cid:134)B}@=A}
9:;<=:>(cid:4)¡(cid:129);(cid:138)B;=B@
¤(cid:129)(cid:132)(cid:140)A}:;(cid:160)(cid:4)(cid:176)(cid:140)(cid:137)A(cid:132)=@(cid:140)
¤@(cid:160)>(cid:135)=:(cid:134);=>(cid:151)(cid:176)(cid:140)A(cid:158)A}:(cid:132)(cid:4)?=@A;<B;@
¡(cid:160)}>A(cid:142)B
?=––=}B@@
Approved on 28 Mar 2023 GMT
¡(cid:129)(cid:137)@(cid:134):}>B(cid:4)(cid:130)(cid:137)(cid:129)@B
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:30)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:31)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4) !(cid:20)"(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4) #$$"(cid:4)$%%(cid:14)(cid:29)$&’(cid:4)((cid:10)(cid:4)%)*’
+,-./(cid:4)012.34.(cid:4)41.56789:
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
;<=>?@<A(cid:4)B@CD=(cid:4)EFGHI=H(cid:4)=FHA<JKL
(cid:4)
MNO3//-8,-P654:
R485-63,/65(cid:4)P.S653OTN4:
+,-./4:
V?WA?X<>IW>(cid:4)YHZ=(cid:4)E<WAGCZH(cid:4)F@H=A@<F[?W\(cid:4)=C]=>IWAH\(cid:4)^_V(cid:4)IWZ(cid:4)‘H@]IGL
a6,/3,.4ba6,/6,.4
de(cid:4)P.S653OTN(cid:4)012.34.(cid:4)41.56789:
MNO-81./,.N46Q.4:
MNOU6TO54:
M21-3(cid:4)U2T5c./
+,-./4:
f.2.Q3N,(cid:4)g3UT/3,T/8(cid:4)h.4,4
aT/P32(cid:4)f3Ni.(cid:4)7T/(cid:4)jTk/
lN4O,kOTN
m34.26N.(cid:4)n32k.(cid:4)7T/(cid:4)R3O.N,
MUNT/P32(cid:4)n32k.
lP1/TQ.P.N,(cid:4)n32k.
(cid:4)
o3/S635(cid:4)dNp8P.(cid:4)0R2.34.(cid:4)41.56789:
e3,.:
e3,.:
e3,.:
q./kP(cid:4)RT,3446kP
q./kP(cid:4)o3256kP
1+r
+r(cid:4)q3,k/3OTN
+,-./(cid:4)e63iNT4O5(cid:4)h.4,4
f.4k2,4
dst(cid:4)0u(cid:4)v3Q.49bdst(cid:4)0uho(cid:4)lN,./Q329
(cid:4)
w8T53/S632(cid:4)q53N
d5-T53/S6Ti/3P(cid:4)0dox+9
oT/TN3/8(cid:4)MNi6Ti/31-8
dy./564.(cid:4)q,/.44(cid:4)h.4,
uh(cid:4)lN,./Q32(cid:4)0P62264.5TNS49
uh5(cid:4)0oT//.5,.S(cid:4)n32k.9
xTv(cid:4)v34(cid:4)uh(cid:4)6N,./Q32(cid:4)P.34k/.Sz
uh(cid:4)5T//.5OTN(cid:4)7T/Pk23
+,-./:
(cid:4)
_@HI>XHW>
(cid:4)
o3/S6TQ./46TNbS.}U/6223OTN
w.S653OTN(cid:4)012.34.(cid:4)41.56789:
+,-./(cid:4)012.34.(cid:4)41.56789:
w35-6N.(cid:4) w3Nk3228(cid:4) +,-./
m3p.{(cid:4) |/.S./653(cid:4) +,-./
h/.3,P.N,(cid:4)NT,(cid:4)/.~k6/.S
MU23OTN
(cid:4)
(cid:127)34(cid:4),-64(cid:4).Q.N,(cid:4)/.23,.S(cid:4),T(cid:4)3(cid:4)g6228(cid:4)S/kiz
(cid:4)
(cid:4)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:30)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:31)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4) !(cid:20)"(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4) #$$"(cid:4)$%%(cid:14)&$’((cid:4))(cid:10)(cid:4)%*(cid:29)(
+,-./(cid:4)01/203-
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
70/(cid:4)4-20,-5-6
4-20,-5-6
(cid:4)4-20,-58.9
:05;-.-6
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
(cid:4)<.=.0>.
4-20,-5-6(cid:4)>8/?(cid:4)@-A1-BBC(cid:4)DEB-C;-(cid:4)F50,86-(cid:4)6-/C8B;GH
EB-C;-(cid:4)F50,86-(cid:4)5CI0.CB-(cid:4)J05(cid:4)5-BC/-6.-;;(cid:4)C;;-;;3-./H
(cid:4)
(cid:4)
(cid:4)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:29)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:30)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:31) (cid:20)!(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4)(cid:31)"##!(cid:4)#$$(cid:14)%#&’(cid:4)((cid:10)(cid:4)$)*’
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
,-./01-2(cid:4)34-5167(cid:4)89:9;:<=>?@AB>:(cid:4)C@@DE9FG
(cid:20)(cid:13)(cid:11)(cid:8)(cid:18)(cid:7)(cid:8)(cid:19)(cid:11)(cid:24)(cid:22)(cid:4)*(cid:11)(cid:2)(cid:2)(cid:11)+(cid:14)(cid:24)(cid:13)(cid:4)*(cid:11)(cid:25)(cid:12)
JKLLM(cid:4)NI6-(cid:4)O7
XKY5I1Z0-[R5KUIL67
(cid:4)
P
\I]7
^_‘‘a(cid:4)bcde(cid:4)f‘ghi‘(cid:4)jik_lmk(cid:4)dinlka(cid:4)o(cid:4)bpqqe(cid:4)qrrosqtu(cid:4)vw(cid:4)rxyu
(cid:4)
,I(cid:132)-7
8>A@>?D>F
C?D>F
(cid:136)-KY|17
(cid:133)B>@(cid:130)
(cid:134)G(cid:135)9:
VIU-51z6(cid:4)WK01|(cid:4)HI1-(cid:4)/0(cid:4)}Y-7
P
(cid:138)-KY|17
B;
(cid:130)(cid:137)
Q
DF
@(cid:139)
HI1-7(cid:4)
R5S/0TIU/5(cid:4)V0/4K2-2(cid:4)WM7
(cid:4)
VIU-51z6(cid:4){IT-(cid:4)/0(cid:4)R5KUIL67
P
(cid:127)(cid:4) (cid:128)(cid:4) (cid:129)F(cid:130)F<(cid:131)F
~-52-07(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:4)
(cid:156)FED@>(cid:157)<F(cid:143)
(cid:127):9(cid:158)A9F@(cid:159)(cid:143)
(cid:127)<:(cid:139)AB>(cid:157)<F(cid:143)
(cid:142)<?9(cid:4)(cid:131)(cid:135)9F(cid:4)9=9FG(cid:4)<@@A:9E(cid:143)
(cid:140)<AG9(cid:143)
(cid:142)>G9(cid:4)(cid:142)(cid:151)8(cid:143)
(cid:142)>G9(cid:4)(cid:140)9?G>:G9E(cid:143)
(cid:156)(cid:154)(cid:4)(cid:142)D?@<F(cid:157)FA9E£(cid:4)EDE(cid:4)G(cid:135)9(cid:4)9=9FG(cid:4):9?<B=9¡ ¢9? (cid:152)<
(cid:156)(cid:154)(cid:4)(cid:140)9?G>:G9E£(cid:4)EDE(cid:4)G(cid:135)9(cid:4)9=9FG(cid:4)<@@A:¡ ¢9? (cid:152)<
(cid:140)9(cid:141)<:G9E(cid:4)(cid:142):A(cid:137)(cid:143)(cid:4)
(cid:4)
(cid:4)
(cid:150)<G(cid:151)8<FG:<B(cid:4)(cid:152)A(cid:139);9:(cid:153)D(cid:154)(cid:4)>=>DB>;B9(cid:155)(cid:143)
(cid:142)<?9(cid:143)
(cid:144)_(cid:145)_(cid:146)_(cid:147)(cid:148)(cid:149)ih
(cid:160)G>:G(cid:4)(cid:142)>G9(cid:143)
(cid:142):A(cid:137)(cid:4)(cid:142)(cid:151)8¡ (cid:152)< ¢9?
(cid:142):A(cid:137)(cid:4)(cid:140)9?G>:G9E¡ (cid:152)< ¢9?
(cid:4)
V0KTI0M(cid:4)HKIY5/6K6(cid:4)S/0(cid:4)1|-(cid:4)0-./01-2(cid:4)-4-51§6¤7
(cid:4)
(cid:10)(cid:19)(cid:25)(cid:19)(cid:16)(cid:25)(cid:11)⁄(cid:7)(cid:22)¥(cid:24)(cid:2)(cid:7)(cid:25)(cid:4)ƒ¥¥(cid:3)(cid:9)(cid:19)(cid:8)(cid:18)
'<?(cid:141)DG>BD“>(cid:157)<F(cid:4)(cid:154)<:(cid:4)G(cid:135)D?(cid:4)9=9FG¡(cid:4) ¢9?(cid:4) (cid:152)<
N/5(cid:132)/TK1I51(cid:4)«-2K(cid:132)IU/56[XZ‹61I5(cid:132)-6§.L-I6-(cid:4)K5(cid:132)LZ2-(cid:4).0-6(cid:132)0K.U/5›(cid:4)ﬁﬂN(cid:4)I52(cid:4)|-0‹IL¤
V0-6-5U5Y(cid:4)XKY56[XMT.1/T6
(cid:134)F?9G(cid:4)(cid:142)>G9(cid:143)
(cid:156)(cid:139)(cid:141)>D:(cid:139)9FG?(cid:143)
–>:>B(cid:159)?D?(cid:4)(cid:153)?(cid:141)9@D(cid:154)(cid:159)(cid:155)(cid:143)
†9>(cid:130)F9??(cid:4)(cid:153)?(cid:141)9@D(cid:154)(cid:159)(cid:155)(cid:143)
(cid:142)(cid:159)?(cid:141)(cid:135)>(cid:137)D>
X-4-0K1M
(cid:176)FE(cid:4)(cid:142)>G9(cid:143)
(cid:142)(cid:159)?>:G(cid:135):D>
(cid:156)(cid:139)(cid:141)>D:9E(cid:4)@<F?@D<A?F9??
‡D?A>B(cid:4)·9BE(cid:4)E9(cid:154)9@G
(cid:160)9D“A:9
C(cid:141)(cid:135)>?D>
(cid:134)G(cid:135)9:(cid:4)·FEDF(cid:137)?(cid:143)
(cid:152)<(cid:151)(cid:128)DBE
(cid:128)<E9:>G9
(cid:160)9=9:9
,-L-4I51(cid:4)«-2K(cid:132)IL(cid:4)(cid:138)K61/0M
(cid:142)D>;9G9?
(cid:160)(cid:139)<(cid:130)DF(cid:137)
C:G:D>B(cid:4)·;:DBB>(cid:157)<F
'9>E(cid:4)G:>A(cid:139)>
'(cid:159)(cid:141)9:G9F?D<F
–:D<:(cid:4)?G:<(cid:130)9
(cid:128)(cid:159)<@>:ED>B(cid:4)DF(cid:154)>:@(cid:157)<F
'(cid:159)(cid:141)9:BD(cid:141)DE9(cid:139)D>
(cid:134)G(cid:135)9:(cid:4)(cid:153)(cid:141)B9>?9(cid:4)?(cid:141)9@D(cid:154)(cid:159)(cid:155)(cid:143)
(cid:140)9B9=>FG(cid:4)(cid:150)>;<:>G<:(cid:159)(cid:4)(cid:181)9?G?
(cid:4)
(cid:152)<:(cid:139)>B(cid:4):>F(cid:137)9(cid:4)(cid:154)<:(cid:4)(cid:159)<A:(cid:4)DF?(cid:157)GA(cid:157)<F
(cid:133)>?9BDF9(cid:4)=>BA9(cid:4)(cid:154)<:(cid:4)(cid:141)>(cid:157)9FG
C;F<:(cid:139)>B(cid:4)=>BA9
(cid:156)(cid:139)(cid:141):<=9(cid:139)9FG(cid:4)=>BA9
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:30)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:31)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4) !(cid:20)"(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4) #$$"(cid:4)$%%(cid:14)(cid:29)$&’(cid:4)((cid:10)(cid:4)%)(cid:30)’
*+,-.
(cid:0)(cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:7)(cid:8)(cid:6)(cid:4)(cid:14)(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)
/-01231456
789
*+,-.
*+,-.
(cid:10)(cid:7)(cid:22)(cid:19)(cid:4)(cid:23)(cid:24)(cid:12)(cid:16)(cid:19)(cid:25)(cid:26)(cid:4)(cid:27)
:3+,-3-,(cid:4)91;6,
<3;=1>-
?@A
+:BB
BCD10456(cid:4)B50-
E54D5612-6
F,C-D.
F,C-D.
F,C-D(cid:4)B->,>
9B
(cid:4)
GA?
H62512D+ICJ
KK<
F,C-D.
LMNOPQNRP
A->;3,>
(cid:4)
S;II1D,(cid:4)+6T(cid:4)1D2+65U+V16
BCD10413JV=(cid:4)+2-6,
H6VI3+,-3-,(cid:4)+2-6,
H6V=1+2;3+6,
H43+V16
F,C-D.
(cid:4)
7+>(cid:4),C5>(cid:4)-W-6,(cid:4)D-3+,-T(cid:4),1(cid:4)+(cid:4)X533J(cid:4)TD;2Y
(cid:4)
(cid:4)
Z[\[]\^_‘abcd‘\(cid:4)ebbfg[hi
KW-6,(cid:4)1;,=10-
(cid:4)j
(cid:4)k->(cid:4)(cid:4)(cid:4)(cid:4)(cid:4) (cid:4)@1
(cid:4)l6m61n6
A-=1W-D-T
@1,(cid:4)A-=1W-D-T
(cid:4)A-=1W-D562
71D>-6-T
(cid:4)l6m61n6
A-=1W-D-T(cid:4)n5,C(cid:4)S-o;-33+(cid:4)p:3-+>-(cid:4)ID1W5T-(cid:4)T-,+53>q.
:3-+>-(cid:4)ID1W5T-(cid:4)D+V16+3-(cid:4)r1D(cid:4)D-3+,-T6->>(cid:4)+>>->>0-6,.
(cid:4)
(cid:4)
(cid:4)
Approved on 28 Mar 2023 GMT
(cid:17)(cid:7)(cid:28)(cid:19)(cid:4)(cid:29)(cid:4)(cid:11)(cid:21)(cid:4)(cid:29)
(cid:17)(cid:2)(cid:19)(cid:7)(cid:22)(cid:19)(cid:4)(cid:21)(cid:7)(cid:30)(cid:4)(cid:18)(cid:11)(cid:26)(cid:4)(cid:5)(cid:3)(cid:2)(cid:2)(cid:6)(cid:4)(cid:31) (cid:20)!(cid:4)(cid:15)(cid:2)(cid:11)(cid:16)(cid:7)(cid:2)(cid:4)(cid:17)(cid:7)(cid:18)(cid:3)(cid:19)(cid:8)(cid:18)(cid:4)(cid:20)(cid:7)(cid:21)(cid:19)(cid:18)(cid:6)(cid:4)(cid:14)(cid:4)(cid:31)"##!(cid:4)#$$(cid:14)%#&’(cid:4)((cid:10)(cid:4)$)(cid:29)’
Annex 6 - Details of Proposed Additional Risk Minimisation Activities (if 
applicable)  
Not applicable.
Approved on 28 Mar 2023 GMT
